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Abstract 
N-terminal acetylation (NTA) is one of the most widespread protein modifications, which occurs on most 
eukaryotic proteins, but is significantly less common on bacterial and archaea proteins. This modification 
is carried out by a family of enzymes called N-terminal acetyltransferases (NATs). To date, 12 NATs have 
been identified, harboring different composition, substrate specificity, and in some cases, modes of 
regulation. In the first chapter, we review the molecular features of NATs.NatA/E, NatB and NatC, are 
multi-subunit enzymes, responsible for the majority of eukaryotic protein NTA. Their mechanisms of 
action and regulation remain poorly understood before this dissertation. In the second chapter, we 
determined the X-ray crystal structure of yeast NatA/Naa50 as a scaffold to understand coregulation of 
NatA/Naa50 activity in both yeast and human. We found that Naa50 makes evolutionarily conserved 
contacts to both the Naa10 and Naa15 subunits of NatA. These interactions promote catalytic crosstalk 
within the human complex, but do so to a lesser extent in the yeast complex, where Naa50 activity is 
compromised. Thirdly, we reported the Cryo-EM structures of human NatE and NatE/HYPK complexes 
and associated biochemistry. We revealed that NAA50 and HYPK exhibit negative impacts on their 
binding to NAA15 in vitro and in human cells by inducing NAA15 shifts in opposing directions. NAA50 and 
HYPK each contribute to NAA10 activity inhibition through structural alteration of the NAA10 substrate 
binding site. Fourthly, we reported the Cryo-EM structure of hNatB bound to a CoA-αSyn conjugate, 
together with structure-guided analysis of mutational effects on catalysis. This analysis revealed 
functionally important differences with human NatA and Candida albicans NatB, resolved key hNatB 
protein determinants for αSyn N-terminal acetylation, and identified important residues for substrate-
specific recognition and acetylation by NatB enzymes. Lastly, we report the Cryo-EM structure of S. 
pombe NatC with a NatE/C-type bi-substrate analogue and inositol hexaphosphate (IP6), and associated 
biochemistry. We find that all three subunits are prerequisite for normal NatC acetylation activity, IP6 
binds tightly to NatC to stabilize the complex, and we determine the molecular basis for IP6-mediated 
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N-terminal acetylation (NTA) is one of the most widespread protein modifications, 
which occurs on most eukaryotic proteins, but is significantly less common on bacterial 
and archaea proteins. This modification is carried out by a family of enzymes called N-
terminal acetyltransferases (NATs). To date, 12 NATs have been identified, harboring 
different composition, substrate specificity, and in some cases, modes of regulation. In 
the first chapter, we review the molecular features of NATs. 
NatA/E, NatB and NatC, are multi-subunit enzymes, responsible for the majority 
of eukaryotic protein NTA. Their mechanisms of action and regulation remain poorly 
understood before this dissertation. In the second chapter, we determined the X-ray 
crystal structure of yeast NatA/Naa50 as a scaffold to understand coregulation of 
NatA/Naa50 activity in both yeast and human. We found that Naa50 makes 
evolutionarily conserved contacts to both the Naa10 and Naa15 subunits of NatA. These 
interactions promote catalytic crosstalk within the human complex, but do so to a lesser 
extent in the yeast complex, where Naa50 activity is compromised.  
Thirdly, we reported the Cryo-EM structures of human NatE and NatE/HYPK 
complexes and associated biochemistry. We revealed that NAA50 and HYPK exhibit 
negative impacts on their binding to NAA15 in vitro and in human cells by inducing 
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NAA15 shifts in opposing directions. NAA50 and HYPK each contribute to NAA10 
activity inhibition through structural alteration of the NAA10 substrate binding site. 
Fourthly, we reported the Cryo-EM structure of hNatB bound to a CoA-αSyn 
conjugate, together with structure-guided analysis of mutational effects on catalysis. This 
analysis revealed functionally important differences with human NatA and Candida 
albicans NatB, resolved key hNatB protein determinants for αSyn N-terminal acetylation, 
and identified important residues for substrate-specific recognition and acetylation by 
NatB enzymes.  
Lastly, we report the Cryo-EM structure of S. pombe NatC with a NatE/C-type bi-
substrate analogue and inositol hexaphosphate (IP6), and associated biochemistry. We 
find that all three subunits are prerequisite for normal NatC acetylation activity, IP6 binds 
tightly to NatC to stabilize the complex, and we determine the molecular basis for IP6-
mediated stability of the complex and the overlapping yet distinct substrate profiles of 
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CHAPTER 1: Protein N-Terminal Acetylation: Structural Basis, Mechanism, 













This chapter is adapted from Trends Biochem Sci (Deng and Marmorstein 2021) © Cell Press 
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1.1 Evolutionarily conserved NTA has diverse biological functions 
The majority of eukaryotic proteins are subject to several N-terminal 
modifications at the early stage of their biogenesis by the ribosome, including Nt-
methionine excision (NME), Nt-acetylation (NTA), Nt-myristoylation (MYR), Nt-
methylation and Nt-arginylation (Eldeeb and Ragheb 2018; Varland, Osberg, and 
Arnesen 2015; Giglione, Fieulaine, and Meinnel 2015). The evolutionarily conserved and 
irreversible NME and NTA modifications affect the functions of many proteins and 
increase the diversity of the proteome (Varland, Osberg, and Arnesen 2015; Giglione, 
Fieulaine, and Meinnel 2015). NTA occurs when the iMet is removed or retained, co-
translationally or post-translationally (Aksnes, Ree, and Arnesen 2019; Aksnes et al. 
2016; Linster and Wirtz 2018) and on 50-90% of eukaryotic proteins but only 10-29% of 
bacterial and archaea proteins (Arnesen et al. 2009; Bienvenut et al. 2012; Kelkar et al. 
2011; Bienvenut, Giglione, and Meinnel 2015; Schmidt et al. 2016; Kirkland et al. 2008; 
Aivaliotis et al. 2007), correlating the abundance of NTA with organism complexity. 
NTA changes the chemical properties of the protein N-termini: neutralizing the 
charge, creating a new h-bond acceptor, changing the α-amino nitrogen nucleophilicity 
and basicity, and increasing its hydrophobicity and size. These changed chemical 
properties have diverse biological consequences on protein function including protein 
half-life, folding, complex formation, and localization (Aksnes et al. 2016; Oh, Hyun, and 
Varshavsky 2017). Correlating with these diverse functions, knockout of individual 
eukaryotic N-terminal acetyltransferases (NATs) display different phenotypes, 
presumably associated with the differential misregulation of their respective client 
proteins (Aksnes et al. 2016). Alteration in NTA activity is also linked to disease such as 
various developmental and neurodegenerative disorders and cancers (Myklebust, Stove, 
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and Arnesen 2015; Kalvik and Arnesen 2013; Dorfel and Lyon 2015) in humans and 
stress response in plants (Linster and Wirtz 2018; Huber et al. 2020).  While several 
other reviews cover the biology of NATs (Aksnes, Ree, and Arnesen 2019; Ree, 
Varland, and Arnesen 2018; Aksnes et al. 2016; Dorfel and Lyon 2015) , this chapter will 
focus on their structure, mechanism and regulation over evolution.     
     
1.2 General molecular features of NATs 
The GCN5 related N-acetyltransferases (GNAT) superfamily of proteins is one 
of the largest protein families, with over 10,000 protein members present in all domains 
of life. These proteins catalyze a bi-reactant process: transferring an acetyl group from 
the donor acetyl-CoA cofactor to the primary amine group of a variety of biomolecules 
including small molecules and protein or peptides lysine sidechains and N-termini. 
GNATs share a common structurally conserved α/β fold, despite their low degree of 
sequence identity; and mode of acetyl-CoA binding (Salah Ud-Din, Tikhomirova, and 
Roujeinikova 2016). GNATs typically contain distinct flanking N and C terminal regions 
that directly contributing to their distinct functions. 
   NTA is carried out by the NAT subfamily of GNATs, which typically contain four 
α-helices and seven β-strands, although addition secondary structural elements are 
often present at their N or C termini (Figure 1.1A). β1-β4 and β5-β6 are arranged 
antiparallelly, while the parallel β4 and β5 strands split to create a splay in between for 
binding peptide and acetyl-CoA (Figure 1.1A). The peptide binding site of NATs is 
typically flanked by the β6-β7 and α1-α2 loops, which directly participate in N-terminal 
substrate binding and take on a relatively closed configuration relative to GNATs that 
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acetylate internal lysine substrates, thereby disfavoring lysine sidechain binding (Magin, 
March, and Marmorstein 2016; Evjenth et al. 2009; Abboud et al. 2020).  NATs typically 
make extensive h-bond interactions with the backbone atoms of the first 2-3 N-terminal 
residues further contributing to specificity for protein N-termini. These two distinct 
features distinguish NATs from KATs (lysine acetyltransferases) and other members 
of GNATs. NTA by NATs follows an ordered Bi-Bi reaction mechanism, where acetyl-
CoA cofactor binding promotes subsequent N-termini binding prior to direct acetyl-group 
transfer from the cofactor to protein (Evjenth et al. 2012).  One or two residues function 
as a general base (s) (often through an intervening water molecule) to deprotonate the 
terminal amino group to facilitate its nucleophilic attack of the acetyl group of acetyl-CoA 
(Figure 1.1B).  This reaction proceeds through a tetrahedral intermediate, thus making 
CoA-peptide conjugate bi-substrate analogues in which N-terminal peptides are linked to 
CoA through an acetaldehyde group potent NAT inhibitors (Figure 1.1C) (Foyn et al. 
2013). 
  A wealth of mechanistic information about the substrate specific activities of 
NATs has been derived from their structures and associated biochemical studies. The 
NATs that have been structurally characterized to date are listed in Table 1.1. As 
described below, each NAT employs a unique strategy to achieve substrate-specific 














   Table 1.1 N-terminal acetyltransferases are characterized in all domains of life 
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Figure 1.1 NAT catalytic domains share common topology and related catalytic 
mechanism 
(A) The general topology of NAT catalytic subunits is depicted as in 2D cartoon on the 
left and 3D on the right panel with secondary structures shown. NATs usually contain 
seven β strands and four helices, but additional secondary structural elements within this 
topology and at their N-, C- termini are sometimes present. The α1- α2 and β6-β7 
substrate binding loops are highlighted in yellow. The length of α helices and β strands 
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does not accurately reflect actual scale in the 2D representation. The transparent 
magenta dots and spheres in the 3D representation represent the peptide and acetyl-
CoA substrates, respectively. The 3D representation was generated using human 
NAA50 PDB: 3TFY. (B) General catalytic mechanism of NATs, which transfer an acetyl 
group from acetyl-CoA to protein Nt-amino group is depicted. The acetyl and Nt-amino 
groups are colored as blue and red, respectively. A general base (or two, sometimes 
through a coordinated water molecule) is utilized to deprotonate the protein Nt-amino 
group, which subsequently attacks the acetyl group to form a tetrahedral intermediate. 
The deprotonated CoA is then deprotonated by a general acid (not shown) and released 
as the tetrahedral intermediate collapses. (C) The chemical structure of a CoA-peptide 
conjugate Bi-substrate analogue is shown. A linker (acetaldehyde group) is used to 
covalently link the CoA and peptide substrate. Abbreviations: NAT, N terminal 
acetyltransferase; CoA, Coenzyme A; PDB, Protein Data Bank. 
 
1.3 Bacterial NATs 
The three E. coli homologs, RimI, RimJ and RimL were among the first 
characterized NATs, showing post-translational NTA activity towards the ribosomal 
proteins S18, S5, and L7/L12, respectively (Favrot, Blanchard, and Vergnolle 2016). 
Some recombinant proteins overexpressed in E coli were later found to undergo NTA 
(Bernal-Perez et al. 2012), and more recent proteome-wide analysis found that ~30-100 
E. coli N-termini are at least partially acetylated, predominantly at N-terminal serine, 
alanine, methionine and threonine residues (Bienvenut, Giglione, and Meinnel 2015; 
Schmidt et al. 2016). The abundance of NTA in Pseudomonas aeruginosa PA14 and 
Mycobacterium tuberculosis appears to be in the range of 10% ~ 29% (Kelkar et al. 
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2011; Ouidir et al. 2015), although their biological importance have not been rigorously 
evaluated. 
Bacterial orthologs of each of the Rim proteins have been structurally 
characterized. The Salmonella typhimurium RimI (StRimI) structure was determined in 
complex with CoA, acetyl-CoA or a CoA-peptide conjugate showing a typical GNAT fold 
(Figure 1.2A) (Vetting et al. 2008). Several StRimI residues change conformation when 
in complex with the peptide portion of the conjugate with several residues making 
backbone h-bonds to carbonyl and nitrogen atoms of the first three residues of the 
peptide portion, while several RimI residues make van der Waals and h-bonds to side 
chains 2-4 (Figure 1.3). RimI Glu103 is proposed to function as a general base through 
an intervening water molecule, while Tyr115 is proposed to act as the general acid 
(Figure 1.3). A more recent biochemical characterization of Mycobacterium tuberculosis 
RimI demonstrated a conventional eukaryotic NatA/NatC/NatE substrate preference, 
consistent with a relaxed substrate specificity for RimI (Pathak et al. 2016).  
Crystal structures of StRimL in apo form and in complex with CoA reveals a 
similar overall fold to bacterial StRimI, however StRimL forms a homodimer through 
antiparallel b-strands (b6) from opposing subunits to form a contiguous b-sheet that 
spans the entire dimer (Figure 1.2B) (Vetting et al. 2005). This 2-fold symmetry appears 
to be precisely configured to acetylate its cognate dimeric L7 N-termini (Wahl et al. 2000; 
Bocharov et al. 2004). Compared to the apo StRimL structure, the bound of CoA 
appears to stabilize the α1-α2 loop, which could also facilitate the cooperative binding of 
the dimeric L7/L12. Like StRimI, StRimL is proposed to use a ternary complex 
mechanism involving a glutamate general base residue (Glu160), while a tyrosine 
9 
 
(Tyr98) is proposed to stabilize the tetrahedral intermediate, with a serine residue 
(Ser141) functioning as a general acid.  
Mycobacterium smegmatis RimJ structures alone and in complex with cofactor or 
cofactor analogs has recently been deposited to the PDB (PDB: 6C32, 6C30, 6C37. 
Taken together, the bacterial NAT proteins reveal a general GNAT fold in either 
monomeric or homodimeric form with substrate protein recognition occurring through 
backbone and sidechain interaction to the first few N-terminal residues, with acid-base 
catalysis proceeding through dedicated residues.    
 




(A) Structures of monomeric StRimI (PDB: 2CNM), SsNAT (PDB: 4LX9), uncomplexed 
SpNAA10 (PDB: 4KVX), hNAA50 (PDB: 3TFY), hNAA40 (PDB: 4U9W), and DmNAA80 
(PDB: 5WJE) are shown in cartoon and color in cyan. The α1- α2 and β6-β7 substrate 
binding loops are highlighted in yellow. Substrates in the structures are shown in stick 
and colored in magenta. The hNAA40-specific N terminal domain is highlighted in grey. 
(B) Dimeric RimL (PDB:1S7N) and hNAA60 (PDB: 5ICW) are shown. The α1-α2 and β6-
β7 substrate binding loops are highlighted in yellow. Substrates in the structures are 
shown in stick and colored in magenta. To form a dimer, StRimL utilizes the two β6 
strands from each subunit, while hNAA60 uses the extended β6-β7 loops. The NAA60-
specific N terminal domain is highlighted in grey. NAT catalytic subunits that have not 




Figure 3.3  NATs use related but distinct mechanism to recognize their peptide 
substrate N-termini 
Peptide binding sites of StRimI (PDB: 2CNM), complexed SpNAA10 (PDB: 4KVM, with 
SpNAA15 hidden), CaNAA20 (PDB: 5K04, with CaNAA25 hidden), hNAA40 (PDB: 
4U9W), hNAA60 (PDB: 5ICV), and DmNAA80 (PDB: 5WJE) are shown in cartoon. 
Peptide substrates are shown in magenta sticks. The residues labeled with a * symbol 
are proposed catalytic residues. Broken lines indicate h-bonds formed between atoms. 
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The α1- α2 and β6-β7 substrate binding loops are highlighted in yellow. Water-mediate 
interactions in the PDB structures are not shown. 
 
1.4 Archaea NATs 
Like in bacteria, while earlier studies indicated that NTA occurs on only ribosomal 
proteins in archaea, more recent N-terminomics studies reveal that NTA occurs on 14–
29% of archaeal proteins (Falb et al. 2006; Aivaliotis et al. 2007; Kirkland et al. 2008). 
Archaea contains only one conserved NAT, which exhibits a very relaxed substrate 
spectrum including substrates by eukaryotic NatA/B/C/E (Mackay et al. 2007; Liszczak 
and Marmorstein 2013). The Sulfolobus solfataricus NAT (SsNAT) shows the greatest 
sequence conservation with the NAA10 catalytic subunit of the eukaryotic NatA complex, 
with 33% sequence identity (Liszczak and Marmorstein 2013), as confirmed by its 
structure bound to acetyl-CoA (PDB: 4LX9) (Figure 1.2A) (Liszczak and Marmorstein 
2013). Interestingly, the monomeric SsNAT is more structurally similar to the active form 
of Naa10 within the binary NatA complex, rather than NAA10 alone, which is not active 
towards NatA substrates. A notable place where SsNAT and NAA10 diverge is in the C-
terminal end of the a1 helix that is part of the a1-a2 loop substrate binding region of 
NATs. This region of SsNAT is more similar to the eukaryotic NAA50, which is also 
active towards NatE substrates as a monomer. This suggests that SsNAT is a hybrid of 
the NAA10 and NAA50 eukaryotic NATs. This is consistent with biochemical studies on 
SsNAT demonstrating that different catalytic residues are used to acetylate NatA (Glu84) 
and NAA50/NatE (Tyr73/His112) -like substrates, analogous to corresponding residues 
in these eukaryotic NATs (Liszczak and Marmorstein 2013). It is possible that the 
archaea NAT serves as one of the ancestors of eukaryotic NATs, which subsequently 
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evolved to be substrate-specific. An unusually long β3-β4 loop in SsNAT, was also 
shown to play a more selective role in acetylating NAA50-type substrates, although the 
mechanism for this is still unclear. A more recent SsNAT structure (called Ard1) (Chang 
and Hsu 2015) and Thermoplasma volcanium Ard1 (Ma et al. 2014), were consistent 
with the earlier study, reinforcing the substrate flexibility of the archaeal NATs. 
Interestingly, it was demonstrated that mutations of the catalytic Glu residue of ssNAT 
could shift its substrate preference (Chang and Hsu 2015). 
 
1.5 Eukaryotic NATs 
NatA: NatA acetylates ~ 40% of human proteins, the most of any NAT (Arnesen 
et al. 2009).  NatA is a heterodimer of catalytic NAA10 (also named ARD1) and auxiliary 
NAA15 subunits (Mullen et al. 1989; Park and Szostak 1992). Notably, NAA10 can also 
exist independently (Arnesen et al. 2005; Van Damme, Evjenth, et al. 2011a). When the 
second residue of a protein is relatively small and uncharged (Table 1.1), it will be 
acetylated by NatA after the initiator methionine is cleaved (Polevoda et al. 1999; 
Arnesen et al. 2009). In contrast, the NAA10 monomer is not able to acetylate canonical 
NatA substrate, but instead exhibits specificity for acidic N-terminal sequences in vitro 
(Van Damme, Evjenth, et al. 2011a; Drazic et al. 2018; Goris et al. 2018).  
The structure of Schizosaccharomyces pombe NatA (SpNatA) bound to a CoA-
peptide conjugate reveals that the SpNAA15 auxiliary subunit adopt a ring-like structure 
of tetratricopeptide repeat (TPR) motifs, which completely wraps around the SpNAA10 
catalytic subunit, with the two proteins making extensive hydrogen bonding and van der 
Waals interactions (Figure 1.4A) (Liszczak et al. 2013). The Chaetomium thermophilum 
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(Weyer et al. 2017) and  Saccharomyces cerevisiae (Deng et al. 2019) NatA display 
similar overall folds. A structural comparison of the SpNatA complex with SpNAA10 
alone, reveals that SpNAA15 binding to SpNAA10 induces a conformational change of 
the a1-a2 loop region of SpNat10 to position key catalytic residues for substrate-specific 
recognition and catalysis (Liszczak et al. 2013). The SpNAA10 active site reveals that h-
bonds to the backbone carbonyl groups of the first two residues and van der Waals 
contacts to Ser1 anchor the peptide portion of the CoA-peptide conjugate (Figure 1.3). 
Glu24 was also proposed to play role as a general base for catalysis. Each of the 
residues revealed to play important roles in substrate binding and catalysis are highly 
conserved within NatA orthologs and shown to result in decreased NatA activity when 
mutated (Liszczak et al. 2013). Importantly, modeling of amino acid side chains in the 
Ser1 position, reveals that only small uncharged amino acids could be accommodated, 
consistent with the known substrate specificity of NatA (Liszczak et al. 2013). 
Interestingly, this same study showed that a non-cognate EEE peptide could be 
acetylated by the SpNAA10-E24A mutant but not by WT SpNatA, suggesting that free 
NAA10 uses a different catalytic strategy to acetylate NatH-type substrates.  
The structure of the human NatA (hNatA) shows a high degree structural 
conservation with SpNatA (Gottlieb and Marmorstein 2018), except for the presence of 
an extended metazoan-specific Sel1-like repeat region at the C-terminal end of the 
hNAA15 auxiliary subunit, which was shown to play a role in overall hNatA stability 
(Gottlieb and Marmorstein 2018). In addition, the hNatA structure reveals the presence 
of an endogenously bound inositol hexaphosphate (IP6) molecule at an interface region 
between hNAA10 and hNAA15 via electrostatic interactions (Gottlieb and Marmorstein 
2018; Deng, McTiernan, et al. 2020). A recently identified hNatA mutant K450E displays 
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defects in IP6 binding and leads to NatA activity loss which can be rescued by the 
addition of IP6 (Cheng et al. 2019), consistent with a role of IP6 in hNatA stability and 
activity.  
NatB: NatB, conserved from yeast to man, acetylates ~21% of human proteins, 
such as actin, tropomyosin, CDK2, and α-synuclein. NatB is a binary complex containing 
catalytic NAA20 and auxiliary NAA25 subunits and has specificity for N termini 
containing MD-, ME-, MN- and MQ- sequences (Van Damme et al. 2012). The structure 
of Candida albicans NatB (CaNatB) was determined alone and in complex with a CoA-
peptide conjugate (Hong et al. 2017). The catalytic CaNaa20 subunit shows a typical 
GNAT fold, and the CaNAA25 auxiliary subunit also displays high structural similarity to 
SpNAA15, particularly in the way it wraps around the catalytic subunit (Figure 1.4A). 
Unlike NAA10, NAA20 is unstable in the absence of NAA25. Extensive interactions are 
observed between CaNAA25 and CaNAA20, with the major contact interface mediated 
by the α1- α2 loop of CaNAA20 (Hong et al. 2017), similar to the NatA complex. The 
interaction between NAA20 and the peptide substrate mainly involves h-bond 
interactions to the backbone amides of the first three residues of the peptide portion of 
the CoA-peptide conjugate, with side chain contacts to residues Met1 and Asp2 through 
van der Walls and h-bond interactions (Figure 1.3).  Mutation of contact residues 
generally reduce NatB acetylation activity, consistent with the structural observations 
(Hong et al. 2017).  A more recent Cryo-EM structure of human NatB bound to a CoA-a-
synulein peptide conjugate shows a high degree of structural similarity to CaNatB, 
although provides structural and biochemical data consistent with a role for Tyr124 
(hNAA20-Tyr123) acting as a general base for catalysis (Deng, Pan, et al. 2020).  
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NatC: NatC is a heterotrimer of a catalytic subunit NAA30 and two auxiliary 
subunits NAA35 and NAA38 (Polevoda and Sherman 2001). NatC acts co-translationally 
on the peptide substrate staring with ML-, MF, MI, MW-, playing roles in viral particle 
assembly, maintaining mitochondrial integrity and apoptosis (Van Damme et al. 2016a; 
Starheim et al. 2009). Recent x-ray crystal structures of S. cerevisiae NatC with cofactor 
and ligand bound revealed that it has distinct divergent architecture compared to other 
NATs (Grunwald et al. 2020). Overall, the larger auxiliary subunit NAA35 serves as the 
central assembly hub to form extensive interaction with the smaller auxiliary subunit 
NAA38 and NAA30. NAA38 displays an Sm fold, consisting of an α-helix followed by a 
five-strand β-sheet, and interacts with the N-terminal region of NAA35. The absence of 
NAA38 compromises NatC activity in vitro, indicating its indispensable role in the whole 
complex. NAA30 adopts a typical GNAT fold, however, unlike NatA or NatB, its α1–α2 
and β6–β7 loops are both buried inside the interface between NAA30 and NAA35. 
Biochemical analysis suggested that NatC preferably recognizes its substrates not just 
by the identity of the second residue, but also residues beyond position 2 (Grunwald et 
al. 2020). It was proposed that ScNaa30-Glu118 functions as the general base residue 
to deprotonate the substrate and ScNaa30-Tyr130 serves as the general acid to re-
protonate the initially formed thiolate anion of CoA (Grunwald et al. 2020).  Our recent 
structural and biochemical studies on SpNatC showed some distinct features but agreed 
mostly with the results on ScNatC describe above (See chapter 5).     
NatD: NatD (NAA40), which functions as a monomer, is conserved from yeast to 
human, and is the most selective NAT, carrying out NTA of only histones H4 and H2A 
(Song et al. 2003; Hole et al. 2011), which most commonly contain the sequence 
SGRGK. The structure of hNatD bound to acetyl-CoA and CoA and an N-terminal 
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histone H4/H2A peptide, reveals that while NatD adopts a GNAT fold, it also contains a 
unique N terminal helix-loop-strand segment, which wraps around the GNAT domain 
and plays an important role in hNatD stability, partially mimicking similar roles of the 
auxiliary subunits of NatA and NatB (Magin, Liszczak, and Marmorstein 2015) (Figure 
1.2A). Another unique feature of NatD is found in its substrate binding loops, where the 
α1- α2 loop is extended and flipped towards the peptide substrate, such that the 
opposing β6-β7 loop is flipped away (Magin, Liszczak, and Marmorstein 2015). This 
alters the peptide binding site to make it uniquely suited for its cognate N-termini. 
Indeed, the structure of hNatD bound to CoA and peptide reveals that nearly every 
hydrogen bond donor and acceptor atom within the first four residues are engaged in 
hydrogen bounding interactions, with Arg3 playing a particularly important role, and the 
small sizes of Gly2 and Gly4 also being critical (Figure 1.3). Activity assays also 
revealed that Glu139 is essential for catalyst, possibly acting as a general base (Figure 
1.3).   
NatE: NatE refers to the complex between the NAA50 catalytic subunit and the 
NatA complex (also containing the NAA10 catalytic subunit). Monomeric NAA50 is also 
stable. However, yeast NAA50 is inactive, while in higher eukaryotes, such as human 
and Drosophila, NAA50 is active in the absence or presence of NatA (Evjenth et al. 
2009; Liszczak, Arnesen, and Marmorstein 2011; Van Damme et al. 2015; Rong et al. 
2016; Deng et al. 2019). NAA50 has specificity for N-terminal Met residues followed by a 
less restricted set of amino acids at the second position (Table 1.1) (Evjenth et al. 2009) 
. The structure of hNAA50 bound to CoA and an N-terminal peptide reveals that the 
peptide is recognized almost exclusively through interactions to residues one and two 
(Liszczak, Arnesen, and Marmorstein 2011) (Figures 1.2A and 1.3). While the carbonyl 
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and amino groups of residues Met1 and Leu2 engage in h-bond interactions, the side 
chains make extensive van der Walls interactions. Consistent with the known specificity 
of NAA50, the active site appears exquisitely suited for Met1, while the Val2 binding site 
appears to have greater flexibility to accommodate several amino acid substitutions 
(Figure 1.3). A combination of mutagenesis, kinetics and structural observations 
suggest that hNAA50 Tyr73 and His112 are essential for catalysis via an ordered water 
molecule, likely serving as general acid or base residues (Liszczak, Arnesen, and 
Marmorstein 2011) (Figure 1.3). Interestingly, these two catalytic residues of hNAA50 
are absent in the corresponding positions of yeast homologous, which likely explains the 
inactivity of the yeast NAA50 proteins. A recent structure of ScNatE and related 
biochemical studies also shows that ScNAA50 has relatively poor acetyl-CoA binding 
capacity, consistent with its catalytic inactivity (Deng et al. 2019).  
The binding affinity between NAA50 and NatA is in the nanomolar range (Deng 
et al. 2019), consistent with the fact that a significant portion of NAA50 in the cell is 
bound to NatA (Hou et al. 2007). The molecular basis for association between NAA50 
and NatA from yeast and human were recently revealed (Deng et al. 2019; Deng, 
McTiernan, et al. 2020) , demonstrating that NAA50 docks onto a unique surface of the 
NAA15 auxiliary subunit primarily through hydrophobic interactions, while making 
significantly more modest electrostatic interactions with NAA10 (Figure 1.4). 
Nonetheless biochemical experiments reveal that NAA10 and NAA50 can influence each 
other’s activity within the NatE complex (Deng et al. 2019; Deng, McTiernan, et al. 2020) 
.  
NatF: NatF (NAA60), found only in higher eukaryotes (Rathore et al. 2016; Van 
Damme, Hole, et al. 2011), is located on the cytosolic side of Golgi membranes to 
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acetylate transmembrane protein (Aksnes et al. 2015; Aksnes et al. 2017).  It has an 
unique membrane binding domain at its C-termini (Aksnes et al. 2015; Chen et al. 2016; 
Stove et al. 2016; Aksnes et al. 2017), which mediates Golgi membrane binding (Aksnes 
et al. 2017). Recently, Arabidopsis thaliana NatF was demonstrated to associate with the 
plasma membrane also via its C-termini (Linster et al.). NatF has specificity for N-
terminal Met residues followed by Leu, Ile, Phe, Tyr and Lys residues (Table 1.1). Unlike 
other NATs, NatF is homodimeric in solution but shifts to a monomer state when peptide 
substrate binds (Figure 1.2B) (Stove et al. 2016). The structure of hNatF in complex 
with CoA or a CoA-peptide conjugate reveals that it has a unique extended β -β7 loop, 
which mediates dimerization and sterically occludes peptide binding, but participates in 
peptide recognition of the NatF monomer when cofactor and peptide are both bound 
(Stove et al. 2016). hNatF peptide recognition in hNatF is mainly to the first two residues, 
through backbone h-bonds and a hydrophobic pocket (similar to NAA50) that recognizes 
Met1 with less specificity for residue Lys2 (Figure 1.3) (Stove et al. 2016). Tyr97 and 
His138 are proposed to function as general base residues in hNatF, similar to roles 
played by residues of Tyr73 and His112 from hNAA50 (Stove et al. 2016), which is 
consistent with mutagenesis studies (Figure 1.3) (Chen et al. 2016).  
NatG: NatG is localized within the chloroplast of plant, processing M-, A-, S-, T- 
staring-termini as substrates (Dinh et al. 2015). As of the writing of this review, a detailed 
structure/function analysis of NatG had not yet been reported. 
NatH: NatH (NAA80) is widespread only in animals (Drazic et al. 2018), and 
post-translationally active toward processed cytoplasmic β- and γ-actin in vivo with acidic 
N termini DDDI and EEEI, respectively (Drazic et al. 2018; Arnesen, Marmorstein, and 
Dominguez 2018; Wiame et al. 2018). The structure of Drosophila melanogaster Naa80 
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(DmNaa80) bound to a CoA-peptide conjugate reveals a more open and highly basic 
substrate binding site than other NATs, which is specifically configured to bind its acidic 
substrates (Goris et al. 2018) (Figure 1.2A). H-bonds extend through the first three 
backbone and side-chain residues (Figure 1.3), explaining the specificity for highly 
acidic substrates. An unusual intramolecular hydrogen bond is also observed between 
the backbone amide nitrogen of I4 and the sidechain of D2 (Figure 1.3). Mutational and 
activity assays is consistent with substrate preference deriving mostly from the acidic 
residues at positions two and three (Goris et al. 2018), which is unusual for NAT proteins 






Figure 4.4 Some NATs function by forming complexes with auxiliary subunits or 
regulatory proteins 
 (A) Structures of SpNatA (PDB:4KVM), CaNatB (PDB:5K04), ScNatE (PDB: 6O07), and 
hNAA80-actin-profilin complexes (PDB:6NBE) are shown in cartoon. (B) In humans, the 
dynamics and interplay between hNatA, hNAA50, and HYPK are shown. hNAA10 can 
exist independently. Two subunits and Inositol hexaphosphate (IP6) form hNatA (PDB: 
6C9M) complex. HYPK and hNAA50 each can associate with hNatA to form competing 
complexes (hNatA/HYPK PDB: 6C95 and hNatE PDB:6PPL). Tetrameric complex 
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hNatE/HYPK (PDB: 6PW9) can be formed when both HYPK and hNAA50 are bound to 
hNatA. hNAA10, HYPK, hNAA50, and hNAA15 are shown in chartreuse, salmon, teal, 
and grey, respectively. (C) Structure of ScNatE bound to ribosome (PDB: 6HD7) is 
shown. Two rRNA expansion segments ES27a and ES7a are contacting NAA15 and 
NAA50, respectively. Two electropositive regions ERP1 (N terminus of NAA15), and 
EPR2 (internal basic helix) on NAA15, which directly contact ribosome, are shown in the 
zoom-in view. 
 
1.6 Regulation of NATs 
1.6.1 Huntingtin-Interacting Protein K regulates both NatA and NatE activity 
The Huntingtin-Interacting Protein K (HYPK)  , was found to associate with the 
human NatA complex (Arnesen et al. 2010). It is absent in most yeast , but found in 
Chaetomium thermophilum (Weyer et al. 2017) and human (Deng, McTiernan, et al. 
2020; Gottlieb and Marmorstein 2018) where it was structurally characterized bound to 
NatA. In both cases, HYPK was shown to have intrinsic NatA inhibitory activity, and in 
the study of the human complex proposed to contribute to cognate substrate specificity 
as HYPK was shown to be partially uncompetitive and noncompetitive with respect to 
acetyl-CoA and peptide substrate, respectively (Gottlieb and Marmorstein 2018). When 
bound to NatA, HYPK forms a bipartite structure: a C-terminal ubiquitin-associated 
domain (a3-a5) binds extensively to the NAA15 auxiliary subunit, a N-terminal loop-a1-
helix region binds across the catalytic NAA10 subunit to distort its active site, and a long 
a2 helix connects these two ends of HYPK. Biochemical data is consistent with the 
structural findings that the ubiquitin-associated domain forms the high affinity interaction, 
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while the loop-a1-helix region harbors the catalytic inhibitory activity. More recently, 
structural and biochemical studies reveal that HYPK can also form a stable complex with 
the NatE complex (Figure 1.4B), although HYPK and NAA50 where shown to 
allosterically reduce the binding affinity of each other (Deng, McTiernan, et al. 2020).  
 
1.6.2 NAA80 activity is regulated by the actin chaperone profilin 
Naa80 is preferentially active towards monomeric actin and the presence of 
profilin has been shown to increase its catalytic efficiency (Rebowski et al. 2020). The 
crystal structure of hNaa80 in complex with monomeric actin and profilin with cofactor 
and cofactor analogs reveals the first structure of a NAT bound to its intact protein 
substrate (Rebowski et al. 2020). The structure shows that a Naa80-specific extended 
β6-β7 proline-rich loop and α2-helix of hNAA80 is utilized to meditate interaction with 
both actin and profilin (Rebowski et al. 2020). Thus formation of hNAA80-actin-profilin 
complex orients the N termini of actin perfectly into the substrate binding groove of 
hNAA80 (Figure 1.4A) (Rebowski et al. 2020). It is proposed that, with the aid of profilin, 
hNAA80 can act more efficiently to compensate for the low abundance of hNAA80 
relative to actin in the cell.  
 
1.6.3 Ribosome association by NATs 
In eukaryotes, NatA/B/C/E associate with the ribosome for co-translational 
activity, utilizing their auxiliary subunits as the predominant anchoring point (Polevoda et 
al. 2008), while NatD could potentially use its extended N terminal region (Magin, 
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Liszczak, and Marmorstein 2015; Hole et al. 2011). This proximity of the NATs to the 
ribosome likely facilitates the relatively high stoichiometry of NTA that is observed in 
vivo.  
 The current molecular understanding of the interactions between NATs and the 
ribosome is limited to NatA or NatE. Early studies suggested that NatA contacts 
ribosomal protein uL23 and uL29 around the peptide exit tunnel (Polevoda et al. 2008) to 
interact with the nascent chain (Gautschi et al. 2003). The ratio of ribosome to NatA is 
around 40:1 in yeast, leading to questions about the dynamics of NatA/ribosome 
interactions (Raue, Oellerer, and Rospert 2007). Purified non-translating ribosome can 
also interact with NatA in vitro via two conserved electropositive regions (EPR) on 
NAA15 (Magin et al. 2017), which is confirmed through mutational studies (Magin et al. 
2017) and in vivo (Varland and Arnesen 2018). A recent structure of a ScNatE/ribosome 
complex reveals that ScNatE docks at the nascent peptide exit tunnel near uL31 and 
uL22, with rRNA expansion segments making key contacts to ScNAA15 and ScNaa50 
(Figure 1.4C) (Knorr et al. 2019).  
 
1.7 Remaining Questions 
NTA occurs on countless proteins in three domains of life both co-translationally 
and post-translationally, impacting diverse cellular functions of their client protein.  
Although sharing an evolutionarily conserved GNAT fold and related catalytic 
mechanism, each NAT employs unique elements to mediate substrate-specific activity to 
carry out their distinct cellular functions. NAT auxiliary and regulatory subunits also play 
NAT-type specific roles. While some NATs have dedicated co-translational and post-
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translational roles, the mechanisms that may toggle some NATs such as NAA10 and 
NAA50 between the two roles requires further investigation. Still missing from the PDB 
are the chloroplast localized NATs, which may have unique functions. Do other NAT 
agonists or antagonists exist and how might they work? Finally, a greater molecular 
understanding of how NATs carry out and navigate between each other co-translational 


































CHAPTER 2: Structure and Mechanism of Acetylation by the N-Terminal Dual 














The majority of nascent peptides biosynthesized by the eukaryote cytosolic 
ribosome undergo several N-terminal co-translational modifications before they become 
fully functional and mature proteins. Along with initial methionine cleavage by methionine 
aminopeptidase (iMAP) and N-terminal myristoylation, N-terminal acetylation (Nt-
acetylation), which transfers an acetyl moiety from acetyl-CoA to the N-terminal amino 
group of proteins, is an irreversible, highly conserved and abundant modification 
(Giglione, Fieulaine, and Meinnel 2015). About 50-70% of S. cerevisiae proteins, 70%-
75% of A. thaliana proteins, and 70-90% of H. sapiens proteins are subject to Nt-
acetylation by a family of N-terminal acetyl transferases (NATs) (Starheim, Gevaert, and 
Arnesen 2012).  Nt-acetylation is generally considered to be a co-translational process, 
with most NATs making direct interactions with both nascent peptide and the ribosome 
(Gautschi et al. 2003; Polevoda et al. 2008; Magin et al. 2017; Knorr et al. 2019).  
Numerous studies have demonstrated that Nt-acetylation can affect diverse 
protein and cellular activities including gene regulation, apoptosis, protein folding, protein 
degradation, protein complex formation and subcellular localization (Aksnes et al. 2016; 
Holmes et al. 2014; Shemorry, Hwang, and Varshavsky ; Behnia et al. 2004; Yang et al. 
2013; Dikiy and Eliezer 2014; Hwang, Shemorry, and Varshavsky 2010; Schiza et al. 
2013; Starheim et al. 2009; Arnesen, Gromyko, et al. 2006; Setty et al. 2004b; Pavlou 
and Kirmizis 2016). Knockout of NATs frequently results in severe cellular defects 
including slow growth and reduced mating efficiency in yeast. In higher eukaryotes, 
misregulation of N-terminal acetylation can lead to numerous developmental disorders 
and cancers (Kalvik and Arnesen 2013; Myklebust, Stove, and Arnesen 2015; Lee et al. 
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2010; Yu et al. 2009; Arnesen, Gromyko, et al. 2006; Ametzazurra et al. 2008; Starheim 
et al. 2008; Starheim et al. 2009; Fluge et al. 2002; Hua et al. 2011). For example, the 
NatA catalytic subunit, Naa10, plays important roles in mammalian cells including 
cellular hypoxia, bone formation and DNA damage (Dorfel and Lyon 2015; Jeong et al. 
2002; Yoon et al. 2014; Yi et al. 2007). Mutation in human Naa10 causes the genetic 
disorder Ogden syndrome (Rope et al. 2011). 
Several NATs, including NatA, NatB, NatC, NatD, NatE, and NatF are conserved 
across eukaryotes (Aksnes et al. 2016) (Aksnes et al. 2015; Aksnes et al. 2017; Stove et 
al. 2016). NatG is resident in chloroplasts of plant cells (Dinh et al. 2015), and the 
recently identified NatH/Naa80 exists only in animals to acetylate a subset of processed 
actins (Drazic et al. 2018). The presence of NatF, NatG, and NatH indicates that this 
modification can also occur post-translationally. NATs can acetylate the N-termini either 
when the initiator methionine (iMet) is cleaved or retained, mostly depending on the 
identity of the first two amino acids of the nascent peptide (Aksnes et al. 2016), which 
further enriches the complexity of the eukaryote proteome. Both NatA and NatD 
complete the process after iMet is cleaved. NatA shows specificity toward the N-termini 
of exposed A-, S-, T-, V-, C-, and sometimes G-, while NatD can only acetylate the N-
terminal serine of histones H2A and H4 (Magin, Liszczak, and Marmorstein 2015; 
Gottlieb and Marmorstein 2018; Liszczak et al. 2013; Arnesen et al. 2009; Song et al. 
2003). Other NATs like NatB, NatC, NatE, and NatF modify peptides with the iMet 
retained. NatB prefers the Met-Asx/Glx type N-termini (MD-, ME-, MN-, and MQ-starting) 
, whereas NatC, NatE, and NatF have some substrate overlap, and they acetylate 
peptides with “hydrophobic/amphipathic” residues like L, I, F, Y, K directly following iMet 
(Liszczak, Arnesen, and Marmorstein 2011; Stove et al. 2016; Van Damme et al. 2016b; 
29 
 
Tercero, Dinman, and Wickner 1993; Evjenth et al. 2009; Van Damme, Hole, et al. 
2011). NatA, B and C are the three major contributors to the Nt-acetylome, as they cover 
about 80% of all NAT substrates (Aksnes et al. 2016). Notably, NatA, B and C contain at 
least one auxiliary subunit to couple with the catalytic subunit for enzymatic activity 
towards cognate substrates and anchoring of the catalytic subunit to the ribosome, while 
NatD, F, G, H are each composed of only one single catalytic subunit. NatE is composed 
to two catalytic and one auxiliary subunit.  
NatA is comprised of the catalytic subunit Naa10 and the auxiliary subunit Naa15 
(Liszczak et al. 2013; Gottlieb and Marmorstein 2018). Naa10 can also exist 
independently of Naa15, exhibiting altered substrate specificity and might also be 
involved in transcriptional activity inside the nucleus (Arnesen et al. 2005; Van Damme, 
Evjenth, et al. 2011b). Alternatively, NatA can also form a complex with another catalytic 
subunit Naa50 to form a ternary NatA/Naa50 complex (also called NatE) (Gautschi et al. 
2003), and NatA from some eukaryotic species including Chaetomium thermophilum and 
human exhibit tight binding affinity with a regulatory protein called HYPK (Gottlieb and 
Marmorstein 2018; Weyer et al. 2017; Arnesen et al. 2010). Deletion of Naa50 in yeast 
shows no phenotype (Gautschi et al. 2003), while Naa50 knockout can affect sister 
chromatid cohesion in higher organisms like Drosophila and human (Hou et al. 2007; 
Chu et al. 2011; Ribeiro et al. 2016; Williams et al. 2003). Endogenous pulldown of 
NatA/Naa50 complexes from human cells indicates that over 80% of Naa50 is not 
associated with NatA in vivo (Hou et al. 2007), whereas the remaining ~20% forms a 
stable and stoichiometric complex. Furthermore, another recent study demonstrates that 
loss of Naa50 in Drosophila leads to a decrease of NatA in vivo acetylation activity 
(Rathore et al. 2016). A recent Cryo-EM structure of a yeast NatA/Naa50-ribosome 
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complex with an 8 Å NatA local resolution reveals that both Naa50 and the Naa15 
regulatory subunit of NatA contribute to ribosome interaction, with the Naa10 active site 
about 50 Å from the ribosome exit tunnel, and the Naa50 active site about 2-times that 
distance (Knorr et al. 2019). The underlying molecular basis for the potential functional 
coupling and interplay between the catalytic subunits of the NatA/Naa50 complex is still 
poorly understood.  
To understand the molecular basis for NatA/Naa50 co-regulation of N-terminal 
protein acetylation across species, we determined the X-ray crystal structure of a yeast 
NatA/Naa50 complex and used it as a scaffold to understand coregulation of 
NatA/Naa50 activity in yeast and human. We find that NatA/Naa50 forms a stable 
complex in yeast and human through conserved interactions: Naa50 makes contacts to 
both the Naa10 and Naa15 subunits of NatA. We demonstrate that NatA-Naa50 
interactions can significantly promote the catalytic activities of the two catalytic subunits 
within the human complex relative to NatA or Naa50 alone.  In contrast, in the yeast 
complex, Naa50 modestly increases the activity of NatA, and Naa50 is defective in 
catalytic activity, likely through compromised peptide binding. These studies have 
implications for understanding the role of the NatA/Naa50 complex in modulating the 





2.2.1 NatA and Naa50 form stable complexes in yeast and human 
We used recombinant proteins to characterize the interaction between Naa50 
and NatA from human (h) and S. pombe (Sp) in vitro. Recombinant SpNatA, SpNaa50, 
and human Naa50 were overexpressed and purified from E. coli, while hNatA was 
prepared from baculovirus-infected Sf9 insect cells. Consistent with previous data 
reporting a direct interaction between NatA and Naa50 (Gautschi et al. 2003; Hou et al. 
2007), we found that N-terminal GST-tagged Naa50 can pull-down NatA. We also found 
that human and S. pombe NatA and Naa50 co-migrate by size-exclusion 
chromatography to form stochiometric complexes under near native salt concentration 
(200 mM NaCl) (Figure 2.1A). Interestingly, SpNaa50 maintained the ability to co-
migrate with SpNatA in sizing buffer with NaCl concentration as high as 1 M (Figure 
2.1A), suggesting that this interaction in S. pombe is robust and not dominated by 
electrostatic interactions, while hNatA and hNaa50 failed to form a stochiometric 
complex in the high salt buffer (Figure 2.1A) suggesting some divergence of the NatA-
Naa50 interaction between the yeast and human complexes. In addition, we observed 
that SpNaa50 displays similar comigration with ScNatA under both native and high NaCl 
concentrations (Figure 2.1A), strongly indicating that the NatA-Naa50 interaction within 
yeast is highly conserved.  
To more quantitatively assess the interaction between NatA and Naa50, we 
carried out a Fluorescence Polarization (FP) assay, using Naa50 labeled with 
Fluorescein-5-Maleimide via exposed surface cysteines. We observed that Naa50 tightly 
binds to NatA in both the S. pombe and human systems with Kd values of 17 ± 3.4 nM 
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and 29 ± 5.6 nM, respectively (Figure 2.1B). These data, together with the high degree 
of sequence conservation of the interaction interfaces between Naa50 and NatA in the 
two species, suggest that Naa50 and NatA from yeast and human are very likely to have 
similar association mechanisms. However, we found that GST-hNaa50 failed to pull 
down SpNatA, and that hNaa50 and SpNatA could not form a stoichiometric complex in 
size-exclusion chromatography (data not shown), indicating that the details of the 
hNatA/Naa50 interaction have diverged over evolutionary time. This was further 
validated using differential scanning fluorimetry experiments, where we found that the 
addition of SpNaa50 to SpNatA and hNaa50 to hNatA had thermal melting temperature 
increases of 37.8 °C to 40.4 °C and 44 °C to 46.6 °C, respectively; while the addition of 
hNaa50 to SpNatA had a thermal melting temperature of 37.5 °C, very close to SpNatA 
alone (Figure 2.1C). Notably, SpNaa50 significantly extended the melting temperature 
of ScNatA by 7.4°C, further confirming the existence of a conserved robust interaction 







Figure 5.1 NatA and Naa50 form stable complexes in yeast and human 
 (A) Gel filtration elution profiles of Naa50 with NatA in S. pombe (top), human (middle), 
and cross-species between yeast S. pombe and S. cerevisiae (bottom), using a 
SuperdexS200column, with either 200 mM or 1MNaCl in sizing buffer. Coomassie-
stained SDS-PAGE of peak fractions are shown to the right of the chromatograms. (B) 
Fluorescence polarization assays with NatA titrated into fluorescein-5-maleimide-labeled 
Naa50 in both S. pombe (left) and human (right) systems. The data are fit to calculate a 
dissociation constant between NatA and Naa50. Errors bars are reported in SD with n = 
3. (C) Differential scanning fluorimetry assays of NatA alone or with Naa50 in both yeast 
and human systems. Recorded melting temperature transitions are indicated. Error bars 
in the figure indicate the SD of each sample, n = 3. 
 
2.2.2 Crystal structure of the ternary NatA/Naa50 complex shows that Naa50 contacts 
both subunits of NatA 
To reveal the molecular basis for the association and regulation mechanism of 
the NatA/Naa50 complex, we determined its crystal structure. We were unable to obtain 
crystals of the human complex, and crystals of the S. pombe complex diffracted X-rays 
poorly. However, we found that full-length ScNaa15 (residues 1–854) from S. cerevisiae 
(Sc) with a C-terminal truncation of ScNaa10 (1–226 out of 238 total residues) and full-
length ScNaa50 (residues 1–176) produced crystals with good diffraction quality, in the 
presence of inositol hexaphosphate (IP6) and bi-substrate analogs for both Naa50 and 
Naa10. The crystals formed in the P212121 space group with one ternary complex in the 
asymmetric unit. The diffraction data set was collected to 2.7 Å resolution, and the 
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structure was determined by molecular replacement with an unpublished ScNatE 
complex (Protein Data Bank code: 4XNH) as an initial search model. The final structure 
was refined to Rwork and Rfree values of 22.21% and 25.03%, respectively. Refinement 
statistics can be found in Table 2.1.  
Not surprisingly, the ScNaa15 auxiliary subunit of NatA displays a high degree of 
structure conservation with SpNaa15 and hNaa15, with root-mean square deviation of 
1.409 Å (over 577 common Cα atoms) and 1.537 Å (over 640 common Cα atoms), 
respectively. Shaped like a horseshoe, ScNaa15 is comprised of 15 TPR motifs, which 
often mediate protein-protein interactions. The electron density for the first two alpha 
helices (N terminal 1-53 residues) is poorly resolved and not built in our model. This 
auxiliary subunit, consisting of a total 42 α-helices, serves as the binding scaffold for 
both catalytic subunits. ScNaa10 is completely wrapped by the Naa15 helices (from α11 
to α30, encompassing residues Lys198- Gly595) with extensive interactions, with an 
overall contact surface area of 3555.5 Å2 (Figure 2.2A). The longest alpha helix is α29, 
expanding to be as long as 70 Å across almost the entire length of the protein. This 
extremely long helix bridges the overall ring-like tertiary structure of Naa15 and locks 
Naa10 into the well-formed cradle made by the surrounding helices. Naa50 sits adjacent 
to Naa10 and interacts mostly with several Naa15 helices (α21, α22, α23, α24, 
encompassing residues Pro380-Asp448), and more modestly with the 2- 3 loop of 
Naa10, with an overall contact surface area of only 632.3 Å2 (Figure 2.2B). 
The significantly less contact surface between Naa50 and Naa15, relative to 
between Naa10 and Naa15, is probably one reason that Naa50 in this ternary complex 
displays surprising flexibility, as indicated by its high average B factor (87.6 Å2) 
compared to Naa10 (48.9 Å2) and Naa15 (56.2 Å2). Several Naa50 residues away from 
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the Naa50-Naa15 interface have poor side chain density and are therefore modeled as 
alanine residues and some parts of α helices and β strands are built as loops. 
Interestingly, the NatA bisubstrate analog used in the cocrystallization could not be 
resolved due to its poor electron density and was therefore omitted from the model, 
while only the CoA portion of the Naa50 bisubstrate inhibitor was well resolved and are 
therefore included in the model.  
Previous studies have revealed that human NatA contains a bound IP6 molecule 
that bridges interactions between helices α19, α24, α25 of hNaa15 and the β2-loop-β3 of 
hNaa10 (Gottlieb and Marmorstein 2018). To identify whether a similar IP6 binding 
pocket exists in ScNatA, IP6 was added to the crystallization of the ternary 
ScNatA/Naa50 complex. Clear electron density for IP6 was visible between Naa10 and 
Naa15, in almost the same position identified in the corresponding human NatA complex 
(data not shown). Extensive electropositive and hydrogen-bond interactions contribute to 
this interaction including K80, Y85, and K91 from Naa10, and K429, K457, R464, R426, 
H430 and Y461 from Naa15 (Figure 2.2C). All these residues in Naa15 are conserved 
from yeast to human, which suggests that this binding mode is structurally conserved. 
We validated the conserved intimate binding of IP6 by also showing its robust binding to 
SpNatA using isothermal titration calorimetry (ITC), measuring a dissociation constant of 







Figure 6.2 Crystal structure of the ternary NatA/Naa50 complex shows that Naa50 
contacts both subunits of NatA 
 (A) ScNaa10 (yellow), ScNaa15 (cyan), and ScNaa50 (violet) are shown in cartoon. The 
N-terminal two alpha helices (residues 1-53) of Naa15 are not resolved and not shown in 
the structure. Several alpha helices of Naa15 that contribute to Naa10 and Naa50 
binding are labeled. (B) Zoom-in view of the interface between Naa50, Naa10 and 
Naa15. Residues that contribute to interactions between Naa10 and Naa50 are shown. 
(C) Zoom-in view showing key residues involved in interactions with IP6. (D) 
Representative isothermal titration calorimetry (ITC) of curve of IP6 titrated into SpNatA 





















2.2.3 Hydrophobic interactions dominate the ScNatAScNaa50 binding interface 
The NatA/Naa50 structure reveals that Naa15 is the primary docking site for 
Naa50. The contact interface is mediated primarily by the Naa50 β2-β3 and β4-α2 loops 
with the Naa15 α22-α23 loop. These regions form a network of hydrophobic interactions 
mediated by several non-polar residues, including Met18, Leu22, Tyr65, Pro70, and 
Val71 from Naa50 and Leu447, Val418, Thr416, Leu417 from Naa15 (Figure 2.3A). A 
few H-bonds are observed: the Naa15 Thr414 sidechain bridges and interaction with the 
side chain of Naa50 Tyr102 and Naa15 His413, and the Naa15 Thr416 sidechain 
interacts with the backbone carbonyl group of Naa50 Pro70 (Figure 2.3A). The largely 
hydrophobic nature of the interface is consistent with our biochemical observation that 
the SpNatA and Naa50 interaction can be maintained under high salt. Importantly, we 
found that the TPTLXE (where X represents either V or I) motif in the Naa15 α20-α21 
loop is highly conserved in both yeast and human, thus suggesting that yeast and 
human share a similar NatA-Naa50 binding mode. 
Unlike Naa10, which is surrounded on all sides by interactions with Naa15 helical 
segments, thereby locking Naa10 in place, contacts between Naa50 and Naa10 are 
more modest and mediated by the α3-β4 loop of Naa10. Specifically, contact between 
Naa10 and Naa50 involves several basic residues within the α3-β4 loop of Naa10 
(Arg122, Arg125 and Arg126) and Glu68 within the β2-β3 of Naa50, which make a 
network of electrostatic interactions (Figure 2.3B). The distance of Glu68 to Arg122, 
Arg125 and Arg126 is 2.3 Å,3.8 Å, and 6.2 Å, respectively.  The relative paucity of 
Naa50-NatA interactions likely allows Naa50 to be conformationally flexible to allow it to 
impose regulatory effects on Naa10 activity. Supporting this notion is the fact that Naa10 







Figure 7.3 Hydrophobic interactions dominate the ScNatA-ScNaa50 binding 
interface 
 (A) Zoom-in view of the major hydrophobic binding interface between Naa15 and Naa50 
with residues that participate in interaction shown. (B) Zoom-in view of the contacts 
between Naa10 and Naa50 with residues that participate in interaction shown. 
 
2.2.4 The NatA/Naa50 complex promotes catalytic crosstalk 
Since deletion of ScNaa50 shows no phenotype (Gautschi et al. 2003), while 
Naa50 knockout in higher organisms has been shown to perturb sister chromatid 
cohesion (Hou et al. 2007; Chu et al. 2011; Ribeiro et al. 2016) and NatA acetylation 
activity in vivo (Rathore et al. 2016), we hypothesized that there might be fundamental 
functional differences in the catalytic properties of Naa50 within the NatA/Naa50 
complexes in yeast and human. To test this hypothesis, we took advantage of the fact 
that NatA and Naa50 have distinct substrate preferences. Canonical NatA substrates 
include peptides with the first four amino acids of SASE (Arnesen et al. 2009; Liszczak 
et al. 2013) (hereinafter called “SASE peptide”) and Naa50 substrates include peptides 
with the first four amino acids MLGP (Liszczak, Arnesen, and Marmorstein 2011; Evjenth 
et al. 2009) (hereinafter called “MLGP peptide”). These peptides were used because of 
their high specificity by their cognate NATs. For our kinetic analysis, we ignored any 
background activity contribution of NatA toward MLGP peptide and Naa50 toward SASE 
peptide, based on our data that NatA has negligible activity towards an MLGP peptide 
(Figure 2.7) and previously published data showing that Naa50 has negligible activity 




We found that hNaa50, either alone or in complex with hNatA, harbored robust in 
vitro acetylation activity toward the Naa50 cognate peptide, MLGP (Figure 2.4A). Unlike 
hNaa50, we found that both SpNaa50 alone or with SpNatA, and ScNaa50 alone or with 
ScNatA, were enzymatically inactive toward the MLGP peptide (Figure 2.4A), consistent 
with the reported lack of in vivo phenotype of ScNaa50 deletion (Gautschi et al. 2003). 
Notably, we found that that hNaa50 activity was significantly promoted within the ternary 
hNatA/Naa50 complex (Figure 2.4B). Indeed, kinetic analysis as a function of peptide 
substrate demonstrated that hNaa50 harbored a 14-fold decrease in Km value and 11-
fold increase of catalytic efficiency when bound to hNatA (Figure 2.4B, Table 2.2). The 
dramatic change in Km value suggested that either hNaa15 or hNaa10 can affect 
hsNaa50 activity by increasing its substrate binding affinity.   
We also investigated the effect of Naa50 binding on hNatA activity towards its 
cognate SASE peptide in both the yeast and human systems. We observed that hNatA 
showed about a 2.29-fold decrease of Km value and 1.75-fold decrease of Vmax when it 
bound to hNaa50 (Figure 2.4C, Table 2.2). Similarly, we found that SpNatA showed 
about a 2.45-fold decrease of Km value and 1.60-fold decrease of Vmax when bound to 
SpNaa50 (Figure 2.4D, Table 2.2). Overall, SpNatA and hNatA showed comparably 
significant but modest increases in catalytic efficiencies of 1.53-fold and 1.31-fold, 
respectively. It is noteworthy that both the Naa10 catalytic subunit of the NatA complex 
and hNaa50 display a lower Km for peptide when in the ternary complex, while SpNaa10 
also displays a lower Km in the yeast complex. Taken together, we conclude that the 
acetylation activities of both catalytic subunits- Naa10 and Naa50 are promoted in this 
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ternary human NatA/Naa50 complex and Naa10 activity is more modestly promoted in 
the S. pombe complex.  
 
Figure 8.4 The NatA/Naa50 complex promotes catalytic crosstalk 
 (A) Time course acetylation activity of SpNaa50, SpNatA/Naa50, hNaa50, 
hNatA/Naa50, ScNaa50 and ScNatA/Naa50 against the MLGP peptide substrate. (B) 
Michaelis–Menten kinetic curve of hNaa50 and hNatA/Naa50 against the MLGP peptide 
substrate. (C) Michaelis–Menten kinetic curve of hNatA and hNatA/Naa50 against the 
SASE peptide substrate. (D) Michaelis–Menten kinetic curve of SpNatA and 







Table 3.2 Catalytic parameters for NatA, Naa50, and NatA/Naa50 











2.2.5 Narrow substrate binding sites likely contribute to the catalytic inactivity of yeast 
Naa50s 
Since we were unable to observe catalytic activity for SpNaa50 and ScNaa50, 
we were surprised to observe electron density in the ScNaa50 active site that could be 
used to model the acetyl-CoA portion of the acetyl-CoA-MLGP bisubstrate inhibitor that 
was used in the cocrystallization. Moreover, sequence alignment of Naa50 in human and 
yeast reveals that SpNaa50 and ScNaa50 do not contain an optimal Q/RxxGxG/A 
consensus acetyl-CoA binding motif, where in both SpNaa50 and ScNaa50 the first 
glycine residue is replaced with a serine residue. Using ITC, we were able to detect 
acetyl-CoA binding to hNaa50 (Figure 2.5A) but not to SpNaa50 (Figure 2.5B). We also 
observed that the SpNatA/Naa50 complex bound acetyl-CoA about 4.5-fold more 
strongly than SpNatA alone (Figures 2.5C and 2.5D). Given that SpNaa50 alone 
binding is not detected in ITC, we propose that the 4.5-fold increase in acetyl-CoA 
binding affinity for SpNatA/Naa50 relative to SpNatA alone suggests that SpNaa50 
binding to SpNatA facilitates acetyl-CoA binding activity to SpNatA. This is consistent 
with our structural observation that ScNaa50 sits closely to the Q/RxxGxG/A acetyl-CoA 
binding motif of ScNaa10, and thereby able to modulate the acetyl-CoA binding activity 
of ScNatA. Surprisingly, binding signal was detected by ITC between GST-ScNaa50 and 
acetyl-CoA (Figure 2.5E), but not the free GST or GST-SpNaa50 controls (Figure 2.5F 
and 2.5G). This result suggests that the lack of acetyltransferase activity of ScNaa50 is 
unlikely due to a defect in acetyl CoA binding.  
Consistent with the catalytic inactivity of SpNaa50 and ScNaa50, we found that 
the α1-α2 and β6-β7 loops of ScNaa50 that typically flank the peptide substrate, form a 
much narrower groove compared to hNaa50 for peptide binding, with the most intimate 
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distance between the loops of less than 2.8 Å (Figure 2.5H). In addition, both SpNaa50 
and ScNaa50 lack the characteristic YY motif found in the β6- β7 loop which is important 
for substrate binding in all NATs except for Naa40 and Naa80 (Liszczak et al. 2013; 
Liszczak, Arnesen, and Marmorstein 2011; Magin, Liszczak, and Marmorstein 2015; 
Goris et al. 2018; Hong et al. 2017; Aksnes et al. 2015). Taken together, it appears that 
the acetyl-CoA and N-terminal peptide substrate binding sites of SpNaa50 are not 
properly configured for catalytic activity, while ScNaa50 binds acetyl-CoA but likely does 






Figure 9.5 Weak acetyl-CoA binding activity and a narrow substrate binding grove 
contributes to the catalytic inactivity of yeast Naa50 
 (A) Representative ITC curve of acetyl-CoA titrated into hNaa50. (B) Representative 
ITC curve of acetyl-CoA titrated into SpNaa50. (C) Representative ITC curve of acetyl-
CoA titrated into SpNatA. The calculated dissociation constant is indicated. (D) 
Representative ITC curve of acetyl-CoA titrated into SpNatA/Naa50. The calculated 
dissociation constant is indicated. (E) Representative ITC curve of acetyl-CoA titrated 
into GST-ScNaa50. (F) Representative ITC curve of acetyl-CoA titrated into GST-
SpNaa50. (G) Representative ITC curve of acetyl-CoA titrated into free GST. (H) 
Superimposition of ScNaa50 and hNaa50 (PDB: 3TFY) structures. 
 
2.2.6 NatA-Naa50 from yeast and human make conserved interactions 
To evaluate the degree of evolutionary conservation of the NatA-Naa50 interface, 
we first used the ScNatA/Naa50 complex as a scaffold to carry out mutagenesis and 
binding studies of the yeast NatA/Naa50 complex, using S. pombe for mutagenesis for 
consistency with the earlier biochemical studies in S. pombe. Superimposition of the 
ScNatA/Naa50 and SpNatA structures highlighted a few potential key S. pombe 
candidate residues for interaction, including SpNaa10 R117, SpNaa15 T412, and 
SpNaa50 Y49 and V53 (Figures 2.3). Using pull-down assays, we demonstrated that 
SpNaa10-R117E had an insignificant effect on SpNatA binding, while SpNaa50-V53K 
and -Y49A displayed some decrease in SpNatA binding (Figure 2.6A, left). As 
expected, the double mutation, SpNaa50- Y49A/V53K was significantly defective in 
SpNatA and ScNatA binding (Figure 2.6A). As these two residues are conserved from 
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yeast to human, it was not surprising that the double mutation of hNaa50-Y50A/I54K 
displayed similar defects in hNatA binding. The ScNatA/Naa50 crystal structure reveals 
that ScNatA-T412 sits roughly in the middle position of the conserved Naa15 TPTLXE 
motif and is located in the center of the binding interface within Naa15 and Naa50 
(Figure 2.3A). Interestingly, we found that a single SpNaa15-T412 mutation to either 
tyrosine or lysine completely disrupted complex formation with SpNaa50 (Figure 2.6A). 
As expected, sequence alignment demonstrates that SpNaa15-T412 is well conserved 
in both human and yeast. We further observed that both ScNaa15-T416Y and hNaa15-
T406Y (hereinafter referred to as TY mutants) lost their ability to association with Naa50 
in pull down assays (Figure 2.6A). Consistent with the pull-down results (Figure 2.6A), 
the Naa15 TY mutant from S. pombe, S. cerevisiae and human did not co-migrate with 
Naa50 by size-exclusion chromatography (Figure 2.6B). For further studies, we focused 
on SpNatA T412Y and the conserved hNatA T406Y and characterized their roles in 
NatA-Naa50 association. While the addition of Naa50 to NatA showed robust binding 
using a FP assay (Figure 2.1A) and increased thermal melting temperature of NatA by 
about 2.5 °C using DSF assay (Figure 2.1B), addition of Naa50 to the NatA TY mutants 
did not show detectable binding (Figure 2.7A) or increase in NatA TY mutant thermal 
melting temperature (Figure 2.7B). We further tested the effect of the NatA TY mutants 
on NatA acetylation activity and found that they maintained acetylation activity towards 
cognate substrates although the hNatA TY mutant showed an apparent increase in 
acetylation activity relative to WT (Figure 2.7C). The reason for this is unclear. Taken 
together, the Naa15 TY mutants can disrupt the association between NatA and Naa50 in 
yeast and human. These studies highlight the important roles of this conserve threonine 




Figure 10.6 NatA TY mutants are unable to pull-down Naa50 and co-migrate with 
Naa50 
 (A) GST pull-down assay with NatA/Naa50 mutants to interrogate the contribution of 
residues in Naa50-NatA association. (B) Gel filtration elution profiles of Naa50 with 
either wild-type (dotted red line taken from Figure 1A) or TY mutants (blue line) of NatA 
using a Superdex S200 column. Coomassie-stained SDS–PAGE of peak fractions of 




Figure 11.7 NatA TY mutants disrupt NatA/Naa50 complex interactions 
 (A) Fluorescence polarization assays of NatA TY mutants and Naa50 in S. pombe and 
human. (B) Differential scanning fluorimetry assays of NatA TY mutants with and without 
Naa50. Recorded melting temperature transitions are indicated. (C) Comparison of 
acetylation activity of NatA wild-type and TY mutants. Activities are normalized to WT 
protein activity level. 
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2.3 Discussion  
While the molecular basis for acetylation activity by either NatA or Naa50 
independently has been previously described, the underlying molecular mechanism of 
how these enzymes work in complex was poorly understood before this study. Although 
similar to an unpublished structure of ScNatE that has been deposited in the PDB 
(4XNH), our reported crystal structure of the ScNatA/Naa50 complex in combination with 
related biochemical data provides a peer reviewed and comprehensive analysis of the 
structure and mechanism of acetylation by the N-terminal dual enzyme NatA/Naa50 
complex across evolution. Overall, the Naa50 electron density is poorly resolved relative 
to NatA, which suggested that its association with NatA is likely dynamic. Indeed, the 
major contact region between Naa50 and Naa15 is mediated by loop-loop interactions, 
unlike the extensive interactions made between Naa10 and Naa15 within the NatA 
complex. We also found that ScNaa50 makes direct electrostatic interactions with 
Naa10, providing a path of contact for Naa10 and Naa50 to influence each other’s 
catalytic functions. 
Because of their conserved association motif, the hNaa50 docking site on 
hNaa15 could be identified, and was further supported by mutational analysis. We 
propose that the proper distance between Naa10 and Naa50 that is required for cognate 
acetylation of N-terminal protein substrates by the respective NATs, coupled to the less 
rigid positioning of Naa50, relative to Naa10, may allow Naa50 to adopt multiple 
conformations within the NatE complex to facilitate both Naa50 and Naa10 cognate 
substrate binding. Indeed, we found that hNaa50 and hNatA displayed significant 
enhancement in substrate affinity and catalytic efficiency in the context of the complex, 
although such enhancement was not observed in the yeast complex, where we found 
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that Naa50 is catalytically defective. This is consistent with our structural data showing 
that unlike Naa10, Naa50 harbors a narrow substrate binding site that is incompatible 
with N-terminal protein substrate binding. However, we cannot exclude the possibility 
that yeast Naa50 is enzymatically active against another substrate. Regardless, our 
findings suggest some evolutionary divergence between yeast and human NatE 
complexes. Nonetheless, we also found that SpNaa50 does not bind human NatA and 
vice versa, yet from conservation analysis there is no obvious reason why this should be 
the case. There may be subtle differences in the yeast and human systems that have co 
evolved, perhaps to reflect the regulatory role of the HYPK protein in the human but not 
S. pombe and S. cerevisiae yeast systems (Arnesen et al. 2009). 
Based on our in vitro activity data, it is noteworthy that both human Naa10 and 
Naa50 catalytic subunits display lower Km values for their respective peptide substrates 
and increased catalytic efficiencies, when they are in the NatA/Naa50 relative to when 
they are not in complex. Meanwhile, we observed that the other substrate, acetyl-CoA, 
while not showing detectable binding to SpNaa50, binds to SpNatA/Naa50 about 4.5-fold 
tighter than SpNatA alone. It is likely that SpNaa50 facilitates acetyl-CoA binding to 
SpNatA and the structural observation that ScNaa50 sits closely to the Q/RxxGxG/A 
acetyl-CoA binding motif of ScNaa10 provides a plausible explanation for how SpNaa50 
may modulate the acetyl-CoA binding activity of SpNatA. Taken together, we conclude 
that in human, NatA and Naa50 have cooperative effects on their acetylation activities 
when associating together, while in yeast, the inactive Naa50 still contributes to NatA 
activity, which is consistent with previous result that reduction of some NatA type N-
termini was detected in yeast Naa50 deletion mutants (Van Damme et al. 2015) We note 
that the cooperative effects between NatA and Naa50 that we observed in vitro are 
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based only on single cognate NatA and Naa50 peptide substrates. It is currently 
unknown if the degree of cooperation varies with different peptide substrates.  
One surprising aspect of the ScNatA/Naa50 structure is the identification of 
Inositol hexaphosphate (IP6), which bridges interactions between the Naa10 and Naa15 
subunits of NatA with a dissociation constant in the sub-mircomolar range. A similar role 
for IP6 was identified in the recently reported hNatA/HYPK complex (Gottlieb and 
Marmorstein 2018), suggesting an evolutionarily conserved role of IP6 in stabilizing the 
NatA complex. Since IP6 has long been appreciated to have many signaling properties in 
diverse organisms including yeast and mammals (Kalam Shamsuddin and Bose 2012), it 
is also possible that IP6 may have a yet unidentified signaling role in NatA function.  
HYPK is an important regulatory protein that binds to hNatA but is not conserved 
in S. pombe or S. cerevisiae. Recent structural studies suggest that HYPK was a 
nanomolar dissociation constant NatA binding partner and that HYPK binding likely 
inhibits Naa50 binding (Weyer et al. 2017; Gottlieb and Marmorstein 2018). Here we 
have demonstrated that hNaa50 can promote hNatA acetylation activity. We propose 
that the slightly divergent association mechanism between NatA and Naa50 in yeast and 
human may be related to the presence of HYPK in human and higher eukaryotes but not 
in most yeast. It will be of interest to further investigate the interplay among these 
binding partners within the tetrameric human NatA/Naa50/HYPK complex.   
We find in our study that SpNaa50 is catalytically inactive, and this is likely due to 
its reduced affinity for acetyl-CoA and the relative narrowness of the peptide substrate 
binding site of ScNaa50 observed in the ScNatA/Naa50 structure. Surprisingly, we 
observed binding between ScNaa50 and acetyl-CoA, although the optimal acetyl-CoA 
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binding motif is missing in both ScNaa50 and SpNaa50. Nonetheless, both ScNaa50 
and SpNaa50 are catalytically inactive in out acetyltransferase assays. We propose that 
the yeast lineage lost catalytically active Naa50 at least due to the lack of peptide 
substrate binding. Indeed, unlike metazoans, ScNaa50 knock out displays no phenotype 
(Gautschi et al. 2003). In another study, no impact on Met-starting yeast N-termini was 
observed where yeast Naa50 was deleted (Van Damme et al. 2015). Meanwhile, Naa50 
has functional roles in sister chromatic cohesion in higher organism, independent of the 
NatA complex, which is not observed in yeast (Rong et al. 2016; Ribeiro et al. 2016; 
Williams et al. 2003). Thus, yeast Naa50 is very likely enzymatically inactive, only 
providing extra stability and regulatory roles for NatA, including participation in ribosome 
binding (see below). We propose that Naa50 substrates are processed by NatC, which 
recognizes a similar cognate sequence. 
A recent Cryo-EM structure of a native ScNatA/Naa50-ribosome structure, where 
the ribosome is resolved to 3.4 Å and the NatA/Naa50 portion is resolved to about 8 Å 
resolution, indicates that NatA/Naa50 associates with the ribosome through interaction 
with the ribosomal RNA expansion segments involving predominantly Naa15, but also 
Naa50 (Knorr et al. 2019). While Naa10 is positioned proximal to the ribosome peptide 
exit tunnel, Naa50 is remote from the peptide exit tunnel. A docking of our 2.7 Å 
resolution NatE structure onto the Cryo-EM structure (PDB: 6HD7) provides a pseudo-
3.4 Å resolution structure of the NatE-ribosome complex (Figure 2.8). This superposition 
reveals that Naa50 is positioned ~80 Å away from the peptide exit tunnel of the 
ribosome, consistent with the finding of Knorr et al. that approximates this distance to be 
~ 85 Å (Knorr et al. 2019). As this observation suggests that peptides emerging from the 
ribosome exit tunnel encounter the Naa10 active site prior to the Naa50 active site, we 
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speculate that it is likely that Naa50 requires a longer nascent chain for acetylation. 
However, we found that SpNaa50 binding slightly promotes SpNatA acetylation catalytic 
efficiency. This effect could be more significant in the context of the ribosome, given that 
Knorr et al. observe that Naa50 makes contact to the ribosome RNA expansion 
segment, thus also playing a role in NatA recruitment to the ribosome. Such a 
contribution to NatA-ribosome recruitment by Naa50 is consistent with a recent 
observation that D. melanogaster Naa50 knockout impairs NatA acetylation activity in 
vivo (Rathore et al. 2016). We placed the Naa10 acetyl CoA binding site by overlapping 
our structure to the SpNatA structure in complex with bi-substrate analogue 
(PDB:4KVM) and found that the acetyl-CoA binding sites for both Naa10 and Naa50 are 
oriented in the same direction and facing the ribosome nascent peptide exit tunnel and 
separated by a distance of only 26.6 Å (Figure 2.8). It is likely that the relative position of 
these two catalytic subunits, Naa10 and Naa50, might change on the ribosome to 
accommodate the cognate peptide substrate that emerges out of the ribosome exit 
tunnel. We propose that the flexibility of the hNatA-Naa50 interface (as suggested by the 
relatively high B-factor of Naa50 relative to NatA) may also facilitate movement of Naa50 
closer to the ribosome exit tunnel once its cognate substrate is in proximity for N-
terminal acetylation. This might be facilitated further if human Naa50 did not participate 
in NatA anchoring to the ribosome as it does in the yeast system. Additional interactions 
might be compensated through the binding of HYPK.  
Taken together, our biochemical and structural characterization of ternary 
NatA/Naa50 complexes in yeast and human in this study has provided new and 
significant insights into the association and regulatory mechanism of this unusual dual 
enzyme system. These studies set the stage for future studies to decipher the molecular 
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mechanism of the human NatA/Naa50/HYPK complex.  In addition, our identification of 
mutants that prevent NatA/Naa50 association in yeast and humans will facilitate analysis 
of the uncoupling of co- and post-translational protein acetylation by Naa50. 
 
Figure 12.8 Docking of our ScNatA/Naa50 crystal structure onto the ribosome-
NatA/Naa50 Cryo-EM structure 
The ScNatA/Naa50 crystal structure is aligned to the NatA/Naa50-ribosome structure 
(PDB: 6HD7). The magnified view shows that Naa10 is most proximal to the ribosome 
peptide exit tunnel, while the acetyl-CoA binding sites of Naa10 and Naa50 are facing 




2.4 Materials and methods 
2.4.1 NatA and Naa50 expression and purification 
Human NatA (hNatA), human Naa50 (hNaa50), and Schizosaccharomyces 
pombe NatA (SpNatA) were expressed and purified as described previously (Liszczak et 
al. 2013; 2018; Liszczak, Arnesen, and Marmorstein 2011). Full-length 
Schizosaccharomyces pombe Naa50 (spNaa50) was cloned into pRSF with a N-terminal 
GST fusion, and expressed and purified with the same method as described for spNatA 
(Liszczak et al. 2013). Full-length Saccharomyces cerevisiae Naa15 (ScNaa15) was 
cloned into pRSF_Duet vector with a N terminal PolyHis tag and a Tobacco Etch Virus 
(TEV) cleavage site. C-terminal truncated ScNaa10 (1-226) with no tag was cloned into 
pET_Duet, and un-tagged full-length ScNaa50 was cloned into pCDF-Duet. To express 
the ternary ScNaa10-ScNaa15-ScNaa50 complex (ScNatA/Naa50 complex), these three 
plasmids were co-transformed into Rosetta (DE3)pLysS competent E. coli cells, which 
were grown to an OD600 of 1 and induced with 0.5 mM of Isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 16 °C for ~16 h. ScNatA/Naa50 complex purification 
procedure was modified from SpNatA as described (Liszczak et al. 2013). Cells were 
isolated by centrifugation for 20 mins at 4500 rpm and lysed by sonication in a buffer 
containing 25 mM Tris, pH 8.0, 500 mM NaCl, 0.1 mg/mL PMSF. After centrifugation, the 
supernatant was isolated and passed over Ni-resin (Thermo Scientific), which was 
subsequently washed with 10 column volumes of lysis buffer supplemented with 25 mM 
imidazole and 10 mM 2-mercaptoethanol. Protein was eluted with 300 mM imidazole 
and dialyzed into buffer containing 25 mM sodium citrate monobasic, pH 5.5, 10 mM 
NaCl and 10 mM 2-mercaptoethanol. Protein was purified with a 5-mL HiTrap SP ion-
exchange column and eluted in a salt gradient (10–700 mM NaCl). Peak fractions were 
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concentrated to ~ 0.5 mL with a 100-kDa concentrator (Amicon Ultra, Millipore), and 
loaded onto an S200 gel-filtration column (GE Healthcare) in a buffer containing 25 mM 
HEPES, pH 7.0, 200 mM NaCl, 5% glycerol and 1 mM TCEP. Proteins were aliquoted, 
snap-frozen in liquid nitrogen, and stored at −80 °C for further use. Full-length ScNaa50 
was cloned into pRSF with a N-terminal GST tag and a TEV cleavage site, to express 
and purify ScNaa50 alone. We observed that ScNaa50 was not stable in the absence of 
the GST tag and absorbs minimally at 280 nm. We therefore only worked with GST-
ScNaa50 in biochemical experiments. GST-ScNaa50 was purified using the same 
method as described above. Concentrations of hNatA, hNaa50, SpNatA, SpNaa50, 
ScNatA/Naa50 and GST-ScNaa50 were determined by absorbance at 280 nm and using 
their extinction coefficient of 132,480 cm-1M-1,13,410 cm-1M-1, 120,000 cm-1M-1, 14,440 
cm-1M-1, 151,800 cm-1M-1, and 58,790 cm-1M-1, respectively. All protein mutants were 
generated using the QuikChange protocol from Stratagene and obtained following the 
expression and purification protocols described above. 
 
2.4.2 Fluorescence polarization (FP) assays 
There are five cysteine residues present in SpNaa50 (Cys22, Cys54, Cys60, and 
Cys96) and four cysteine residues in hNaa50 (Cys60, Cys61, Cys79, and Cys100). We 
found that we did not have to make mutations to obtain the fluorescein labeled Naa50, 
which suggested that at least one cysteine in each is exposed to solvent. 25-fold excess 
of Fluorescein-5-Maleimide (ThermoFisher) was added into about 100 μL of 1 mg/ml 
purified hNaa50 or SpNaa50 in sizing buffer. The reaction was quenched with 2-
mercaptoethanol after overnight incubation at 4°C. Excess Fluorescein-5-Maleimide was 
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removed by S75 gel-filtration chromatography. To run the assays,10 nM of labeled 
Naa50 was used in all reactions, and NatA concentrations were varied to determine the 
dissociation constant (Kd). 5 mg/mL BSA and 0.2% v/v Tween were added into the 
reaction buffer (25 mM HEPES, pH 7.0, 200 mM NaCl and 10 mM DTT) to prevent non-
specific binding. FP readings were recorded with a Perkin Elmer EnVision and each 
curve was repeated in triplicate. GraphPad Prism, version 5.01, was used for all data 
fitting. Errors were reported in SD with n = 3. 
 
2.4.3 Acetyltransferase activity assays 
All the acetyltransferase assays were performed essentially as previously 
described (Liszczak et al. 2013; Liszczak, Arnesen, and Marmorstein 2011) and carried 
out at room temperature in the reaction buffer containing 75 mM HEPES, pH 7.0, 120 
mM NaCl, 1 mM DTT. The SASE substrate peptide (NH2-
SASEAGVRWGRPVGRRRRP-COOH; GenScript) and the MLGP substrate peptide 
(NH2-MLGPEGGRWGRPVGRRRRP-COOH; GenScript) were used to determine the 
enzymatic activity of NatA and Naa50, respectively. For Naa50 activity test in time 
course manner, 500 nM of SpNaa50, SpNatA/SpNaa50, hNaa50, hNatA/hNaa50, 
ScNaa50, and ScNatA/Naa50 were mixed with 300 μM of C14 labeled acetyl-CoA (4 mCi 
mmol−1; PerkinElmer Life Sciences), 500 μM MLGP peptide in a 100 μL reaction. To 
quench the reaction at specific time, 15 µL of the reaction mixture was added to P81 
paper discs (Whatman), and the paper discs were immediately placed in wash buffer 
with 10 mM HEPES, pH 7.5. Unreacted acetyl CoA should be removed by washing at 
least three times. Paper discs was then dried with acetone and mixed with 4 scintillation 
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fluid for signal measurement by a Packard Tri-Carb 1500 liquid scintillation analyzer. 
Data was plotted with GraphPad Prism, version 5.01. To determine steady-state catalytic 
parameters, enzymes were mixed with 500 µM C14 labeled acetyl-CoA and 
corresponding peptide substrate concentration was varied. 20 µL reaction were 
performed but only 15 µL reaction mixture was quenched onto the paper discs after 
specific time. For hNaa50 and hNatA/hNaa50 against MLGP peptide, 300 nM enzyme 
was used in 40-minute reaction. For hNatA and hNatA/hNaa50 against SASE peptide, 
100 nM enzyme was used in 12-minute reaction. For SpNatA and SpNatA/SpNaa50 
against SASE peptide, 50 nM enzyme was used in 10-minute reaction. Paper discs 
washes and signal reading steps were performed in the same manner as mentioned 
above. GraphPad Prism, version 5.01, was used for all kinetic data fitting to the 
Michaelis–Menten equation. Each curve was repeated at least 3 times. In NatA TY 
mutant activity tests, 100 nM of SpNatA, SpNatA-T412Y, hNatA, hNatA-T406Y were 
mixed with 300 μM of C14 labeled acetyl-CoA and 500 μM peptide substrate for a 30-
minutes reaction. Signals were normalized to the WT activity, and errors were reported 
in SEM with n = 3. 
2.4.4 Size exclusion chromatography assays 
A total of 500 μl of purified NatA (4.2 µM) and purified Naa50 (12.6 µM) was 
injected onto a S200 gel-filtration column (GE Healthcare). UV absorbance values were 
normalized to the maximum value at first elution peak, then plotted against the elution 
volume in GraphPad Prism, version 5.01. Only elution volume around two peaks were 
shown in the figure. Corresponding peak fractions were run on SDS-PAGE and stained 




2.4.5 GST pull-down assays 
1 µM of GST tagged Naa50 and 5 µM of NatA was incubate with 50 µL of 
glutathione agarose resin at 4 °C for 1 hour in reaction buffer containing 25 mM HEPES, 
pH 7.0, 200 mM NaCl and 1 mM TCEP. Resin was then washed extensively with the 
same buffer and eluted with glutathione. Samples were collected for analysis on SDS-
PAGE. 
  
2.4.6 Differential scanning fluorimetry assays 
Sypro Orange (5000X stock, ThermoFisher Scientific) was diluted 1:200 and 4 µL 
was mixed with 16 µL solution with 5 µM NatA and 5 µM Naa50 in sizing buffer. 
Fluorescent readings were recorded using a qPCR (ABI 7900 RealTime PCR) with a 2% 
ramp rate, while heated from 20 °C to 95 °C. Melting curves were generated from these 
readings and melting temperatures were determined by taking the first derivative of the 
curves. DSF scans of all samples were performed in triplicates. Error bars in the figure 
indicated the SD of each sample. 
 
2.4.7 ITC measurements 
Measurements were recorded on a MicroCal iTC200 at 20 °C. Samples were 
dialyzed into buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl, 1 mM DTT. Protein 
samples (SpNaa50, SpNatA, SpNatA/Naa50, GST-SpNaa50, GST-ScNaa50, GST) with 
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concentrations of 50 μM in the cell and 1mM of acetyl-CoA in the syringe were used in 
the experiments.  For hNaa50, 100 μM protein and 0.5 mM of acetyl-CoA were used. 
The raw data was analyzed with MicroCal ITC analysis software. 
 
2.4.8 ScNatA/Naa50 crystallization and data collection 
Ternary ScNatA/Naa50 complex was mixed with 3 molar excess of NatA 
bisubstrate inhibitor (CoA-SASEA), Naa50 bisubstrate inhibitor (CoA-MLGPE) and IP6. 
Bisubstrate inhibitors were prepared as previously described (Liszczak et al. 2013). 
Crystals were grown within ~3 days by hanging drop vapor diffusion at 20 °C at 7.5 
mg/ml, using one to one drop ratios against reservoir solution containing 10% PEG 
3350, 0.1 M Sodium Malonate (pH 5.0). Crystals were transferred into mother liquor 
supplemented with 25% glycerol and flash-frozen in liquid nitrogen. Data were collected 
at the Advanced Photon Source (beamline 24-ID-C) and processed using HKL2000 
(Otwinowski and Minor 1997). 
 
2.4.9 ScNatA/Naa50 structure determination and refinement 
The collected diffraction data showed strong anisotropy and ellipsoidal truncation 
and anisotropic scaling was performed (Strong et al. 2006). The resolution limit along a*, 
b*, c* are 2.7 Å, 3.4 Å, 2.7 Å, respectively. The crystal structure of ScNatA/Naa50 was 
determined by molecular replacement using a structure of unpublished ScNatE (PDB ID 
Code: 4XNH) without ligand or solvent molecules as a search model. Molecular 




Initial Manual model building was done in Coot (Emsley and Cowtan 2004) and 
all subsequent rounds of refinement were performed using Phenix refine and Coot 
interchangeably. Refinement statistics can be found in Table 2.1. The final model and 
structure factors were submitted to the Protein Data Bank with code 6O07 (Research 
Collaboratory for Structural Bioinformatics). 
Distance calculations, as well as three-dimensional alignment r.m.s. deviations 
and graphics were generated in PyMOL (http:// www.pymol.org/) 
Sequence alignments in the manuscript were performed using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) and visualized using ESPript 3.0 (Robert and 
Gouet 2014a) (http://espript.ibcp.fr/ESPript/ESPript/) 
All surface area calculations were performed using PDBePISA (Proteins, 



















CHAPTER 3: Molecular Basis for N-terminal Acetylation by Human NatE and Its 














About one-half of the human N-terminal acetylome is mediated by hNatA. 
Mutations in either the NAA10 catalytic or NAA15 auxiliary subunits have been 
correlated with a broad spectrum of pathologies including intellectual disabilities, 
developmental delay, autism spectrum disorders, craniofacial dysmorphology, congenital 
cardiac anomalies and Ogden syndrome (Dorfel and Lyon 2015; Lee et al. 2010; Yoon 
et al. 2014; Saunier et al. 2016; Popp et al. 2015; Esmailpour et al. 2014; Casey et al. 
2015; Cheng et al. 2019; Ree et al. 2019; Rope et al. 2011).  Aberrant NatA activity has 
also been correlated with neurodegenerative disorders and cancer although a causative 
role of NatA is less clear (Kalvik and Arnesen 2013). NatA forms complexes with at least 
two other proteins, NAA50 and the chaperone protein Huntingtin interacting protein K 
(HYPK) (Arnesen et al. 2010; Gautschi et al. 2003; Arnesen, Anderson, et al. 2006; 
Liszczak et al. 2013; Weyer et al. 2017). The trimeric hNAA10/hNAA15/hNAA50 
complex is referred to as hNatE, and we refer to the tetrameric 
hNAA10/hNAA15/hNAA50/HYPK complex as hNatE/HYPK. Previous studies have 
demonstrated that HYPK may be important for cellular NatA activity and that NAA50 and 
NatA can affect each other’s function (Weyer et al. 2017; Arnesen et al. 2010; Gottlieb 
and Marmorstein 2018; Rathore et al. 2016; Deng et al. 2019). Previous studies also 
demonstrated that hNatA can physically associate with hNAA50 (Gautschi et al. 2003) 
and HYPK (Arnesen et al. 2010), separately. Moreover, the crystal structures of hNatA 
with HYPK and related pull-down experiments indicated that HYPK and hNAA50 binding 
to hNatA might be mutually exclusive (Gottlieb and Marmorstein 2018). However, 
another study suggested that HYPK and NatE form a tetrameric complex in Drosophila 
cells (Rathore et al. 2016).  
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To delineate the mechanistic basis for how the NAA10 and NAA50 catalytic 
subunits of the NatE complex coordinate function and how this is regulated by HYPK, we 
characterized the human NatE and NatE/HYPK complexes biochemically, structurally 
and in cells. We show that NAA50 and HYPK exhibit negative cooperative binding to 
NatA in vitro and in human cells, by inducing NAA15 shifts in opposing directions. We 
show that NAA50 and HYPK both mediate NAA10 inhibition through structural alteration 
of the NAA10 substrate binding site. We show that NatE is about 10-fold more active 
than NAA50, likely due to a reduced entropic cost for substrate binding through NatA 
tethering, but is inhibited by HYPK through structural alteration of the NatE substrate 
binding site. Taken together, these studies reveal the molecular basis for coordinated N-
terminal acetylation by the NAA10 and NAA50 catalytic subunits of NatE and its 
modulation by HYPK. 
 
3.2 Results 
3.2.1 hNatE and HYPK form a tetrameric complex 
To determine if human NAA50 and HYPK can simultaneously bind to NatA to 
form a NatE/HYPK complex, we prepared the recombinant hNatA/HYPK complex from 
insect cells and mixed it with recombinant hNAA50 for analysis on size exclusion 
chromatography (Fig. 3.1a – left). Analysis of the peak fractions on SDS-PAGE 
revealed that the four protein components (hNAA10, hNAA15, hNAA50 and HYPK) co-
eluted in a single major peak with excess hNAA50 eluting in later fractions (Fig. 3.1a). 
This result demonstrates that HYPK and hNAA50 can bind to hNatA simultaneously to 




Figure 13.1 HYPK and hNatE form a tetrameric complex 
(a) Left - gel filtration elution profile of the hNatA/HYPK complex with excess hNAA50, 
using a Superdex S200 column. Right - Coomassie-stained SDS-PAGE of peak 
fractions. Red bars indicated the peak of complex. (b) Fluorescence polarization assays 
with either hNatA or hNatA/MBP-HYPK titrated into fluorescein-5-maleimide labeled 
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hNAA50. The data is fit to calculate a dissociation constant (Kd). Replicates were shown 
in the curve with n = 3 independent experiments. Source data are provided as a Source 
Data file. (c) Representative ITC curve of MBP-HYPK titrated into hNatA. The calculated 
dissociation constant is indicated. (d) Representative ITC curve of MBP-HYPK titrated 
into hNatE. (e) The ITC fitting information and calculated dissociation constant (Kd) is 
provided for (c) and (d) curves.  
 
3.2.2 HYPK and hNAA50 display negative cooperative binding to hNatA 
Previous studies demonstrated that both human HYPK and hNAA50 bind 
tightly to hNatA, with dissociation constants in the nanomolar range (Gottlieb and 
Marmorstein 2018; Deng et al. 2019). We set out to determine if the HYPK and 
hNAA50 binding properties to hNatA are altered in the context of the tetrameric 
complex. Using fluorescence polarization (FP) assays, we observed that hNAA50 
bound to hNatA with a Kd of 46 ± 8.8 nM (Fig. 3.1b), consistent with previous 
results. However, in the presence of MBP-HYPK, this binding Kd decreased 
about ~3-fold to 127 ± 13 nM (Fig. 3.1b). This data demonstrates that HYPK can 
negatively affect the stability of the hNatE complex by about 3-fold. Based on this 
data, we hypothesized that in the presence of hNAA50, the binding affinity 
between hNatA and HYPK would also decrease. Using isothermal titration 
calorimetry (ITC), we determined that the Kd between hNatA and MBP-HYPK 
was 29.9± 16.7 nM (Fig. 3.1c), which is consistent with the previously reported 
Kd in the thermophilic fungus Chaetomium thermophilum (Weyer et al. 2017). 
71 
 
The reason for the apparent two-binding transition when HYPK is titrated into 
hNatA is unknown. We further determined the Kd between HYPK and hNatE and 
observed that the affinity was 154 ± 55.3 nM, ~ 5-fold weaker than HYPK binding 
to hNatA (Fig. 3.1d). A control ITC run of MBP titrated into hNatA failed to show 
binding. Taken together, these data indicate that HYPK and NAA50 display 
negative cooperative binding with respect to hNatA.  
 
3.2.3 hNAA50 and HYPK inhibit hNatA activity, and HYPK is dominant 
While our previous studies demonstrated that yeast and human NatA have 
slightly elevated catalytic efficiencies in the presence of NAA50, we set out to make a 
more direct comparison of NatA activity as a function of added NAA50 vs. HYPK. To do 
this, we used an in vitro acetylation assay using a cognate SASE NatA substrate to 
compare the hNatA catalytic activity as a function of added hNAA50 or MBP-HYPK. This 
comparison revealed that while MBP-HYPK showed about 90% inhibition of hNatA 
activity at an MBP-HYPK concentration beyond ~100 nM, hNAA50 only decreased 
hNatA activity by about 50% at concentrations between ~ 100 nM - 1µM (Fig. 3.2a), 
consistent with previous data (Gottlieb and Marmorstein 2018; Deng et al. 2019). 
Titrating both MBP-HYPK and hNAA50 into hNatA showed a similar degree to hNatA 
inhibition as did titrating in MBP-HYPK alone, illustrating that HYPK inhibition of hNatA 




Figure 14.2 HYPK binding negatively affects hNatE acetylation activity 
(a) Either MBP-HYPK (green), hNAA50 (red), or both (blue) are titrated into hNatA 
(100 nM) to evaluate their modulatory effect on hNatA activity against an SASE peptide 
substrate. A best line is drawn through the data points for ease of visualization. Source 
data are provided as a Source Data file. (b) Comparison of time course acetylation 
activity of hNAA50 (black), preformed hNatE (red), and preformed hNatE/HYPK (blue; all 
500 nM) against an MLGP peptide substrate. Source data are provided as a Source 
Data file. (c) hNatA acetylation activity against an SASE peptide with addition of buffer, 
wild type (WT), or hNAA50 mutants. Errors were reported in SEM with n = 3 independent 
experiments. Source data are provided as a Source Data file. (d) Activity of hNAA50 WT 
and mutants against MLGP peptide was tested, either alone (black), in the context of 
73 
 
hNatE (+hNatA; red), or in the context of preformed hNatE/HYPK (+hNatA/HYPK; blue). 
Data were normalized to WT hNatE activity as 100%, represented as mean ± SD, n = 3 
independent experiments.  
 
3.2.4 HYPK inhibits hNatE activity 
Given that HYPK was shown to be a negative regulator for hNatA acetylation 
activity (Weyer et al. 2017; Gottlieb and Marmorstein 2018), we asked if it also inhibited 
the activity hNatE. To do this, we used the same in-vitro acetyltransferase activity assay 
but employed a cognate MLGP hNatE substrate in the absence or presence of HYPK, 
as well as a hNAA50 only control. This analysis revealed that while hNatE was more 
active than hNAA50, this improvement was essentially nullified with the addition of 
HYPK (Figs. 3.2b, 3.2c and 3.2d). A full kinetic analysis of hNAA50, hNatE, and 
hNatE/HYPK revealed the kinetic parameters responsible for this modulation of hNAA50 
function. Specifically, we found that hNatE displayed ~8.6-fold decrease of Km, and ~1.1-
fold decrease of kcat, with an overall ~7.7-fold increase of catalytic efficiency, compared 
to hNAA50 (Table 3.1). These findings are in general agreement with previous studies 
with the orthologous yeast proteins (Deng et al. 2019). A comparison of the activities of 
hNatE and hNatE/HYPK revealed that in the presence HYPK, hNatE displayed an ~1.3-
fold decrease in Km, and an ~3.8-fold decrease of kcat, with an overall ~2.9-fold decrease 
in catalytic efficiency (Table 3.1). This data suggests that HYPK can compromise hNatE 
activity. Taken together, while hNatA significantly enhances the catalytic efficiency of 
hNatE, HYPK binding to hNatE largely nullifies this effect, demonstrating that HYPK can 




 Table 4.1 Catalytic parameters for hNAA50, hNatE, and hNatE/HYPK 
 
 
3.2.5 hNatA forms competing complexes with hNAA50 and HYPK in cells 
To further confirm the existence of the tetrameric hNatE/HYPK complex 
observed in vitro in human cells, we immunoprecipitated hNAA15 (c-terminal V5 tagged) 
from HeLa cells to evaluate the associated proteins. Mass spectrometry analysis of this 
sample revealed that endogenous hNAA10, hNAA50 and HYPK were all co-
immunoprecipitated with NAA15-WT-V5, in agreement with the tetrameric hNatE/HYPK 
complex formation (Fig. 3.3a). 
In prior studies, we reported that a hNAA15-T406Y mutant can disassociate 
hNAA50 from hNatA in vitro (Deng et al. 2019), while a hNAA15-L814P mutant is 
defective for HYPK inhibition and reduces hNatA thermostability (Cheng et al. 2019). 
Based on these observations, we also carried out a mass spectrometry analysis of the 
V5-immunoprecipitates of the hNAA15-T406Y-V5 and hNAA15-L814P-V5 mutants to 
evaluate the effect of the mutation’s on formation of the hNatE/HYPK tetrameric 
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complex. For relative quantification of the hNatA proteins, the IBAQ intensities of the 
hNatA components in each sample were normalized to the IBAQ intensity of hNAA15 in 
the respective sample and to the corresponding protein in the WT sample (Fig. 3.3a). 
This analysis demonstrated that hNAA15-T406Y-V5 and hNAA15-L814P-V5 had 
reduced binding of hNAA50 and HYPK respectively, indicating that the mutations 
negatively affected the ability of hNAA15 to bind hNAA50 and HYPK, respectively. 
Furthermore, it appeared that the reduced binding of HYPK or hNAA50 resulted in 
greater binding of the other component: hNAA15-T406Y-V5 bound less hNAA50, but 
more HYPK than hNAA15-WT, while hNAA15-L814P-V5 bound less HYPK and more 
hNAA50 than hNAA15-WT (Fig. 3.3a). These observations are in agreement with the in 
vitro FP and ITC assays, demonstrating that HYPK and hNAA50 display negative 
cooperative binding with respect to hNatA. Taken together, these cellular studies agree 
with the in vitro studies by confirming the existence of the tetrameric hNatE/HYPK 
complex and indicating that HYPK and hNAA50 display negative cooperative binding 
with respect to hNatA. 
The intrinsic hNatA catalytic activities of the hNAA15-T406Y-V5 and hNAA15-
L814P-V5 variants were also tested in a Nt-acetylation assay and westernbloted (Fig. 
3.3b). Importantly, equal levels of hNAA10 were pulled out with the lysates supporting 
that none of the mutants affect hNAA10 binding. The hNAA15-T406Y-V5 hNatA complex 
displayed a decreased catalytic activity towards the hNatA substrate SESS24 compared 
to WT hNatA. This could be explained by an increased binding and inhibitory effect of 
HYPK and/or due to the reduced binding of hNAA50. The hNAA15-L814P-V5 hNatA 
complex showed an increased catalytic activity compared to WT hNatA, which is 
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consistent with the in vitro findings of reduced binding of HYPK and consequently less 
inhibition of the catalytic activity and/or an increased binding of hNAA50. 
 
Figure 15.3 hNatA forms competing complexes with hNAA50 and HYPK 
(a) Heat map showing the mean relative IBAQ intensity of NatA components from three 
independent MS analyses of immunoprecipitated NAA15 variants, NAA15-WT-V5, 
NAA15-T406Y-V5, and NAA15-L814P-V5. The IBAQ intensities of each component 
were normalized to the IBAQ intensity of NAA15 in the respective sample and to the 
corresponding NatA WT protein. Source data are provided as a Source Data file. 
(b) Western blot analysis and NatA Nt-acetylation assay of V5-immunoprecipiated 
NAA15 variants. The measured DPM signal for each reaction was normalized to the 
corresponding V5-band in the IP. The immunoprecipitation and activity assay were 
performed in n = 3 independent experiments, each with three technical replicates 




3.2.6 hNatE structure reveals molecular basis for enzyme crosstalk 
To determine the molecular basis for interaction and enzymatic crosstalk 
between human NAA10 and NAA50 enzyme subunits within the NatE complex, we 
determined the single particle Cryo-EM structure of the hNatE complex in the presence 
of inositol hexaphosphate IP6 and bi-substrate analogues of both hNatA and hNAA50. 
The model of the human complex was rigid-body fitted with the coordinates of the crystal 
structure of hNatA (PDB: 6C9M) and hNAA50 (PDB: 3TFY), with all ligands removed. 
After refinement of the model, we observed clear density of IP6 and acetyl-CoA cofactors 
in each catalytic subunit, but the peptide portion of the bisubstrate inhibitors were not 
resolved. The structure was refined to an overall resolution of 3.0 Å, with most residues 
of hNAA10 and hNAA50 subunits resolved to 2.5 Å. The refinement statistics can be 
found in Table. 3.2. The N-terminal 112 residues of hNAA15 subunit were not modeled 
due to a lack of traceable Cryo-EM density for this region.  
Consistent with previous studies with the orthologous yeast proteins (Deng et al. 
2019), hNAA50 predominantly interacts with hNAA15 (α21, α22, α23 and α24), and 
makes relatively few interactions with hNAA10 (Fig. 3.4a), burying a solvent excluded 
surface of 34,316 Å2 with hNAA15, and 9,100 Å2 with hNAA10. Based on the structure of 
the ScNatE complex, a hNAA15-T406Y mutant was shown to disrupt the hNatA-NAA50 
interaction (Deng et al. 2019). Indeed, we find that hNAA15-Thr406 is located at the 
center of the hNAA50-hNAA15 interface, making hydrogen bond interactions with the 
backbone carbonyl group of hNAA50-Ala55 (Fig. 3.4b). Additional hydrogen bonds are 
formed between the backbone carbonyl of hNAA50-His14 with the backbone amide of 
hNAA15-Thr439, between hNAA50-Arg21 and the backbone carbonyl of hNAA15-
Pro405, and between hNAA50-Asn52 and hNAA15-Thr371 (Fig. 3.4b). hNAA50-Arg21 
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also makes direct ionic interaction with hNAA15-Glu433, which is absent in yeast (Fig. 
3.4b). It is possible that this ionic interaction underlies the increased salt sensitivity of the 
human vs. yeast NatE complex (Deng et al. 2019). Interestingly, we do not observe 
significant hydrophobic interactions at the hNAA15-hNAA50 contact interface. 
hNAA50-hNAA10 interactions are less extensive than hNAA50-hNAA15, yet still 
significant. Interactions are observed between hNAA50-Glu7 and hNAA10-Arg116, and 
between hNAA50-Asp53 and hNAA10-Arg83 (Fig. 3.4c). This structural observation 
highlights the recent identification of a missense mutation of hNAA10 R83H which 
exhibits decrease acetylation activity in boys with intellectual disability and 
developmental delay (Ree et al. 2019). It is noteworthy that hNAA10-Arg83 also makes 
interaction with the 3’ phosphate of the acetyl-CoA molecule bound to hNAA10 (Fig. 
3.4c).  
To assess the importance of the NatA-NAA50 interactions on the catalytic 
crosstalk of the two enzymes, we prepared hNAA50-E7A, -D53A and -E7A/D53A 
mutants and evaluated their effect on hNatA activity (Fig. 3.2c).  We found that the 
single and double mutants were able to restore between 12-17% of hNatA activity 
relative to the activity of hNatA bound to WT-hNAA50 (Fig. 3.2c). These results 
demonstrate that the observed hydrogen bond interactions between NatA and NAA50 
make a small, albeit significant, contribution to the catalytic crosstalk between the two 
enzymes. 
An overlay of the Saccharomyces cerevisiae (PDB: 6O07) and human NatE 
structures reveals a high degree of structural conservation with a root-mean square 
deviation (RMSD) of 1.517 Å (over 622 common Cα atoms). However, it is noteworthy 
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that when bound to NatA, we observe that NAA50 shifts significantly closer to NAA10 in 
the human over the yeast complex, resulting in more significant and intimate NAA10-
NAA50 interactions in the human complex (Fig. 3.5a). α3 and β7 of hNAA50 shift toward 
NAA10 about 10 Å and 11 Å, respectively (Fig. 3.5a). Such significant shift in NAA50 
position relative to NatA is surprising and may reflect a functional importance when 
these proteins are associated with the ribosome (see discussion).  
To understand other structural contributions that hNAA50 might have on hNatA 
activity, we superimposed the hNatE structure with the hNatA crystal structure 
(PDB:6C9M). We found that hNAA15 and hNAA10 in the ternary hNatE complex 
displayed an RMSD of 0.747 Å (over 624 common Cα atoms), and 0.897 Å (over 141 
common Cα atoms), respectively (Fig. 3.5b). The NAA10 β6-β7 loop displayed about a 
4 Å shift toward hNAA50 in the hNatE complex relative to the hNatA complex (Fig. 
3.5b). Given that the β6-β7 loop of NAA10 plays an important role in peptide substrate 
recognition, we propose that this shift in position also contributes to the inhibitory effect 
that hNAA50 binding has on hNatA activity.  
To understand the molecular basis for why hNatA binding increases the catalytic 
efficiency of hNatE by nearly 8-fold (Fig. 3.2b and Table 3.1), we superimposed the 
hNAA50 crystal structure (PDB: 3TFY) with the hNAA50 subunits of the NatE structure. 
Remarkably, we did not observe any significant structural changes in hNAA50 with an 
overall RMSD for all atoms of 0.437 Å (Fig. 3.5b). Notably, the β6-β7 and α1-α2 peptide 
substrate binding loops of hNAA50 within the hNatE complex superimposed well with 
hNAA50 bound to CoA and substrate peptide (Fig. 3.5b). Based on this observation, we 
hypothesize that the increased activity of hNatE is due to a reduced entropic cost for 
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substrate binding to the hNAA50 subunit due to hNatA tethering. This is consistent with 
























Figure 16.4 Cryo-EM structure of the hNatE complex 
(a) hNAA50 (magenta), hNAA15 (green), and hNAA10 (orange) within the hNatE 
complex shown in cartoon. (b) Zoom-in view of the contacts between hNAA15 and 
hNAA50 with residues that participate in interaction labeled. (c) Zoom-in view of the 
contacts between hNAA10 and hNAA50 with residues that participate in interaction 






Figure 17.5 Subunit crosstalk within the hNatE complex 
(a) hNAA50 (magenta), hNAA15 (green), and hNAA10 (orange) within the hNatE 
complex overlay with ScNatE (grey, PDB: 6O07). The α3 helix and β7 strand of Naa50 is 
shown to shift towards Naa10 in the human structure (b) hNatE aligned with hNatA (light 
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blue, PDB:6C9M) and hNAA50 (wheat, PDB: 3TFY). The top zoom-in area shows the 
alignment of free hNAA50 and hNatE. The below zoom-in area shows the hNAA10 
conformational change induced by hNAA50 binding. 
 
3.2.7 hNatE/HYPK structure reveals negative cooperative mechanism 
To obtain a molecular understanding of how NAA50 and HYPK can both bind 
NatA we determined the structure of the hNatE/HYPK complex by Cryo-EM, which we 
were able to resolve to an overall resolution of 4.0 Å. The starting structure was modeled 
using the Cryo-EM NatE structure and the HYPK portion from the hNatA/HYPK crystal 
structure (PDB: 6C95), which was placed into the Cryo-EM map through rigid-body fitting 
into the EM density map, followed by adjustment and refinement. The refinement 
statistics can be found in Table. 3.2.  
In the tetrameric structure, we observe that both hNAA50 and HYPK 
simultaneously dock onto the same binding regions on hNatA as previously identified in 
the absence of the other protein (Gottlieb and Marmorstein 2018). While both hNAA50 
and HYPK contact both subunits of hNatA, no direct interactions are observed between 
hNAA50 and HYPK (Fig. 3.6a). HYPK binds NatA mainly through interactions with the 
hNAA15 subunit of hNatA: only the α1 helix of HYPK interacts with hNAA10, while the 
α2 and C-terminal UBA domain (α3, α4, and α5 helices) of HYPK interact with hNAA15 
(Fig. 3.6a). Previous studies demonstrated that the UBA domain and α2 helix play key 
roles in hNatA binding, while α1 is essential for hNatA activity inhibition (Gottlieb and 
Marmorstein 2018; Weyer et al. 2017).  
85 
 
Over the HYPK and hNatA interaction interface within the tetrameric complex, we 
observe polar interactions between HYPK-Glu74 and hNAA15-Tyr158, between the 
backbone carbonyl of HYPK-Thr100 and hNAA15-Lys687, between the backbone 
carbonyl of HYPK-Asn129 and hNAA15-Arg697, between HYPK-Asn129 and hNAA15-
Lys696, which were all overserved similarly in the hNatA/HYPK crystal structure 
(Gottlieb and Marmorstein 2018) (Fig. 3.6b). However, HYPK-Glu103 , hNAA15-Lys685 
and hNAA15-Glu655 which form a salt bridge in the hNatA/HYPK structure do not show 
a similar contact in the tetrameric hNatE/HYPK complex (Gottlieb and Marmorstein 
2018) (Fig. 3.6b). We speculate that the absence of this interaction might contribute to 
the slightly weaker affinity of HYPK for hNatE over hNatA.  
hNAA15 and hNAA50 also make similar interactions in the absence or presence 
of HYPK. The backbone carbonyl of hNAA50-His14 hydrogen bonds with the backbone 
amide of hNAA15-Thr439, and hNAA50-Asn52 hydrogen bonds with hNAA15-Thr371 
(Fig. 3.6c). Interestingly however, a key residue that stabilizes the hNatA-hNAA50 
interaction, hNAA15-Thr406, shifts from in interaction with the carbonyl of hNAA50-A55 
to a hydrogen bond to the hNAA50-Gln18 side chain in the tetrameric complex (Fig. 
3.6c). An additional H-bond is formed between hNAA50-Gln18 and the backbone 
carbonyl of hNAA15-Thr406 (Fig. 3.6c). hNAA50-Arg21, a residue that makes extensive 
contacts to NAA15 in the hNatA/NAA50 complex (Fig. 3.4b) is only contacting hNAA15-
Glu433 in the tetrameric complex (Fig. 3.6c). In addition, while hNAA50-Asp53 and 
hNAA10-Arg83 maintain interaction as observed in the hNatA/hNAA50 complex, 
hNAA50-Glu7 and hNAA10-Arg116 loose interaction in the tetrameric complex (Fig. 
3.6d). These observations correlate with the observed weaker binding interaction 
between hNAA50 and hNatA in the presence of HYPK.  
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To understand the molecular basis for the biochemical findings that the binding of 
hNAA50 and HYPK to hNatA exhibit negative cooperativity, we superimposed the 
ternary hNatA/HYPK and hNatE complexes onto the hNatE/HYPK complex (Fig. 3.7). 
To align the hNatE and hNatE/HYPK complexes we superimposed the hNAA50 position 
to delineate how the HYPK binding regions are affected by hNAA50 binding (Fig. 3.7a). 
The overall overlay suggests that both the hNAA10 and hNAA15 subunits of hNatA shift 
in the direction that is away from the hNAA50 binding region to make closer and more 
optimal contacts with HYPK (Fig. 3.7a).  The hNAA15 α36-α40 helices, which bind to the 
C-terminal UBA domain (α3-α5) of HYPK in the tetrameric hNatE/HYPK complex, clearly 
shift away from the binding interface, when only hNAA50 is bound to hNatA (Fig. 3.7c). 
Notably, α40, α38, α37, α36 display shift of ~4.5 Å, ~2.3 Å, ~1.6 Å, and ~1.8 Å, 
respectively.  The important residues of hNAA15 (Lys696, Arg697, Lys687, Lys685), 
which mediate HYPK interactions in this region suggested that most of them in the 
hNatE structure exhibit an ~ 2 Å shift away from HYPK (Fig. 3.7c). Meanwhile, hNAA15 
N-terminal helices of α7, α8, α9, α10 which are in close contact with HYPK-α2 also show 
~3.0 Å, ~4.1 Å, ~1.9 Å, ~3.5 Å shifts, respectively (Fig. 3.7d), while Tyr 158 is about ~2 
Å further away. Lastly, we observe that α2 and β3- β4 of hNAA50-bound hNAA10 move 
~2.5 Å closer to contact the HYPK N-terminal α1 helix (Fig. 3.7e). Thus, it appears that 
hNAA50 binding to hNatA, destabilizes hNatA-HYPK interactions through moving hNatA 
away from its optimal binding position to HYPK. 
Similarly, a superposition of hNatE/HYPK with the crystal structure of 
hNatA/HYPK by aligning to the HYPK position to delineate how the hNAA50 binding 
regions are affected by HYPK binding reveals that hNAA15 is shifted away from HYPK 
and closer to hNAA50 in the hNatE/HYPK complex (Fig. 3.7b). A further zoom-in view of 
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the hNAA50 binding regions in hNAA15 demonstrates that residues Glu433, Thr406, 
Thr371 and Thr439 of hNAA15 are shifted by ~ 2-3 Å away from hNAA50 when HYPK is 
bound relative to their positions in the absence of hNAA50 (Fig. 3.7f). Regarding the 
hNAA50-hNAA10 binding interface, a 4.3 Å shift of hNAA10-Arg116 was observed, with 
a 1.7 Å for hNAA10-Arg83 (Fig. 3.7g). It is also noteworthy that significant 
conformational shift of the C-terminal hNAA15 helices α41- α45 (~2.2 - 4.2 Å) was 
induced in order to have hNAA50 bound in the tetrameric hNatE/HYPK complex (Fig. 
3.7h). This suggests that HYPK bound hNatA is also not optimal for hNAA50 binding. 
Taken together, these comparisons reveal that hNAA50 and HYPK destabilize 
the binding of the other protein to hNatA, despite their independent binding surfaces to 









Figure 18.6 Overall structure of the hNatE/HYPK complex 
(a) hNAA50 (pink), hNAA15 (green), hNAA10 (orange), and HYPK (red) within the 
hNatE complex is shown in cartoon. (b) Zoom-in view of the contacts between HYPK 
and hNAA15 with residues that participate in interaction shown. (c) Zoom-in view of the 
contacts between hNAA15 and hNAA50 with residues that participate in interaction 
shown. (d) Zoom-in view of the contacts between hNAA10 and hNAA50 with residues 







Figure 19.7 Molecular basis for NAA50 and HYPK binding to NatA 
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(a) hNatE/HYPK overlayed onto hNatE (purple) with NAA50 aligned. (b) hNatE/HYPK 
overlayed onto hNatA/HYPK (PDB: 6C95, blue) with HYPK aligned. (c) zoom-in view of 
HYPK C-terminal binding region as indicated in (a). (d) zoom-in view of HYPK α2 
binding region as indicated in (a). (e) zoom-in view of HYPK N terminal α1 domain 
binding region as indicated in (a). (f) zoom-in view shows the NAA50 binding region on 
NAA15 as indicated in (b). (g) zoom-in view shows the NAA50 binding region on NAA10 
as indicated in (b). (h) zoom-in view shows the NAA15 C-terminal helices conformal 
changes when HYPK bound as indicated in (b). 
 
3.2.8 Molecular basis for decrease of hNatE activity by HYPK 
Our kinetic data demonstrated that the catalytic efficiency of hNatE is greater 
than hNAA50 but that this increase is partially nullified in the presence of HYPK (Table 
3.1 and Fig. 3.2b). To understand the molecular basis for this, we overlay structures of 
hNatE and hNatE/HYPK with the common hNatA subunits aligned. This superposition 
reveals that the largest structural differences within the hNAA50 subunit map to the β6-
β7 and α1-α2 loops, which shift such that the hNAA50 peptide substrate binding groove 
is ~2.4 Å wider in the hNatE/HYPK complex relative to the hNatE complex (Fig. 3.8). In 
addition, the hNAA50 β3-β4 loop is shifted in the direction away from hNatA by about 3.5 
Å in the presence of HYPK (Fig. 3.8).  Previous studies demonstrated that Tyr73 and 
Met75 from hNAA50-β4 and Tyr138, Tyr139 and Leu142 from the hNAA50 β6-β7 loop 
are important for hNAA50 catalytic function and substrate binding (Liszczak, Arnesen, 
and Marmorstein 2011). To directly test this, we prepared the following mutants: 
hNAA50-Y73F, -M75A, -Y138A, -Y139A and -I142A, and tested their effects on hNatE 
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activity when HYPK was bound (Fig. 3.2d). Consistent with previous studies, Y73F, 
Y138A and Y139A decreased hNAA50 activity to undetectable levels (Liszczak, 
Arnesen, and Marmorstein 2011). For hNAA50-M75A and -I142A, we observed 
increased activity when bound to hNatA to form the hNatE complex, as we observed for 
hNAA50-WT.  As expected, the hNatE/HYPK complex displayed reduced activity 
compared to both hNAA50 alone and hNatE. However, we observed that hNatE-
M75A/HYPK and hNatE-I142A/HYPK exhibited similar activity, compared to their 
corresponding hNAA50 mutants alone. This data is consistent with the conclusion that 
perturbation of the hNAA50 β3-β4 and  β6-β7 loops within the hNatE/HYPK complex 
underlies the observed reduced catalytic efficiency of hNatE in the presence of HYPK. 
 
 
Figure 20.8 Molecular basis for the decrease of NAA50 activity by HYPK 
hNatE/HYPK (green) overlayed onto hNatE (magenta) with hNatA aligned. Zoom-in view 






While the interaction and catalytic crosstalk within NatE in the yeast system had 
previously been reported, the corresponding human system and the influence of HYPK 
binding on hNatE activity had not previously been characterized. Here, we biochemically 
and structurally characterize the mechanistic interplay of the hNAA10 and hNAA50 
catalytic subunits within the hNatE complex and the role of HYPK in regulating hNatE 
activity. Similar to the crystal structure of ScNatE (PDB:6O07), we find that hNAA50 
binds hNatA mainly through hNAA15, using highly conserved residues, including a key 
threonine residue located at the center of the binding interface. Notably, the distance 
between hNAA50 and hNAA10 in the human complex is significantly shorter than in the 
yeast complex. We find that these two acidic hNAA50 residues, Glu7 and Asp53 contact 
two hNAA10 arginine residues, inducing a conformational change in hNAA10, which 
contributes to a decrease in hNatA enzymatic activity.  
While both hNAA50 and hNatA are conserved from yeast to human, it had long 
been considered that HYPK is not present in yeast until the recently identified HYPK in 
thermophilic fungus Chaetomium thermophilum (Weyer et al. 2017). Nevertheless, it 
appears that evolutionarily NAA50 appeared as a NatA binding partner earlier than 
HYPK did. In both budding and fission yeast, NAA50 is inactive but regulates NatA 
acetylation activity (Deng et al. 2019). While in higher eukaryotes, NAA50 is 
enzymatically active, either with or without NatA (Liszczak, Arnesen, and Marmorstein 
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2011; Evjenth et al. 2009). Thus, within the tetrameric NatE/HYPK complex, it is likely 
that the regulation of NatA activity by NAA50 was replaced by HYPK.  
Here, we have reconstituted the tetrameric hNatE/HYPK complex to demonstrate 
that HYPK and hNAA50 can bind to hNatA simultaneously. We also confirmed the 
physiological relevance of the tetrameric hNatE/HYPK complex through 
immunoprecipitation of the complex from HeLa cells. We find that while HYPK inhibits 
hNatA activity directly, it also indirectly, but less potently, inhibits hNatE. We also find 
that hNAA50 and HYPK exhibit negative cooperativity with respect to hNatA binding in 
vitro and in vivo. The structure of the hNatE/HYPK complex suggests that this is due to 
the ability of the hNAA50 and HYPK protein to bind to the hNAA15 subunit of hNatA in a 
way that indirectly destabilizes binding of the other protein. This observation, together 
with our findings that HYPK has a dominant regulatory effect on hNatA activity relative to 
hNAA50 may explain why excess free hNAA50 is observed over hNatA in higher 
organism and HeLa cells (Hou et al. 2007).  
The nano-molar dissociation constants of HYPK and hNAA50 for hNatA is 
consistent with our immunoprecipitation of the tetrameric hNatE/HYPK complex from 
cells. Previous studies in Drosophila also reported that a dNAA50 knockout decreases 
in-vivo dNatA catalytic activity in the presence of HYPK (Rathore et al. 2016). In terms of 
the biological function of this tetrameric complex, we propose two non-mutually exclusive 
regulatory mechanism for how hNAA50 protein levels could affect hNatA activity. First, 
since hNAA50 has a negative effect on binding between hNatA and HYPK, the absence 
of hNAA50, would promote HYPK binding to hNatA to inhibit hNatA activity. Second, 
since a recent yeast NatE-ribosome structure demonstrated that yeast NAA50 
participates in ribosome association (Knorr et al. 2019), it is likely that hNAA50 in higher 
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eukaryotes also contributes to the association between tetrameric hNatE/HYPK and 
ribosome. The lower level of hNAA50 could therefore decrease the fraction of ribosome 
associated hNatA to regulate its co-translational activity.  
The overall structures of hNAA50 and ScNAA50 are well conserved with a mix of 
-helices and -strands. However, the overlay of hNatE and ScNatE suggested that 
NAA50 shifts closer to NAA10 in the human over the yeast complex. It is possible that in 
the human system NAA10 and NAA50 have more intimate contact and crosstalk in 
enzymatic activity. However, previous data indicated that the degree of NAA50 and 
NAA10 activity crosstalk is similar in yeast and human (Deng et al. 2019). In a recently 
reported yeast ScNatE-ribosome structure, the ScNAA10 and ScNAA50 catalytic sites 
are 50 Å and 85 Å away from the peptide exit site on the ribosome (Knorr et al. 2019). 
While unlike ScNAA50, hNAA50 is co-translationally enzymatically active (Evjenth et al. 
2009). Thus, we propose that this shift of NAA50 closer to NAA10 in the human over the 
yeast complex may have an impact on the relative distance between the nascent chain 
and active sites of hNAA10 and hNAA50.  
With respect to hNatA binding to the ribosome, it is possible that HYPK may also 
contribute to ribosome binding by hNatA. This could then indirectly affect hNAA50 
recruitment to the ribosome, which would be promoted by hNatA but inhibited by HYPK. 
HYPK contains a UBA domain, which is also present at the C-terminus of the alpha 
subunit of the Nascent Polypeptide-Associated Complex (NAC). Further studies are 
required to test these hypotheses for hNatA recruitment to the ribosome.  
The hNatE/HYPK complex co-translationally acetylates nascent peptides with N 
termini of either methionine maintained or cleaved, which accounts for the largest 
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number of substrates among all NATs. Given that this complex acetylates about 40-60% 
of the human proteome and has altered function in many human diseases, the studies 
presented here provides an important molecular scaffold for potential therapeutic 
development.       
 
3.4 Materials and methods 
3.4.1 Plasmid construction. 
A mammalian expression vector pcDNA3.1/NAA15-V5 was modified by site-
directed mutagenesis (Q5® Site Directed Mutagenesis Kit, New England Biolabs) to 
encode hNAA15 variants c.1216-1218ACA>TAC (p.T406Y) and c.2441T>C (p.L814P). 
Primer sequences for p.T406Y are AAGTACACCTTACTTAATAGAACTCTTTCTCGTG 
and TCAATAGCAGTATTTATGTAC. Primer sequences for p.L814P are 
TGATGGTAGCCCAGGAGACTGTA and TACAAGGCTTCCAATACC. The mutated 
plasmid sequences were verified by sequencing. 
 
3.4.2 Proteomics sample preparation of NAA15-V5 immunoprecipitates. 
For immunoprecipitation of NAA15-V5 variants, two 10 cm dishes of HeLa cells 
(ATCC CCL-2) were transfected with 10 µg of either pcDNA3.1/NAA15-WT-V5, 
pcDNA3.1/NAA15-T406Y-V5 or pcDNA3.1/NAA15-L814P-V5 using X-tremeGENE™ 9 
DNA Transfection Reagent (Roche). The growth medium was replaced after 24 h. 48 h 
post transfection, cells were harvested and lysed in 200 µl IPH lysis buffer (50 mM Tris-
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HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1× complete EDTA-free protease 
inhibitor cocktail (Roche)) per cell dish for 15 min at 4°C on a rotating wheel. Cell debris 
was pelleted by centrifugation (17000 × g, 4°C, 5 min) and the supernatant was mixed 
with 2 µg of V5-tag mouse monoclonal antibody (Invitrogen, R960-25) and incubated for 
2 h at 4°C on a rotating wheel. Thereafter, 20 µl of Dynabeads™ Protein G (Invitrogen) 
washed in IPH lysis buffer was added to the cell lysates and incubated overnight. The 
next day, beads were washed three times in IPH lysis buffer before the retrieved 
immunocomplexes were eluted in 60 µl FASP buffer (2% SDS, 100 mM Tris-HCl pH 7.6, 
0.1 M DTT) and heated for 5 min at 95 °C. Filter-aided sample preparation (FASP) 
method was performed to process the eluates for LC-MS/MS analysis (Wisniewski et al. 
2009). The protein samples were mixed with 200 µl UA buffer (8 M urea, 100 Mm Tris-
HCl pH 8.0), transferred to Microcon 30kDa MWCO filters and centrifuged. All 
centrifugation steps were carried out at 23 °C and 14 000 x g for 15 min. The filters were 
washed three times with 200 µl UA by spinning. Proteins were then Cys-alkylated by 
incubation with 100 µl 50 mM iodoacetamide (IAA) in UA for 20 min, before IAA was 
removed by centrifugation. Filters were then washed three times with 100 µl UA. Finally, 
the UA buffer was exchanged by three washes with 100 µl 50 mM ammonium 
bicarbonate (ABC), before 500 ng trypsin (Sequencing Grade Modified Trypsin, 
Promega) was added to the filters and incubated overnight at 37 °C. Digested proteins 
were collected by centrifugation and the filter was washed once with 75 µl ABC. 
Peptides were acidified with 5% formic acid (FA) and desalted using PierceTM C18-Tips 
(Thermo Scientific) according to manufacturer´s protocol. The final eluates were dried by 




3.4.3 MS analysis of NAA15-V5 immunoprecipitates. 
Mass spectrometric analysis was performed with an Ultimate 3000 RSLC system 
(Thermo Scientific) coupled to a Q-Exactive HF mass spectrometer (Thermo Scientific) 
equipped with EASY-spray nano-electrospray ion source (Thermo Scientific). About 1 µg 
tryptic peptides were loaded and desalted on a pre-column (Acclaim PepMap 100, 2cm x 
75µm ID nanoViper column, packed with 3 µm C18 beads) with 0.1% TFA (flow rate 5 
µl/min, 5 min). Peptides were separated during a biphasic ACN gradient from two 
nanoflow UPLC pumps (flow rate of 200 nl/min) on an analytical column (PepMap RSLC, 
50cm x 75 µm i.d. EASY-spray column, packed with 2 µm C18 beads). Solvent A and B 
were 0.1% FA (vol/vol) in water and 100% ACN respectively. The gradient composition 
was 5% B for 5 min, 5-8% B for 0.5 min, 8–24% B for 109.5min, 24–35% B for 25min, 
and 35–80% B for 15 min, 80% B over 15 min for isocratic elution and 5% B over 20 min 
for conditioning. The eluting peptides were ionized in the electrospray and analyzed by 
the Q-Exactive HF. The mass spectrometer was operated in data-dependent mode to 
automatically switch between full scan MS and MS/MS acquisition. MS spectra (m/z 
375-1500) were obtained with a resolution of 120 000 at m/z 200, automatic gain control 
(AGC) target of 3 x 106 and maximum injection time (IT) of 100 ms. The twelve most 
intense peptides above a threshold of 50 000 counts and charge states 2 to 5 were 
isolated (window of 1.6 m/z, AGC target of 1 x 105 and maximum IT of 110 ms) for 
fragmentation at a normalized collision energy of 28%. Fragments were detected in the 
orbitrap at a resolution of 15 000 at m/z 200, with first mass fixed at m/z 100. Precursor 
masses selected for MS/MS analysis were excluded by dynamic exclusion for 25 s with 
“exclude isotopes” enabled. Lock-mass internal calibration (m/z 445.12003) was used. 
The raw data acquired was processed with MaxQuant v. 1.6.2.6 and Andromeda search 
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engine. The spectra were searched against a database of Swiss-Prot annotated human 
protein sequences (20431 sequences, retrieved 25.06.2019) and a reverse decoy 
database. Cystein carbamidomethylation was selected as a fixed modification and 
variable modifications included methionine oxidation and protein N-terminal acetylation. 
The false discovery rate (FDR) was set to 1% for peptide and protein identification, 
minimum peptide length allowed was 7 and match between runs (0.7 min match time 
window, 20 min alignment time window) was enabled. Label-free quantification (LFQ) 
(Cox et al. 2014) and intensity-based absolute quantification (IBAQ) were selected. All 
other parameters were set to default values. The resulting proteingroups.txt file was 
analysed using Perseus software v. 1.6.5.0. Proteins only identified by site, common 
contaminants and reverse hits were filtered away. The IBAQ intensities of hNAA10, 
hNAA50 and HYPK were normalized to the IBAQ intensity of NAA15 in each IP sample. 
Thereafter, the IBAQ intensity of hNAA15, hNAA10, hNAA50 and HYPK in each sample 
was normalized to the IBAQ intensity of the corresponding protein in the hNAA15-WT-V5 
IP sample. 
 
3.4.4 [14C]-Ac-CoA-based acetylation and western blot analysis 
In order to test the NatA Nt-acetylation activity of hNAA15-T406Y and 
hNAA15-L815P variants, immunoprecipitation of hNAA15-V5 was performed as 
described above with minor adjustments. Five 10 cm dishes of HeLa cells (ATCC 
CCL-2) were transfected with 8 µg pcDNA3.1/NAA15-WT-V5, 8 µg 
pcDNA3.1/NAA15-T406Y-V5 or 10 µg pcDNA3.1/NAA15-L814P-V5. NAA15-WT-
V5 and NAA15-T406Y-V5 were co-transfected with 2 µg of empty pcDNA3.1/V5 
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vector to ensure equal conditions for the cells. As a negative control, five dishes 
of HeLa cells were transfected with 10 µg of pcDNA3.1/LacZ-V5. 
Immunoprecipitation from harvested and lysed cells was performed using 3 µg of 
V5-tag mouse monoclonal antibody (Invitrogen) and 30 µl of Dynabeads™ 
Protein G (Invitrogen, R960-25). The beads were washed three times in IPH lysis 
buffer and resuspended in 95 µl acetylation buffer (50 mM Tris-HCl pH 8.5, 1 mM 
EDTA, 10% Glycerol). [14C]-Ac-CoA–based Nt-acetylation assays were 
performed as described (Drazic and Arnesen 2017). In brief, three reaction 
mixture replicates were prepared containing 10 µl of immunoprecipitated 
enzyme, 200 µM synthetic 24-mer oligopeptide SESS24: NH2-
SESSSKSRWGRPVGRRRRPVRVYP-COOH (BioGenes), 50 µM [14C]-Ac-CoA 
(Perkin-Elmer) and acetylation buffer to a final volume of 25 µl. Reaction mixtures 
without oligopeptide were used as negative controls. The reaction mixtures were 
incubated at 37 °C at 1400 rpm shaking for 30 min. The reaction was stopped by 
isolating beads on a magnet and transferring 23 µl of the supernatant onto P81 
phosphocellulose filter discs (Millipore). The filter discs were washed three times 
in 10 mM HEPES buffer (pH 7.4) and air dried, before they were added to 5 ml 
Ultima Gold F scintillation mixture (Perkin-Elmer) and the incorporated [14C]-Ac 
was measured by a Perkin-Elmer TriCarb 2900TR Liquid Scintillation Analyzer. 
The immunoprecipitate input was determined by Western blot analysis. Proteins 
were separated by SDS-PAGE, transferred onto a nitrocellulose membrane 
(Amersham Protran 0.2 µM NC) and probed with V5-tag mouse monoclonal 
antibody (1:5000, Invitrogen, R960-25) and NAA10 rabbit monoclonal antibody 
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(1:1000, Cell Signaling #13357). Protein bands were imaged by ChemiDocTM 
XRS+ system (Bio-Rad) and quantified using ImagelabTM Software (Bio-Rad). 
The measured DPM signal for each reaction was normalized to the amount of 
NAA15-V5 in the respective IP sample. 
 
3.4.5 Protein expression and purification 
N-his tagged hNatA, N-his tagged hNatA/HYPK, were expressed in sf9 cells 
(ThermoFisher, cat# 12659017) and purified as described previously (Gottlieb and 
Marmorstein 2018). hNAA50 (Liszczak, Arnesen, and Marmorstein 2011) and MBP-
HYPK (Gottlieb and Marmorstein 2018) were expressed in BL21 (DE3)E. Coli cells 
(Thermo Scientific) and Rosetta (DE3)pLysS E. coli cells (Millipore Sigma), respectively, 
and purified as described previously. For hNatA and hNatA/HYPK sf9 expression, High 
density (2 x106 cells/ml) suspension cultures of Sf9 cells were infected at a multiplicity of 
infection (MOI) of 1 for 48hrs in Fernbach Shake flasks at 27 °C. Cells pellets were 
resuspended in lysis buffer of 25 mM Tris, pH 8.0, 500 mM NaCl, 10 mM Imidazole, 10 
mM β-ME, 10 mg/ml PMSF (phenylmethanesulfonylfluoride), DNase, and complete, 
EDTA-free protease inhibitor tablet (Roche). After sonication, clarified lysate was passed 
on nickel resin (Thermo Scientific), washed with 10 CV of lysis buffer, and eluted with 25 
mM Tris, pH 8.0, 200 mM NaCl, 200 mM Imidazole, 10 mM β-ME. Elute was further 
purified with HiTrap SP ion-exchange column with the salt gradient (200mM to 1M). 
Peak fractions were pooled and run on a Superdex 200 Increase 10/300 GL gel filtration 
column in sizing buffer containing 25 mM HEPES, pH 7.0, 200 mM NaCl, and 1 mM 
TCEP. Peak fractions were pooled and flash-frozen for storage in -80 °C until use.  
101 
 
For E. coli protein expression, transformed cells were cultured at 37 °C until the 
absorbance A600 reached ~ 0.7, induced with 0.5 mM IPTG (isopropyl 1-thio-β-D-
galactopyranoside), and grown overnight at 16 °C. E. coli cells overexpressing MBP-
HYPK were lysed in 25 mM Tris, pH 8.0, 150 mM NaCl, 10 mM β-ME, 10 mg/ml PMSF. 
Clarified lysate was passed on to amylose agarose resin (New England Biolabs), 
washed with lysis buffer, and elute in lysis buffer supplementary with 20 mM maltose. 
Eluted protein was purified with a 5 mL HiTrap Q ion-exchange column (GE Healthcare) 
in the same buffer with a gradient (150 mM to 1M NaCl). Peak fractions were pooled and 
loaded to a Superdex 75 Increase 10/300 GL gel filtration column (GE Healthcare) in 
buffer of 25 mM HEPES, pH 7.0, 200 mM NaCl, and 1 mM TCEP. Peak fractions were 
pooled and flash-frozen for storage in -80 °C until use. E. coli cells over-expressing GST 
tagged NAA50 were lysed in 25mM HEPES pH 7.5, 100 mM NaCl, and 10 mM β-ME by 
sonication. The supernatant was isolated and loaded to GST-binding resin (Clontech), 
washed with 10 CV lysis buffer. TEV (tobacco etch virus protease) was added to the 
resin for on-column cleavage overnight at room temperature. Untagged Naa50 was 
washed off the column with lysis buffer and collected for overnight dialysis in buffer with 
25mM HEPES (pH 7.5), 50 mM NaCl, and 10 mM β-ME. Ion exchange was done with a 
5-ml HiTrap SP ion exchange column (GE Healthcare) in gradient of 50 – 750 mM NaCl.  
Peak fractions were further purified with Superdex 75 gel filtration column (GE 
Healthcare) to homogeneity in buffer containing 25 mM HEPES, pH 7.5, 100 mM NaCl, 
and 10 mM DTT (dithiothreitol). Protein was flash-frozen for storage in -80 °C until use. 
Protein harboring mutations was generated with QuickChange protocol (Stratagene) 
(Braman, Papworth, and Greener 1996) and obtained following the same expression 




CACATCTCCCAGCGCGATCCGGCTACCTT. For hNAA50-D53A: 
CTTGCCTATTTCAATGCTATTGCTGTAGGTGC and 
GCACCTACAGCAATAGCATTGAAATAGGCAAG. For hNAA50-M75A: 
GACTTTACATCGCGACACTAGGATG and CATCCTAGTGTCGCGATGTAAAGTC. For 
hNAA50-Y138A: ACAAAGAAGAACGCCTATAAGAGGATAG and 
CTATCCTCTTATAGGCGTTCTTCTTTGT. hNAA50-Y73F, hNAA50-I142A, hNAA50-
Y139A were generated as previously described (Liszczak, Arnesen, and Marmorstein 
2011). 
 
3.4.6 Acetyltransferase activity assays 
Acetyltransferase assays were modified from previous studies (Liszczak et al. 
2013; Liszczak, Arnesen, and Marmorstein 2011) and carried out at room temperature in 
a reaction buffer containing 75 mM HEPES, pH 7.0, 120 mM NaCl, 1 mM DTT. The 
SASE substrate peptide (NH2-SASEAGVRWGRPVGRRRRP-COOH; GenScript) and the 
MLGP substrate peptide (NH2-MLGPEGGRWGRPVGRRRRP-COOH; GenScript) were 
used to determine the enzymatic activity of hNatA and hNAA50, respectively. Each 
curve was repeated at least 3 times. To test the effect of hNAA50 and HYPK on hNatA 
activity, 100 nM of hNatA was mixed with 500 µM SASE peptide, 300 µM C14 labeled 
acetyl-CoA (4 mCi mmol−1; PerkinElmer Life Sciences), and varied concentrations of 
hNAA50 or HYPK modulator were added for 12-minute reactions. Signals were 
normalized against enzyme without modulator. For time course activity assays, 500 nM 
of hNAA50, hNatE, or hNatE/HYPK were mixed with 500 µM MLGP peptide, and 300 
µM C14 labeled acetyl-CoA (4 mCi mmol−1; PerkinElmer Life Sciences) in a 20 µL 
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reaction volume. Only 15 µL of each reaction mixture was quenched at specific times. 
For kinetic assays of hNAA50, hNatE and hNatE/HYPK against MLGP peptide, 300 nM 
enzyme was mixed with 300 µM C14 labeled acetyl-CoA (4 mCi mmol−1; PerkinElmer Life 
Sciences) and the concentration of the peptide substrate was varied for a 40-minute 
reaction. Data was fit to a Michaelis–Menten equation in GraphPad Prism for 
determination of kinetic parameters.  
 
3.4.7 FP binding assays 
Fluorescence polarization (FP) binding assays were performed essentially as 
described previously (Deng et al. 2019). 10 nM of fluorescein labeled hNAA50 (Deng et 
al. 2019) was used in all reactions, and hNatA or hNatA/MBP-HYPK concentrations 
were varied to determine the dissociation constant (Kd). 5 mg/mL BSA and 0.2% v/v 
Tween were added into the reaction buffer (25 mM HEPES, pH 7.0, 200 mM NaCl and 
10 mM DTT) to prevent non-specific binding. FP readings were taken with a Perkin 
Elmer EnVision and each curve was repeated in triplicate. GraphPad Prism (version 
5.01) was used for all data fitting to determine Kd. A single-site specific binding model 
was used, with equation 1, 
  (1) 
where Fi is the fluorescence reading at ligand (either hNatA or hNatA/HYPK) 
concentration [L]i; Kd is the equilibrium dissociation binding constant; [M] is the 
concentration of hNaa50; F0 is the fluorescence reading extrapolated to no ligand; F1 is 
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the maximum fluorescence increase at saturating ligand concentration. Fit parameters 
for hNatA/HYPK (MBP tagged) binding were F0 = 161.3 ± 3.3, F1 = 222.0 ± 5.2, Kd =127 
± 13 nM, and R2 = 0.98. For hNatA, F0 = 205.8 ± 4.4, F1 = 137.2 ± 5.4, Kd = 46 ± 8.8 nM, 
and R2 = 0.95. 
 
3.4.8 ITC measurements 
ITC measurements were carried out using a MicroCal iTC200 at 20 °C. Samples 
were dialyzed into buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl, 1 mM DTT. 
Protein samples (hNatA, hNatE) with concentrations of 15 μM in the cell and 150 μMof 
MBP-HYPK in the syringe were used in the experiments. The raw data was analyzed 
with the MicroCal ITC analysis software. 
 
3.4.9 Cryo-EM sample preparation and data collection 
To prepare hNatE complex, purified hNatA and three molar excess of hNAA50 
were mixed and loaded onto a Superdex 200 10/30 GL column (GE Healthcare). Peak 
fractions with all subunits present, as confirmed with SDS-PAGE analysis, were 
concentrated to 1 mg/ml.  Fresh sample incubated with 3 molar excess of both hNatA 
and hNAA50 bi-substrate analogues for ~30 min on ice was applied to Quantinfoil 
R1.2/1.3 holey carbon support grids. To prepare hNatE/HYPK complex, purified 
hNatA/HYPK and three molar excess of hNAA50 were mixed and loaded onto an S200 
gel-filtration column (GE Healthcare). Peak fractions with all subunits present, as 
confirmed with SDS-PAGE were concentrated to 1 mg/ml. Fresh sample with 3 molar 
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excess of acetyl-CoA and hNAA50 bi-substrate analogues for ~30 min in ice was applied 
to Quantinfoil R1.2/1.3 holey carbon support grids.  
Both sample grids were blotted for 10-12 seconds (blot force = 2) under 100% 
humidity at 16°C before the sample was plunged into liquid ethane, using a FEI Vitrobot 
Mark IV. An FEI TF20 was used for screening the grids and data collection was 
performed either with a Talos Arctica microscope or Titan Krios equipped with a K2 
Summit direct detector (Gatan). 
 
3.4.10 Cryo-EM data processing 
Original image stacks were summed and corrected for drift and beam-induced 
motion at the micrograph level using MotionCor2 (Zheng et al. 2017). Defocus 
estimation and the resolution range of each micrograph were performed with Gctf 
(Zhang 2016).  For hNatA/hNAA50, ~3,000 particles were manually picked to generate 
several rough 2D class averages. Representative 2D classes were used to autopick 
~1,229,331 particles from 4,025 micrographs using Relion (Kimanius et al. 2016). All 
particles were extracted and binned to accelerate the 2D and 3D classifications. After 
bad particles were further removed by 2D and 3D classification, 353,541 particles were 
used for auto refinement, particle polishing and per particle CTF refinement. The final 
map of the hNatE complex was refined to an overall resolution of 3.02 Å, with local 
resolution estimated by Resmap (Kucukelbir, Sigworth, and Tagare 2014). For the 
hNatE/HYPK complex, image processing workflow was similar as described above. 
477,608 particles were picked from 1,004 micrographs and 168,536 particles were used 




3.4.11 Cryo-EM model building and refinement 
For hNatE model building, the crystal structures of hNatA (PDB: 6C9M) and 
hNAA50 (PDB: 3TFY) were fit into the 3.02 Å EM map as rigid bodies, followed by 
manual adjustment in coot (Emsley and Cowtan 2004) and real-space refinement in 
PHENIX (Adams et al. 2010). For the hNatE/HYPK model building, the crystal structure 
of hNatA/HYPK (PDB: 6C95) and hNAA50 (PDB: 3TFY) were used. All representations 
of Cryo-EM density and structural models were performed with Chimera (Pettersen et al. 










































NatB is conserved from yeast to human in both complex composition and in its 
substrate specificity profile (Starheim, Gevaert, and Arnesen 2012). In Saccharomyces 
cerevisiae, the deletion of NatB subunits produces more severe phenotypes, compared 
to the knockout of NatA or NatC subunits. Deletion of either NAA20 or NAA25 leads to 
similar phenotypes including slower growth rate, diminished mating, defects in actin 
cable formation, and aberrant mitochondrial and vacuolar inheritance (Polevoda et al. 
2003). These observations suggest that the proper function of actin and tropomyosin 
requires NTA by the intact NatB complex (Polevoda et al. 2003). In humans, disruption 
of NatB (hNatB) by knockout leads to defects in proper actin cytoskeleton structure, cell 
cycle progression and cell proliferation (Ametzazurra et al. 2008; Starheim et al. 2008; 
Ametzazurra et al. 2009; Neri et al. 2017). In addition, hNatB is upregulated in human 
hepatocellular carcinoma (Ametzazurra et al. 2008), where it has been suggested as a 
potential therapeutic target as silencing of this complex can block cell proliferation and 
tumor formation (Neri et al. 2017). hNatB-mediated NTA of α-synuclein (αSyn) has been 
shown to increase αSyn stability and lipid binding, and to reduce aggregation capacity 
(Watson and Lee 2019; Mason et al. 2016; Maltsev, Ying, and Bax 2012; Dikiy and 
Eliezer 2014; Trexler and Rhoades 2012; Fernández and Lucas 2018; Fauvet et al. 
2012; Kang et al. 2012; Iyer et al. 2016). Since αSyn is a key protein in Parkinson's 
disease (PD) (Halliday et al. 2011; Spillantini et al. 1998), hNatB might play an indirect 
role in PD pathogenesis in vivo as supported by a recent study (Vinueza-Gavilanes et al. 
2020). It was also recently demonstrated that NTA of αSyn increases its propensity for 
lipid membrane binding without altering its structural properties of the bound state 
(Runfola et al. 2020). 
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  Compared to the comprehensive structural and biochemical characterization of 
NatA (Liszczak et al. 2013; Weyer et al. 2017; Gottlieb and Marmorstein 2018; Deng et 
al. 2019; Knorr et al. 2019; Magin et al. 2017), the study of NatB has been limited, 
particularly in humans.  Recently, the crystal structure of Candida albicans (Ca) NatB 
bound to a bisubstrate CoA-peptide conjugate was determined, providing important 
insights into substrate specificity and NTA by caNatB (Hong et al. 2017). However, 
hNAA20 and hNAA25 share only ~40% and ~20% sequence identity with the Candida 
albicans homologue (Hong et al. 2017), respectively. Moreover, nearly all biological 
studies of NatB have been conducted in Saccharomyces cerevisiae (Lee et al. 2014; 
Caesar, Warringer, and Blomberg 2006; Singer and Shaw 2003), Arabidopsis 
(Ferrandez-Ayela et al. 2013; Huber et al. 2020), mouse (Ohyama et al. 2012) and 
human (Neri et al. 2017; Starheim et al. 2008; Ametzazurra et al. 2008; Ametzazurra et 
al. 2009) as model organisms. As a result, the mode of human NatB-mediated catalysis 
and αSyn-specific NatB recognition remains unresolved. In this study, we report the 3.5 
Å resolution cryo-electron microscopy (Cryo-EM) structure of the ~130 KDa hNatB 
bound to a bisubstrate CoA-αSyn conjugate, together with a structure-guided analysis of 
mutational effects on catalytic activity.  This analysis reveals functionally important 
structural differences between hNaB and related NAT enzymes, as well as insights into 
the molecular mechanisms that define αSyn and related substrates that are recognized 





4.2.1 hNatB is potently inhibited by a CoA-aSyn conjugate 
While attempts to express recombinant hNatB in E. coli were unsuccessful, we 
found that overexpression of hNatB complex with full-length hNAA25 (residues 1-972) 
and C-terminally truncated hNAA20 (residue 1-163 out of 178 total residues) in 
baculovirus-infected Sf9 insect cells produced soluble protein that could be purified to 
homogeneity (Fig. 4.1A). To evaluate the activity of the recombinant hNatB, we tested it 
against different peptide substrates. αSyn with an N-terminal sequence of “MDVF” has 
been widely considered as an in vivo hNatB substrate (Anderson et al. 2006; Ohrfelt et 
al. 2011; Theillet et al. 2016; Van Damme et al. 2012). We therefore incorporated this 
sequence into a peptide substrate named “MDVF” for an in vitro acetyltransferase assay 
(“MDVF” peptide sequence: NH2-MDVFMKGRWGRPVGRRRRP-COOH). In agreement 
with in vivo studies (Theillet et al. 2016; Anderson et al. 2006; Ohrfelt et al. 2011; Van 
Damme et al. 2012), we observed that the purified recombinant hNatB was active 
against this “MDVF” peptide, while no activity could be observed in the absence of either 
the enzyme or peptide (Fig. 4.1B). hNatB also showed no observable activity if either 
the first residue “M” or the first two residues “MD” in this αSyn peptide substrate was 
removed (“DVFM” peptide sequence: NH2-DVFMKGLRWGRPVGRRRRP-COOH; 
“VFMK” peptide sequence: NH2- VFMKGLSRWGRPVGRRRRP-COOH) (Fig. 4.1B), 
suggesting that peptide substrate recognition by NatB is highly dependent on the first 
two N-terminal residues. To further confirm the substrate specificity of hNatB, we tested 
it against several previously identified peptide substrates for other NATs (“SASE” 
peptide sequence (NatA-type): NH2-SASEAGVRWGRPVGRRRRP-COOH; “MLRF” 
peptide sequence (NatC-type): NH2-MLRFVTKRWGRPVGRRRRP-COOH; “SGRG”/H4 
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peptide sequence (NatD-type): NH2-SGRGKGGKGLGKGGAKRHR-COOH; “MLGP” 
peptide sequence (NatE-type): NH2-MLGPEGGRWGRPVGRRRRP-COOH) (Fig. 4.1B). 
Consistent with previous results (Van Damme et al. 2012), hNatB is only active toward 
its unique canonical substrate type, displaying no overlapping activity towards other NAT 
substrates.  
  In order to understand the mechanism of hNatB substrate recognition, we 
synthesized a bi-substrate inhibitor in which the first 10 residues of αSyn are covalently 
linked to CoA (Liszczak et al. 2013) for enzymatic and structural studies. Half-maximum 
inhibitory concentration (IC50) determinations revealed that this CoA-αSyn conjugate had 
an IC50 of about 1.63 ± 0.13 µM (Fig. 4.1C), significantly lower than the Km values we 
had determined for hNatB toward a “MDVF” peptide (45.08 ± 3.15 µM) and acetyl-CoA 





Figure 21.1 hNatB is active toward an α-Synuclein peptide and can be inhibited by 
a CoA-Syn conjugate 
A. Gel filtration elution profile of hNatB, using a Superdex S200 column. Coomassie-
stained SDS-PAGE of peak fractions is reproduced to the right of the chromatograms. B. 
Comparison of hNatB activity toward different peptide substrates. All the activities are 
normalized to the activity of hNatB toward αSyn peptide (MDVF). C. Dose-response 
curve corresponding to the titration of CoA-αSyn conjugate (CoA-MDVFMKGLSK) into 
hNatB acetyltransferase reactions. The calculated IC50 value is indicated. Reactions 






Table 6.1 Catalytic parameter of wild-type hNatB and mutants 
 
 
4.2.2 hNatB reveals potentially biologically significant structural differences with hNatA 
and caNatB 
We performed single particle Cryo-EM of hNatB in the presence of the CoA-αSyn 
conjugate. A 3.46 Å-resolution Cryo-EM three-dimensional (3D) map was determined 
from 982,420 particles, selected from 5,281 raw electron micrographs (Table 4.2, Fig. 
4.2). The central core region of the EM map contains excellent side chain density with a 
local resolution of ~ 2.5 Å, particularly around the catalytic subunit, hNAA20.  
  Consistent with previous NAT structural studies, the atomic model of hNatB 
features a catalytic subunit, hNAA20, that adopts a canonical Gcn5-related N-
Acetyltransferase (GNAT) fold (Neuwald and Landsman 1997). Additionally, the model 
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reveals that the auxiliary subunit hNAA25 is composed of a total of 39 α-helices among 
where the predicted first and second α-helices were built as poly-alanine due to a lack of 
resolvable side-chain density (Fig. 4.2). The 39 α-helices can be roughly divided into 
three groups: an N-terminal region: α1- α8; a core region: α9- α29; and a C-terminal 
region: α30-α39 (Fig. 4.2A). The N terminal region (residue 1-164) displays relatively 
weak EM density compared to other regions, suggesting that it is relatively flexible. The 
eight helices of the N terminal region form four helical bundle tetratricopeptide repeat 
(TPR) motifs, which often participate in protein-protein interactions. While there are no 
visible contacts between the N-terminal TPR motifs and hNAA20, it is possible that this 
region participates in ribosome association, similar to the N-terminal region of the 
NAA15 auxiliary subunits of Schizosaccharomyces pombe (Magin et al. 2017) and 
Saccharomyces cerevisiae (Knorr et al. 2019) NatA.  The 21 helices of the core region 
also form a number of TPR motifs, which come together to form a ring that completely 
wraps around and extensively contacts hNAA20 within its hollow center (Fig. 4.2A). 
Indeed. the interaction between hNAA20 and the TPR motifs of this core region buries a 
total interface area is about 2300 Å2. In the core region, it is noteworthy that there is a 
long α-helix (α28, ranging 30 residues) that traverses almost from one side of the 
complex to the other. The α28 helix closes the core ring structure, locking hNAA20 in 
position, and bridging the N- and C-terminal and regions. This is similar to the role 
played by α29-α30 of the hNAA15 auxiliary subunit of hNatA (Fig. 4.2A and 4.2B). The 
C terminal region features helices that bundle together to protrude out of the plane of the 
core ring structure at an angle of ~ 45° (Fig. 4.2B).  
  The sequence identity of the catalytic and auxiliary subunits of hNatA and 
hNatB are 20%, and 15 %, respectively. To understand how this translates to key 
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structural differences, we superimposed the crystal structure of hNatA (PDB: 6C9M) with 
our model. Between the catalytic subunits, there is a high degree of superposition (1.151 
Å root-mean-square deviation [RMSD] over 105 common Cα atoms), except for an 
additional helix, α5, on the C-terminus of hNatA-NAA10, which is absent in hNatB-
NAA20 (Fig. 4.2B). Between the auxiliary subunits, the core and N-terminal regions of 
both hNatA-NAA15 and hNatB-NAA25 display similar topology, although a higher 
degree of deviation than the catalytic subunits. The core regions both wrap around their 
respective catalytic subunits (8.369 Å RMSD over 262 common Cα atoms), while the N-
terminal regions jut off to the side (7.360 Å RMSD over 55 common Cα atoms). In 
contrast, the C-terminal regions of hNatA-NAA15 and hNatB-NAA25 diverge significantly 
from one another. For hNA25, the C-terminal region of hNAA25 is oriented towards its 
N-terminal region, while the C-terminal region of hNAA15 is positioned ~ 50Å away from 
the relative position of the superimposed C-terminal domain of hNAA25 (Fig. 4.2B).  The 
positioning of hNAA25 may serve to promote hNAA25 intra-termini communication, 
which is similar to the interaction of hNatA and its regulatory protein HYPK (Gottlieb and 
Marmorstein 2018).  HYPK, which does not interact with hNatB, interacts with both the 
N- and C-terminal domains of hNatA-NAA15, potentially serving as bridge to enable 
closer communication between these two domains (Fig. 4.2).  Recent reports have 
described the role of the small molecule IP6 (inositol hexaphosphate) in hNatA activity, 
where it is found to act as “glue” between the C-terminal and core domains in hNAA15 
and hNAA10 via a series of hydrogen bonds and electrostatic interactions (Gottlieb and 
Marmorstein 2018; Cheng et al. 2019). While no corresponding small molecules have 
been identified to play a similar role in hNatB, our model shows that this interaction is 
replaced by an extended loop that connects the 31 helix with the 32 helix of hNatB-
NAA25.  This loop, which is not present in hNatA-NAA15, appears to mediate 
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hydrophobic interactions between hNatB-NAA25 and -NAA20, likely to serve a similar 
role as IP6.  
  We also compared the structures from human and the previously described C. 
albicans NatB (CaNatB, PDB: 5K18).  Although the two superimposed structures 
revealed a high degree of structural conservation (NAA20: 0.698 Å RMSD over 125 
common Cα atoms; NAA25 Core region: 3.267 Å RMSD over 266 common Cα atoms), 
the N-terminal region of hNatB-NAA25 appears to overlay more closely to hNatA-NAA15 
than to CaNatB-NAA25 (Fig. 4.2B and C). Compared to CaNAA25, the N-terminal 
regions of hNatB-NAA25 and hNatA-NAA15 are positioned more closely to the peptide 
substrate binding sites of the respective catalytic subunits. Based on the role that the N-
terminal yeast NatA-Naa15p regions play in ribosome docking (Magin et al. 2017; Knorr 
et al. 2019), we propose that the relative shift in position of the N-terminal regions of the 
human NAT auxiliary subunits, hNAA15 and hNAA25, may reflect a difference in 
mechanism for ribosome association and co-translational NTA in C. albicans compared 
with humans. In addition, the overlay of C terminal regions of hNAA25 and CaNAA25 
displays a RMSD of 15.960 Å over 133 common Cα atoms. We observe that the main 






Figure 22.2 hNatB shows structural differences with hNatA and C. albicans NatB 
hNaa20 (light orange) and hNaa25 (cyan) are shown in cartoon. The CoA- Syn 
conjugate inhibitor is shown in sticks and colored as magenta. The N- and C- terminal 
regions are indicated as “N” and “C”, respectively. Some helices are as labeled.  B. 
hNaa20 (light orange) and hNaa25 (cyan) are shown overlapped with hNatA (marine 
blue, PDB: 6C9M). Small molecule IP6 bound to hNatA is shown as surface 
representation (red). C. hNaa20 (light orange) and hNaa25 (cyan) are shown 




Table 7.2 Cryo-EM data collection, refinement, and validation statistics 
 
 
4.2.3 hNAA25 and hNAA20 make intimate interactions within hNatB 
The hNatB/CoA-αSyn structure reveals an extensive interaction interface 
between the core region of the auxiliary hNAA25 and catalytic hNAA20 subunits (Fig. 
4.3A).  The most intimate contact between the two proteins are made by the α28 - α29 
segment of hNAA25 and almost the entire length of hNAA20 α2, creating a large 
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hydrophobic interface (Fig. 4.3B). Residues that contribute to interaction include Thr26, 
Gly28, Ile29, Pro30, Leu33, Gln34, Leu36, Ala37, His38, Glu41 of hNAA20 and Lys535, 
His536, Ile537, Phe569, Asp576, Thr577, Tyr580, Ala584, Tyr 587, Lys592, Phe596, 
Phe599, Leu603 of hNAA25 (Fig. 4.3B).  Another region of interaction, involving 
predominantly van der Waals interaction occurs between the hNAA20 β4- α3 loop and 
the hNAA25 α18- α19 loop. Here, residues Lys362, Pro363, Lys362-Thr367, Cys364, 
and Pro363 from hNAA25 and residues Arg85, Phe83, Glu82 and Arg84 from hNAA20 
contribute to this small batch of hydrophobic interface (Fig. 4.3C).  
  Additional intimate contacts between hNAA20 and hNAA25 are mediated 
between hNAA20 α1 helix and α26-α27 loop, and the hNAA25 α24-α25 loop, consisting 
of a mix of polar and non-polar interactions.  A few hydrogen bonds are formed, 
centered around hNAA20-Asn16, between the sidechain nitrogen atoms of hNAA20-
Asn16 and sidechain oxygen of hNAA25-Thr541, between the sidechain oxygen atom of 
hNAA20-Asn16 and sidechain nitrogen atom of hNAA25-Gln538, and between the 
sidechain nitrogen of hNAA20-Asn16 and the sidechain of hNAA25-Asp657 (Fig. 4.3D). 
A salt bridge is found between the sidechain of hNAA20-Asp10 and the sidechain of 
hNAA25-Arg602. In addition, there are hydrophobic interactions between residues 
Phe15, Leu12, Phe13, Leu19, Pro22 from hNAA20 and residues Ile537, Asp540, 
His536, Ala506, Phe662, Ser504, Ile542, Leu603 from hNAA25 (Fig. 4.3D).  
  Different sides of hNAA20 feature several potentially hNAA25-stabilizing polar 
interactions. Hydrogen bonds are formed between the Asp261 side chain of the hNAA25 
α14-α15 loop and the hNAA20-Thr2 backbone nitrogen atom (Fig. 4.3E), between the 
Glu227 backbone carbonyl group of hNAA25 α12-α13 loop and the hNAA20-Arg102 
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sidechain (Fig. 4.3F), and between the Lys535 sidechain from NAA25 α26-α27 loop and 
the hNAA20-Ser141 backbone carbonyl group (Fig. 4.3G). 
 
Figure 23.3 hNAA20 and hNAA25 make intimate interactions within hNatB 
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A. hNAA20 (light orange) and hNAA25 (cyan) are shown in cartoon with major 
associated interface denoted. B-G. Zoom-in views of the hydrophobic interface regions 
as indicated in A. 
 
4.2.4 hNatB makes specific interactions with the first 4 N-terminal residues of aSyn 
In the Cryo-EM map, density for the CoA-αSyn conjugate bisubstrate inhibitor is 
well resolved, allowing us to confidently model the CoA portion and the first five N-
terminal residues (of ten residues present) of the αSyn portion (Fig. 4.4A and 4.4B). 
Similar to other NATs, CoA enters the catalytic active site through a groove formed by 
α3 and α4 of the catalytic subunit, while the peptide substrate enters the active site on 
the opposite side of the catalytic subunit flanked by the α1-2 and β6- β7 loops (Fig. 
4.4A).  
  hNAA20 contains a conserved acetyl-CoA binding motif among NATs: 
R84R85XG87XA89. Here, we observe that the positively charged hNAA20-Arg 85 interacts 
with the negatively charged 3'-phosphorylated ADP portion of CoA to form a salt bridge 
while Arg84 makes Van der Waals interactions (Fig. 4.4C and 4.4D). A hydrogen 
bonding network is formed mainly between the 5’-diphosphate group and backbone 
atoms of a few residues including Val79, Gly87, Ala89, and Ala90 (Fig. 4.4C and 4.4D), 
and mediated by the side chains of Arg85 and Gln125. The CoA molecule anchors to the 
binding pocket through a series of van der Waals contacts formed by residues Ser67, 
Val79, Leu77, Leu88, Val118, Met 122, and Tyr123 (Fig. 4.4D).  
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  Four N-terminal residues of αSyn participate in hNAA20 interactions. Anchoring 
of the αSyn peptide is mediated by protein hydrogen bonds with the backbone atoms of 
Met1 and Asp2 of αSyn. Hydrogen bonds are formed between the backbone N-H group 
of αSyn-Met1 and the backbone carbonyl group of hNAA20-Phe111, as well as the 
backbone carbonyl group of αSyn-Met1 with the sidechain of hNAA20-Tyr138. The 
backbone N-H and carbonyl of αSyn-Asp2 also form hydrogen bonds to the sidechain of 
Tyr27, and between the backbone carbonyl group of Asp2 and sidechain of hNAA20-
Tyr27 (Fig. 4.4D). Remarkably, hNAA20 contacts each of the first four N-terminal 
residue side chains of αSyn via van der Waals interactions.  The only side chain that 
forms a hydrogen bond with hNAA20 is αSyn-Asp2, which hydrogen bonds with a 
hNAA20-His73 ring nitrogen and the hNAA20-Thr75 side chain (Fig. 4.4D). The more 
extensive van der Waals interactions include the following: αSyn-Met1 interacts with 
hNAA20 residues Glu25, Phe27, Tyr56 and Ala76; αSyn-Asp2 interacts with hNAA20 
residues Try27, Thr75, His73, Phe111, and Tyr138; αSyn-Val3 interacts with hNAA20 
residues Tyr137 and Tyr138; and αSyn-Phe4 interacts with hNAA20 residues Glu25 and 
Als140. αSyn-Met5 does not appear to make specific interactions (Fig. 4.4D). Consistent 
with the importance of the residues that mediate αSyn binding, most of the residues are 




Figure 24.4 hNAA20 makes key CoA- and substrate peptide-interactions 
A. The structure of hNAA20 bound to the CoA- Syn conjugate bound is shown in 
cartoon, with corresponding secondary structures labeled. B. The fit of the CoA- Syn 
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conjugate ligand in the EM density map. The contour level is 4.0 sigma. C. Interaction 
between CoA- Syn conjugate and hNAA20 residues is generated with LIGPLOT 
(Laskowski and Swindells 2011). Hydrogen bonds are indicated by dashed green lines, 
and van der Waals interactions are indicated with red semicirlcles. D. Highlighted polar 
and hydrophobic interactions between CoA- Syn conjugate and the hNAA20 are 
depicted in 3D view.  
 
4.2.5 Mutational analysis identifies key residues for hNatB catalysis and cognate 
substrate binding 
To determine the functional importance of hNAA20 residues that appear to make 
important peptide or CoA substrate contacts in our model, we used an in vitro 
acetyltransferase assay to kinetically characterize WT and mutant hNatB proteins. Each 
mutant was purified to homogeneity and displayed identical gel filtration chromatography 
elution profiles (data not shown), indicating that they were all properly folded. We 
prepared alanine mutants of several residues involved in the CoA binding including 
Arg84, Arg85, Gly87 and Tyr123. Among them, R84A, R85A and G87A did not show 
significant defects in overall protein catalytic function (Table 4.1). However, a Y123A 
mutant nearly abolished protein activity, with a 95% loss of protein activity, affecting both 
kcat and Km (Table 4.1). To further interrogate the properties of this residue, we prepared 
a Y123F mutant which features a similar aromatic bulky side chain but not the polar p-
hydroxyl group. We observed that Y123F displayed a similar ~88% loss of kcat, but had a 
negligible effect on the peptide Km (Table 4.1). These data suggested that the Tyr123 
hydroxyl group is critical for catalysis but not required for substrate binding, while the 
aromatic ring of Tyr123 plays a role in peptide substrate binding. Given that the hydroxyl 
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group of Tyr123 is about 3.5 Å from the sulfur atom of the CoA- Syn conjugate and 6.3 
Å away from the αSyn N-terminus, it is in a position to play a role as a general base or 
acid for catalysis, potentially through an intervening water molecule (Fig. 4.5A). This is 
analogous to the proposed general base role of Tyr31 as a general base for hNAA50 
catalysis (Liszczak, Arnesen, and Marmorstein 2011) (See discussion).  
  We also prepared alanine substitutions for residues that appeared to play 
important roles in αSyn binding: Glu25, Tyr27, His73, Tyr137, Tyr138. We were 
surprised to find that mutations of hNatB residues that mediated backbone hydrogen 
bond interactions, Y27A and Y138A, had relatively modest effects on αSyn peptide NTA 
with Y27A showing ~2-fold higher Km and Y138A showing ~2-fold reduced Kcat, together 
suggesting that side chain contacts might dominate the binding energy (Table 4.1).  
Consistent with this, and our structural observations, we found that H73A produced a 
~90% reduction in activity (Table 4.1).  This correlates with the importance of the His73 
hydrogen bond and van der Waals contacts with αSyn-Asp2. Of note, other cognate 
hNatB side chain residues at position 2, Glu, Gln, and Asn would also be well positioned 
to form hydrogen bonds with His73. Together, hNAA20-His73 appears to play a critical 
role in cognate substrate recognition by hNatB.   
  hNatB-Asn116 is a highly conserved NatB residue that caps the hNAA20 4 
helix, which also harbors the putative catalytic residue, Tyr123, and is also in position to 
make a water-mediated hydrogen bond with to CoA pantetheine nitrogen (Fig. 4.5A). 
This observation suggests that Asn116 could play an important functional role. To test 
this, we prepared and evaluated an N116A mutant and, consistent with our hypothesis, 
Ans116, we found that this mutant leads to ~ 90% loss in activity (Table 4.1).  
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Taken together, our structural and mutational analysis of hNatB highlight the 
functional importance of hNatB-NAA20 residues His73, Asn116, and Tyr123 in hNatB-
mediated N-terminal acetylation.  While Tyr123 appears to play a critical catalytic role, 
potentially as a general base and/or acid for catalysis; His73 appears to play an 
important role in the recognition of substrate residue 2 and Asn116 likely plays a 
structural role (Fig. 4.5A). Each of these residues could employ a bridging water 
molecule to mediate their functional roles, although these putative water molecules are 





Figure 25.5 Structural comparison between hNAA20 and hNAA50 
A. Bi-substrate inhibitor-bound hNAA20 (light orange) is shown superimposed with 
hNAA50 (grey, PDB: 3TFY). H73, N116, and Y123 (sticks), mediate important functional 
roles in hNatB catalysis. B. Residues forming the Met1 binding pocket of hNAA20 are 





Since the identification of hNatB more than a decade ago, many studies have 
shown that it N-terminally acetylates important proteins such as actin, tropomyosin, 
CDK2, and α-Synuclein, and its function has connections to diseases such as 
hepatocellular carcinoma and Parkinson disease (Spillantini et al. 1998; Polevoda et al. 
2003; Ametzazurra et al. 2008; Starheim et al. 2008; Halliday et al. 2011; Neri et al. 
2017). Despite its clear biological importance, hNatB-mediated NTA by hNatB remained 
poorly understood. Here, we developed a CoA-αSyn conjugate hNatB inhibitor, 
determined the Cryo-EM structure of CoA-αSyn inhibitor-bound hNatB, and carried out 
associated structure-guided mutagenesis and activity assays. This has led to the 
identification of functionally important differences with human NatA and C. albicans 
NatB. These studies have also provided evidence for important hNatB-specific elements 
responsible for αSyn recognition and N-terminal acetylation, providing direct implications 
for NatB recognition of other canonical substrate proteins. 
  Consistent with previous studies, we have demonstrated that hNatB acetylates 
a cognate “MD” N-terminus, and is unable to N-terminally acetylate non-cognate N-
termini that are substrates for other NATs such as NatA, NatC, NatE. We demonstrated 
for the first time that hNatB can acetylate an α-Syn peptide in vitro, directly linking hNatB 
to NTA of α-Syn. We have also demonstrated that αSyn peptides lacking the Met1 or 
both the Met1 and Asp2, do not serve as hNatB substrates, confirming the strict 
substrate specificity of hNatB. This is consistent with our structural model showing 
significant interactions between hNatB-NAA20 and both the first and second N-terminal 
residues of an αSyn peptide, with important but less extensive interactions with the third 
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and fourth residues.  This hierarchy of interactions likely explains how NatB enzymes 
can accommodate cognate substrates that diverge at positions three and four. 
  Here, we have presented hNatB-αSyn interactions that can be used to 
rationalize the substrate specificity of hNatB: N-terminal sequences containing “MD-”, 
“ME-”, “MN-”, and “MQ-”. αSyn-Met1 sits in a hydrophobic pocket that comfortably 
accommodates a methionine residue, whereas shorter side chains or longer polar or 
charged side chains would fit poorly (Fig. 4.5B-C). The nature of this binding pocket is 
similar to the described hNAA50 recognition of Met1 (Liszczak, Arnesen, and 
Marmorstein 2011) (Fig. 4.5B-C). Although both of hNAA50 and hNAA20 can N-
terminally acetylate peptides with Met at the first position, no overlapping activity has 
been observed. This can be rationalized based on the chemical properties of the second 
residue in the cognate peptide. We find that the αSyn-Asp2 sidechain forms hydrogen 
bonds with the hNAA20 side chains His73 and Thr75. These polar residues in the 
peptide binding site of hNAA20 would likely serve as poor acceptors of the largely 
hydrophobic residues targeted by hNAA50. The hNatB substrate client profile featuring 
D-, E-, N- or Q-residues in position two is consistent with the mechanisms of substrate 
recognition observed in the binding pocket for αSyn-Asp2. The aliphatic regions of each 
of these side chains (D, E, N, Q) would all benefit from the extensive hNatB van der 
Waals interactions surrounding the aliphatic region for αSyn-Asp2 (Tyr27, His73, Thr75, 
Phe111, and Tyr138).  This second residue would also form a hydrogen bond interaction 
with His73 and Thr75, which may accommodate the carboxyl side chains of both the 
shorter D- and N- and longer E- and Q- side chains.  Notably, His73 and Thr75 are 
strictly conserved from yeast to man (Fig. 4.5). In contrast, shorter polar or nonpolar side 
chains would less efficiently fill the pocket for residue two, while larger polar or charged 
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side chains would likely result in steric clashes. In agreement with this, we have 
demonstrated that H73A mutation has severe impact on hNatB catalysis (Table 4.1).   
  The hNatB/CoA-αSyn structure has implications for the mode of hNatB 
catalysis. While previous studies have suggested that hNAA50-Tyr31 plays an important 
role in catalysis, mutation of the corresponding hNaa20 residue, Tyr27, had minimal 
effects on hNatB kinetic parameters. Strikingly, our mutational analysis has identified the 
functional importance of hNatB-NAA20 residues His73, Asn116 and Tyr123, although 
Tyr123 is the only residue that is in position to play a catalytic role (Fig. 4.5A). 
Specifically, Tyr123 is in position to play a catalytic role, potentially as a general base 
and/or acid, through a bridging water molecule (although a water molecule is not visible 
at the current resolution). Interestingly, hNAA50 contains a tyrosine residue at the same 
position (hNAA50-Tyr124), although the mechanistic significance of this tyrosine residue 
has not yet been described (Liszczak, Arnesen, and Marmorstein 2011).  It would be of 
interest to determine if hNAA50-Tyr124 also plays an important catalytic role (possibly in 
combination with hNAA50-Tyr31), similar to the corresponding hNAA20-Tyr123 of 
hNatB. 
  The biological importance of hNatB and its connection to various disease 
processes highlights it as an important target for probe and inhibitor development. 
Indeed, a recent study highlights hNatB as a therapeutic target for aSyn toxicity 
(Vinueza-Gavilanes et al. 2020). Our development of a CoA-αSyn conjugate bisubstrate 
with an IC50 of ~ 1.6 µM represents a step in this direction, although the structural 
information provided here could further aid to the rational development of more drug-like 
hNatB inhibitors with possible therapeutic applications. 
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4.4 Materials and methods 
4.4.1 Protein expression and purification 
hNAA20 with a C-terminal truncation (1-163 out of 178 residues) and full-length 
hNAA25 were cloned into two separate insect cell expression vectors pFASTBac HTA. 
hNAA20 was untagged, while hNAA25 contained a Tobacco-etch virus (TEV)-cleavable 
N-terminal 6xHis-tag. Human NatB complex (hNAA201-163/hNAA25FL) was obtained by 
co-expressing these two plasmids in Sf9 (S. frugiperda) cells (ThermoFisher, cat# 
12659017), and purified as described previously (Gottlieb and Marmorstein 2018). Sf9 
cells were grown to a density of 1x106 cells/ml and infected using the amplified 
hNAA201-163/hNAA25FL baculovirus to an MOI (multiplicity of infection) of 1-2. The cells 
were grown at 27 °C and harvested for 48 hours post-infection by centrifugation. Cell 
pellets were resuspended in lysis buffer (25 mM Tris, pH 8.0, 300 mM NaCl, 10 mM 
Imidazole, 10 mM β-ME, 0.1 mg/mL PMSF, DNase, and complete, EDTA-free protease 
inhibitor tablet) and lysed by sonication. After centrifugation, the supernatant was 
isolated and passed over Ni-NTA resin (Thermo Scientific), which was subsequently 
washed with 10 column volumes of lysis buffer. Protein was eluted with a buffer with 25 
mM Tris, pH 8.0, 300 mM imidazole, 200 mM NaCl, 10 mM β-ME, which was dialyzed 
into buffer with 25 mM HEPES pH 7.5 50 mM NaCl 10 mM β-ME. Ion-exchange was 
carried out with an SP ion-exchange column (GE Healthcare) in dialysis buffer with a salt 
gradient (50-750 mM NaCl). Peak fractions were concentrated to ~ 0.5 mL with a 50-kDa 
concentrator (Amicon Ultra, Millipore), and loaded onto an S200 gel-filtration column (GE 
Healthcare) in a buffer with 25 mM HEPES, pH 7.5, 200 mM NaCl, and 1 mM TCEP. 
Proteins were aliquoted, snap-frozen in liquid nitrogen, and stored at −80 °C for further 
use. Protein harboring mutations were generated with the QuickChange protocol 
133 
 
(Stratagene) and obtained following the same expression and purification protocol as 
described for the wild-type protein.  
 
4.4.2 Acetyltransferase activity assays 
All acetyltransferase assays were carried out at room temperature in a reaction 
buffer containing 75 mM HEPES, pH 7.5, 120 mM NaCl, 1 mM DTT as described (Deng, 
McTiernan, et al. 2020; Deng et al. 2019). The “MDVF” peptide substrate was based on 
the first 7 amino acid of α-Synuclein (“MDVF” peptide: NH2-
MDVFMKGRWGRPVGRRRRP-COOH; “SASE” peptide: NH2-
SASEAGVRWGRPVGRRRRP-COOH; “MLGP” peptide: NH2-
MLGPEGGRWGRPVGRRRRP-COOH; “SGRG”/H4 peptide: NH2-SGRGKGGKG 
LGKGGAKRHR-COOH; “MLRF” peptide: NH2-ML    RFVTKRWGRPVGRRRRP-COOH; 
“DVFM” peptide: NH2- DVFMKGLRWGRPVGRRRRP-COOH; “VFMK” peptide: NH2- 
VFMKGLSRWGRPVGRRRRP -COOH; GenScript). Reactions were performed in 
triplicate. To determine steady-state catalytic parameters of hNatB with respect to acetyl-
CoA, 100 nM hNatB was mixed with a saturating concentration of “MDVF” peptide 
substrate (500 μM) and varying concentrations (1.95 μM to 1 mM) of acetyl-CoA (14C-
labeled, 4 mCi mmol−1; PerkinElmer Life Sciences) for 10-minute reactions. To 
determine steady-state catalytic parameters of hNatB with respect to peptide substrate, 
100 nM hNatB was mixed with saturating concentrations of acetyl- CoA (300 μM, 14C-
labeled) and varying concentrations of “MVDF” peptide (1.95 μM to 1 mM) for 10 
minutes. Reactions were quenched by adding the solution to P81 paper discs 
(Whatman). Unreacted acetyl-CoA was removed by washing the paper discs in buffer 
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with 10 mM HEPES, pH 7.5, at least three times, each 5 minutes. The paper discs were 
then dried with acetone and transferred to 4 mL scintillation fluid for signal measurement 
(Packard Tri-Carb 1500 liquid scintillation analyzer). Data was fitted to a Michaelis–
Menten equation in GraphPad Prism to calculate kinetic parameters. Kinetic parameters 
on mutants with respect to peptide were carried out in the same condition as for wild 
type, with 300 μM 14C labeled acetyl-CoA and varied peptide concentration (1.95 μM to 1 
mM). All radioactive count values were converted to molar units with a standard curve 
created with known concentrations of radioactive acetyl-CoA added to scintillation fluid. 
GraphPad Prism (version 5.01) was used for all data fitting to the Michaelis–Menten 
equation. For IC50 determination of the CoA-αSyn conjugate, 100 nM hNatB was mixed 
with 500 μM “MVDF” peptide and 300 μM 14C labeled acetyl-CoA, and inhibitor 
concentrations were varied (0.23 μM to 13.44 μM). Data were fit to a sigmoidal dose-
response curve with GraphPad Prism (version 5.01). Errors represent s.d. (n = 3). 
4.4.3 Cryo-EM data collection 
For initial sample screening, 0.6 mg/ml fresh hNatB sample with three-molar 
excess bisubstrate was used. hNatB particles on these grids exhibited a severe 
preferred orientation, which generated an incorrect 3D initial model (data not shown). To 
solve this issue, 1 μL of 0.05% NP-40 was mixed with 20 μL of hNatB (4 mg/mL). 3 μL of 
this sample was applied to glow-discharged Quantinfoil R1.2/1.3 holey carbon support 
grids, blotted and plunged into liquid ethane, using an FEI Vitrobot Mark IV. An FEI TF20 
was used for screening the grids and data collection was performed with a Titan Krios 
equipped with a K3 Summit direct detector (Gatan), at a magnification of 105,000 x, with 
defocus values from -0.1 to -2.0 µm. Each stack was exposed in super-resolution mode 
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with a total dose of 45 e-/Å2, resulting in 35 frames per stack. Image stacks were 
automatically collected with Latitude software (Gatan, Inc). 
4.4.4 Cryo-EM data processing 
Original image stacks were summed and corrected for drift and beam-induced 
motion at the micrograph level using MotionCor2 (Zheng et al. 2017), and binned 
twofold, resulting in a pixel size of 0.83 Å/pixel. Defocus estimation and the resolution 
range of each micrograph were performed with Gctf (Zhang 2016).  About 3000 particles 
were manually picked to generate several rough 2D classaverages. Representative 2D 
classes were used to automatically pick ~1,927,673 particles from 5281 micrographs in 
Relion 3.0 (Kimanius et al. 2016; Zivanov et al. 2018). All particles were extracted and 
binned to accelerate the 2D and 3D classification. After bad particles were removed by 
2D and 3D classification, 982, 420 particles were used for auto-refinement and per 
particle CTF refinement. After refinement, a mask was created in Relion with an initial 
binarization threshold of 0.005, covering the protein complex and extending the binary 
map and soft-edge by 12 pixels. The map was sharpened with the created mask by 
estimating B-factor automatically in Relion. The final map was refined to an overall 
resolution of 3.46 Å, with local resolution estimated by Resmap (Kucukelbir, Sigworth, 
and Tagare 2014). We attempted particle polishing on this data set, but this surprisingly 
resulted in artifactual density in the resulting map. We believe that this was due to some 
small defects in the K3 camera during data collection, which corrupted the particle 
polishing process. We therefore did not perform particle polishing on this data set. Raw 
micrographs were deposited in EMPIAR with access ID of EMPIAR-10477.                                         
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4.4.5 Cryo-EM model building and refinement 
The hNatB atomic model was manually built de novo using the program COOT 
(Emsley and Cowtan 2004) according to the Cryo-EM map, with the guidance of 
predicted secondary structure and bulky residues such as Phe, Tyr, Trp and Arg. The 
first two alpha helices of hNAA25 were built as poly-alanine, due to the lack of tracible 
density in the 3D map. The complete model was then refined by real-space refinement in 
PHENIX (Adams et al. 2010).  All representations of Cryo-EM density and structural 
models were performed with Chimera (Pettersen et al. 2004) and PyMol 
(https://pymol.org/2/). The sequence alignments with secondary structure display were 
created by ESPript 3.0 (Robert and Gouet 2014b). hNAA25 TPR predictions were 
performed using the TPRpred server (Karpenahalli, Lupas, and Söding 2007; 
Zimmermann et al. 2018) (https://toolkit.tuebingen.mpg.de/#/tools/tprpred). The surface 
area calculation was performed using PDBePISA (Krissinel and Henrick 2007) (Proteins, 




































Substrate recognition by eukaryotic NATs is usually dictated by the first few 
residues of the substrate via the active site structure (Liszczak et al. 2013; Hong et al. 
2017; Magin, Liszczak, and Marmorstein 2015; Stove et al. 2016; Goris et al. 2018; 
Deng et al. 2019; Deng and Marmorstein 2021; Deng, Pan, et al. 2020). The active site 
of NatA contains a relatively small binding pocket to accommodate a small, uncharged 
residue at position 1 such as alanine, valine or threonine residues that remains following 
initiator methionine (iMet) - cleavage (Liszczak et al. 2013). NatB has a hydrophobic 
pocket for a retained iMet and uses a histidine residue to recognize sequences with 
D/E/N/Q at position 2 via hydrogen bonding (Arnesen et al. 2009; Deng and Marmorstein 
2021). Interestingly, NatC and NatE share similar and relatively versatile substrate 
profiles toward substrates containing a retained iMet followed by residues other than 
D/E/N/Q (Van Damme et al. 2016a; Arnesen et al. 2009). NatD is a highly selective 
enzyme with histones H4 and H2A as its only known substrates (Hole et al. 2011; Song 
et al. 2003), arising from extensive and specific interactions with each of the first four 
residues of its substrate (Magin, Liszczak, and Marmorstein 2015). Although NATs vary 
in terms of their modes of substrate recognition, their mechanism of catalysis usually 
involves the use of dedicated residues to serve as general base and acid residues 
(Deng and Marmorstein 2021). 
The activity of some NATs is further regulated by other protein modulators. For 
example, within the human NatE complex, there is catalytic crosstalk between the two 
NAA10 and NAA50 catalytic subunits (Deng et al. 2019). Moreover, the activities of both 
NatA and NatE are inhibited to a different extent by a small protein binding partner called 
Huntingtin-interacting protein K (HYPK) (Deng, McTiernan, et al. 2020; Gottlieb and 
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Marmorstein 2018; Weyer et al. 2017; Arnesen et al. 2010). Inositol hexaphosphate (IP6, 
also named inositol hexaphosphate or phytic acid), a small molecule, usually reserved 
for cellular signaling, appears to act as a stabilizing ligand for both NatA and NatE, by 
binding in a pocket between NAA15 and NAA10, and, thus, plays an indirect role in 
promoting NatA and NatE acetylation activity (Gottlieb and Marmorstein 2018; Deng, 
McTiernan, et al. 2020; Deng et al. 2019; Cheng et al. 2019). 
NatC is distinct from other NATs since it contains two eukaryotic conserved 
auxiliary subunits – Naa38 and Naa35 – that act together with the Naa30 catalytic 
subunit (Polevoda and Sherman 2001; Ochaya et al. 2019; Starheim et al. 2009). Initial 
studies reported that NatC activity requires the interaction of all three subunits, since 
knock out of any single subunit produced a similar phenotype in yeast that was 
accompanied by diminished N-terminal acetylation of a cognate N-terminal substrate, 
MIRLK- (Polevoda and Sherman 2001). However, it was subsequently reported that the 
Naa38 subunit is not required for in vivo acetylation of an Arl3p substrate with an N-
terminal protein sequence of MPHLV- (Setty et al. 2004a). In plants, knockout of 
AtNAA35 did not lead to similar phenotypic effects as the deletion of AtNAA30 (Pesaresi 
et al. 2003), and the single subunit of the A. thaliana analogue AtNAA30 can rescue the 
knockout of yeast NatC complex subunits (Pesaresi et al. 2003). Similarly, recombinant 
human NAA30 (hMak3) was shown to have substrate-specific acetylation activity, even 
in the absence of its auxiliary subunits (Starheim et al. 2009). Thus, the functional roles 
of the NatC auxiliary subunits are not clear, particularly with respect to Naa38, which is 
not well-conserved across species. Although the recently reported crystal structures and 
associated biochemical studies of S. cerevisiae NatC (ScNatC) by Grunwald et al. have 
provided some important insights into NatC substrate specificity and its catalytic 
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mechanism (Grunwald et al. 2020), several questions remain unanswered. In particular, 
those regarding the mechanisms dictating the overlapping yet distinct substrate profiles 
of NatC and NatE and the influence of IP6 on NatC. 
In this study, we report that yeast NatC complex formation of all three subunits is 
a prerequisite for normal NatC acetylation activity and that, like NatA and NatE, IP6 binds 
tightly to and stabilizes NatC. We also report the Cryo-EM structure of ~100 kDa S. 
pombe NatC (SpNatC) bound to a NatE/C-type bisubstrate analogue and IP6, with 
related biochemistry, to reveal the molecular basis for IP6-mediated stabilization of the 
complex and the similar substrate profiles of NatE and NatC. Comparison of these 
studies with the recently published structural and functional studies of the ScNatC 
complex (Grunwald et al. 2020) reveal evolutionarily conserved and divergent features of 
NatC. 
5.2 Results 
5.2.1 NAA38 is required for normal NatC acetylation activity in yeast 
We found that overexpression of the SpNatC complex containing full-length 
SpNaa30 (residues 1–150), N-terminally truncated SpNaa35 (residues 31–708, with 
deletion of divergent residues, 1-30) and SpNaa38 (residues 48-116, with deletion of 
divergent residues, 1-47) in E. coli produced soluble protein that could be purified to 
homogeneity (Figure 5.1a). To evaluate the activity of the recombinant ternary SpNatC, 
we used an in-vitro acetyltransferase activity assay with different peptide substrates. 
Consistent with previous studies, the recombinant SpNatC is active toward both its own 
canonical substrate - “MLRF peptide” and the canonical NatE substrate – “MLGP 
peptide”, but with preference for the “MLRF peptide” (Grunwald et al. 2020) (Figure 
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5.1b, see methods section for full peptide sequences). To investigate the catalytic roles 
of Naa38, we could readily purify both binary (ScNaa301-161 and ScNaa3519-733) and 
ternary ScNatC complexes (ScNaa301-161 and ScNaa3519-733, and ScNaa381-70) from 
Saccharomyces cerevisiae to compare their activities. Consistent with the studies by 
Grunwald et al (Grunwald et al. 2020), evaluation of the activities of the binary and 
ternary ScNatC complexes toward the canonical NatC substrate (MLRF peptide) 
revealed that the ternary complex showed robust activity, while the binary complex 
showed compromised activity (Figure 5.1b). Thus, it appears that Naa38 is required for 
optimal NatC activity in yeast.   
5.2.2 Inositol hexaphosphate (IP6) binding contributes to yeast NatC complex stability 
Earlier reports demonstrated that IP6 interacts with and stabilizes both the yeast 
and human NatA and NatE complexes (Deng, McTiernan, et al. 2020; Deng et al. 2019; 
Gottlieb and Marmorstein 2018; Cheng et al. 2019), but does not appear to interact with 
human NatB (Deng, Pan, et al. 2020). To determine if IP6 could bind to the recombinant 
NatC complex, we employed isothermal titration calorimetry (ITC). We found that IP6 
binds to SpNatC with a Kd of ~225 nM (with a stoichiometry of ~1) (Figure 5.1c), similar 
to its Kd value for yeast NatA (Deng et al. 2019). Differential scanning fluorimetry (DSF) 
was used to evaluate a potential role of IP6 binding in NatC complex stability. We found 
that addition of IP6 increased the thermal stability of ternary SpNatC, binary ScNatC, and 
ternary ScNatC, by ~4.9°C, 2.7°C, and 2.1°C, respectively. Thus, IP6 can provide 






Figure 26.1 Binary NatC displays deficiency in acetylation activity and inositol 
hexaphosphate (IP6) binding stabilizes NatC complex formation 
(a) Gel filtration elution profile of the ternary SpNatC complex using a Superdex S200 
column. Coomassie-stained SDS–PAGE of elution peak is shown in the box, with bands 
for corresponding SpNatC subunits labeled. (b) Comparison of SpNatC activity toward 
different peptide substrates. The activities shown in gray are normalized to the activity of 
SpNatC toward MLRF peptide. The pink and blue columns show the activity of binary 
and ternary ScNatC toward the MLRF peptide, respectively, and are normalized to the 
pink column. Errors are shown in SEM with n = 3. (c) Representative isothermal titration 
calorimetry (ITC) curve of IP6 titrated into SpNatC. The ITC fitting information is N = 
0.830 ± 0.00943 sites, ΔH = -1.091x104 ± 177.0 cal mol-1, ΔS = -6.79 cal mol-1 deg-1. (d) 
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Differential scanning fluorimetry assays of NatC alone or with IP6. Average calculated 
melting temperature transitions are indicated. Error bars in the figure indicate the SD of 
each sample, n = 3. 
 
5.2.3 NatC adopts a distinct NAT architecture 
In order to understand the molecular details underlying the ternary NatC 
complex, its overlapping yet distinct substrate specificity with NatE, and the mode of IP6 
stabilization, we performed single particle Cryo-EM analysis using ternary SpNatC 
prepared in the presence of the CoA-Ac-MLGP bisubstrate conjugate and IP6. The 
MLGP sequence was selected for synthesis of the conjugate inhibitor as it is a predicted 
substrate for both NatC and NatE. A 3.16 Å-resolution Cryo-EM three-dimensional (3D) 
map was determined from 607,131 particles, which were selected from 5,397 raw 
electron micrographs (Figure 5.2). Most areas of the EM map contained excellent 
sidechain density, with a local resolution of ~3 Å, suggesting the relative rigidity of the 
recombinant complex (Figure 5.2 and 5.3). The atomic model was built de novo based 
on the EM map and details for the model refinement statistics can be found in Table 5.1 
(Figure 5.3). 
The ternary SpNatC complex contains three proteins, the catalytic Naa30 
subunit, the large auxiliary Naa35 subunit, and the small auxiliary Naa38 subunit. Upon 
superficial inspection of the complex, it appears as though it is only formed by two 
proteins, as Naa38 is embedded within the Naa35 fold to form a “composite” auxiliary 
subunit (Figure 5.4a and 5.4b). While Naa30 displays a canonical NAT fold with mixed 
α/β secondary structure, the Naa35/38 complex forms a clamp that pinches Naa30 on 
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opposite sides. This clamp-like structure is distinct from the architecture of the large 
auxiliary subunits of NatA and NatB, which surround the base of their respective catalytic 
subunits (Gottlieb and Marmorstein 2018; Liszczak et al. 2013; Hong et al. 2017; Deng, 
Pan, et al. 2020). The Naa35 architecture is mostly helical, with 25 helices, three short β-
strands in its N-terminal region and a single β-hairpin at its C-terminal region that are 
unique to the NatC complex (Figure 5.4b). Naa38 adopts an Sm-like fold, with an N-
terminal α-helix, followed by a sharply bent β-sheet consisting of 5 five antiparallel β-
strands (Figure 5.4b). The Naa35/Naa38 clamp contains α4-α13 from Naa35 at its 
base, and α14-α25 and the C-terminal β-hairpin of Naa35 flanking one side of Naa30. 
The opposing side of Naa30 is flanked by a composite of the N-terminal end of Naa35 
(a2, a3, b1-b3) and the entirety of Naa38 (Figure 5.4a and 5.4b). Consistent with the 
composite nature of the Naa35-Naa38 interaction, the buried surface area between 
Naa38 and Naa35 is ~1925 Å2, which is notably higher than the area buried between 










Table 8.1 Cryo-EM data collection, refinement and validation statistics 
 SpNatC with Bisubstrate and IP6 
EMD-23110 
PDB: 7L1K 
Data collection and processing 
Magnification 105,000 
Voltage (keV) 300 
Electron exposure (e/Å2) 42 
Defocus range (μm) -1.0 to -3.0  
Pixel size (Å) 0.84 
Symmetry imposed C1 
Initial particles (no.) 1,860,276 
Final particles (no.) 607,131 
Map resolution (Å) 3.16 
FSC threshold 0.143 
Map resolution range (Å) 2.5-3.5 
Refinement 
Initial model used (PDB code) - 
Model resolution (Å) 3.4 
FSC threshold 0.5 
Model resolution range (Å) - 
Map sharpening B factor (Å2) 159.1 
Model composition  
Non-hydrogen atoms 7216 
Protein residues 883 
Ligands 2 




Bonds lengths (Å) 0.006 
Bond angles (°)  1.036 
Validation 
MolProbity score  1.76 
Clash score 4.10 
Poor rotamers (%) 0.38 
Ramachandran plot 
Favored (%) 89.55 
Allowed (%) 10.22 




Figure 27.2 Cryo-EM workflow and resolution of SpNatC EM map 
(a) 2D and 3D classification scheme and workflow for SpNatC EM map determination. 
(b) Local resolution of the final SpNatC EM map. (c) Viewing direction distribution of 
SpNatC final EM map 3D reconstruction generated by cryoSPARC v2. (d) Gold standard 
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Fourier Shell Correlation (FSC) curves of SpNatC EM map 3D reconstruction, generated 
by cryoSPARC v2. 
 
Figure 28.3 Correlation between Cryo-EM map of SpNatC EM and its atomic model 
 (a) Atomic model of SpNatC fitted into the Cryo-EM map. (b) FSC curves of the refined 
model versus the overall map that it was refined against (black); of the model refined in 
the first of the two independent maps used for the gold-standard FSC versus the same 
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map (green); and of the model refined in the first of the two independent maps versus 
the second independent map (orange). (c) The fit of several helical segments or β-






Figure 29.4 Overall structure of SpNatC reveals intimate interactions among all 
subunits 
(a) NAA30 (bright orange), NAA38 (deep purple) and NAA35 (lime green) are shown in 
transparent surface and cartoon, with the boxed area labeled. (b) The CoA-MLGP 
bisubstrate conjugate and inositol hexaphosphate (IP6) is shown in sticks and colored in 
blue. (c) Zoom-in view of the first sub-interface between NAA38 and NAA35. Hydrogen 
bonds are indicated by dashed black lines. For simplicity, only some of the hydrophobic 
interactions are shown. (d) Zoom-in view of the second sub-interface between NAA38 
and NAA35. (e) Zoom-in view of the third sub-interface between NAA38 and NAA35, 
which also involves some residues from NAA30 (light orange). (f) Zoom-in view of the 
interface between NAA35 and NAA30 α1-α2 segment. (g) Zoom-in view of the interface 
between NAA35 and NAA30 β6-β7 segment. (h) Zoom-in view depicting key residues 
involved in interactions with IP6. The lower left shows the fit of the IP6 in the EM density 





5.2.4 NAA38 plays a key role in the NatC complex 
The structure of SpNatC was consistent with our biochemical data suggesting 
that Naa38 plays important structural and functional roles within the NatC complex. A 
more detailed view of the Naa35-Naa38 interface reveals that it is nucleated by the 
formation of three anti-parallel β-sheets between Naa35 and Naa38, resulting in 
extensive hydrogen bonding and van der Waals interactions, which also involve the a2 
and a3 helices of Naa35. These interactions can roughly be divided into three regions 
according to the relative position of the β-sheets (Figure 5.4). 
The first sub-interface involves the Naa35 β1-α2 segment (Figure 5.4c). 
Hydrogen bonds are formed between the backbone nitrogen of Naa35-Ala35 and the 
backbone carbonyl of Naa38-Ala116, the backbone carbonyl of Naa35-Val38 and the 
backbone nitrogen of Naa38-Val114, the sidechains of Naa35-Asp39 and of Naa38-
Ser113, the sidechain of Naa35-Thr41 and the backbone nitrogen of Naa38-Phe112, 
and the backbone carbonyl of Naa35-Leu51 and the sidechain of Naa38-Arg79. This 
region also features a large area of van der Waals interactions involving residues Ala35, 
Gly36, Tyr37, Tyr44, Phe45, Ala47, and Thr48 from Naa35 and residues Gly48, Leu52, 
Trp55, His 61, Ile71, Thr77, Asp78, Ile109, Arg115, and Ala116 from Naa38. 
The second sub-interface is mediated by Naa35-β3 and α12 (Figure 5.4d). 
Hydrogen bonds are formed between the backbone nitrogen of Naa35-Phe71 and the 
backbone carbonyl of Naa38-Leu101, the backbone carbonyl of Naa35-Phe71 and the 
backbone nitrogen of Naa38-Leu103, the sidechains of Naa35-Asp79 and Naa38-Arg68, 
the sidechains of Naa35-Ser80 and Naa38-Arg97, and the backbone carbonyl of Naa35-
Gln296 and the sidechain of Naa38-Arg97. Residues involved in van der Waals 
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interactions include Ala70, Glu72, Ile73, Met74, Tyr84, Ala 297, Gln 298, Val30, and 
Ala301, from Naa35, and residues Phe95, Ala98, Leu99, Val102, Ile104, Pro105, and 
His108 from Naa38. 
The third sub-interface is mediated by Naa35-β2 but also involves extensive 
interactions with the catalytic Naa30 subunit (Figure 5.4e). The hydrogen bonds 
between Naa35 and Naa38 are formed between the sidechains of Naa35-Asp59 and 
Naa38-Asn57, the backbone nitrogen of Naa35-Val57 and the backbone carbonyl of 
Naa38-Thr77, and the backbone carbonyl of Naa35-Val57 and the backbone nitrogen of 
Naa38-Thr77. Naa38 engages with the α2 helix of the Naa30 subunit to form an 
extensive hydrogen bonding network via the Naa30-Tyr30 sidechain to the backbone 
carbonyl of Naa38-Ala82, and the sidechains of Naa38-Cys76 and Asp78; the sidechain 
of Naa30-Lys29 hydrogen bonds to the sidechains of Naa38-Asp78 and Glu80; and 
between the sidechains of Naa30-Arg33 and Naa38-Asp78. As the a1-a2 loop of Naa30 
plays a key role in protein N-terminal substrate recognition, these Naa38-Naa30 
interactions likely play a key role in substrate recognition by NatC (see discussion). 
Finally, the Naa30-a2 helix also interacts with Naa35 where Naa35-Glu54 forms 
hydrogen bonds with Naa30-Arg33 and His37. Within this sub-interface, the hydrophobic 
interactions are primarily mediated by residues Glu49, Leu52, Leu56, Leu75, Cys76, 
Asp78, and Ile84 from Naa38 and residues Leu56, Cys58, Asp59 and Phe62 from 
Naa35. Taken together, it appears that Naa38 plays key structural and, likely, functional 




5.2.5 The substrate binding α1-α2 loop and β6-β7 segments of NAA30 are buried within 
NAA35 
Naa30 uses its α1-α2 loop (Figure 5.4f) and β6-β7 segments to interact with 
Naa35 (Figure 5.4g). Analogous segments in the NatA and NatB complexes are used 
for N-terminal substrate recognition. In these complexes, however, the β6-β7 segment is 
exposed to solvent (Gottlieb and Marmorstein 2018; Liszczak et al. 2013; Deng, Pan, et 
al. 2020; Hong et al. 2017). By contrast, this interaction between Naa30 and Naa35 is 
facilitated by hydrogen bonds between the Naa30 α1-α2 loop and Naa35 α3-β3 
segment: the sidechain of Naa30-Ser28 and the backbone carbonyl of Naa35-Ala70; 
between the sidechains of Naa30-Gln20 and Naa35-Glu75; and the backbone carbonyl 
of Naa30-Gln20 and the sidechain of Naa35-Lys77. 
Notably, the interactions between Naa30 β6-β7 and Naa35 are significantly more 
extensive than those found in the NatA and NatB complexes (Figure 5.4g). Here, 
hydrogen bonds are formed between the sidechain of Naa30-Glu122 and the sidechains 
of Naa35-Gln507 and Tyr509, the sidechain of Naa30-Arg128 and the backbone 
carbonyl of Naa35-Lys504, the backbone carbonyl of Naa30-Tyr129 and the sidechain 
of Naa35-Arg446, the sidechain of Naa30-Arg131 and the backbone carbonyl of Naa35-
Gln503, the sidechain of Naa30-Arg134 and the backbone carbonyls of both Naa35-
Glu186 and Asp187, the backbone carbonyl of Naa30-Tyr136 and the sidechain of 
Naa35-Arg306, and the sidechains of Naa30-Tyr148 and Naa35-Arg597. Van der Waals 
interactions are observed between residues Cys127, Leu132, Tyr133, Leu137, Asn138, 
Phe143, Ile146, and Tyr148 from Naa30, and residues Ile308, Asn441, Cys443, Leu505, 
Phe581, Ser590, Tyr591, and Ala594 from Naa35. Together, it appears that the Naa35 
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auxiliary subunit makes extensive contacts with the protein N-terminal substrate binding 
loops of Naa30 to influence substrate recognition. 
 
5.2.6 IP6 is bound to the interface between NAA30 and NAA35 in close proximity to the 
peptide substrate binding site 
EM density corresponding to a bound IP6 molecule is well-resolved, revealing a 
IP6 binding pocket at the interface between the Naa30 and Naa35 subunits (Figure 
5.4h). Notably, the IP6 binding region is distinct from its binding sites in the NatA and 
NatE complexes (Deng, McTiernan, et al. 2020; Deng et al. 2019; Gottlieb and 
Marmorstein 2018). In SpNatC, IP6 engages in polar interactions with Naa30 residues 
His63, Arg64, Arg69, Tyr129, Lys130, and Arg144, and Naa35 residues Arg444, Arg447, 
and Asn451. Interestingly, although the IP6 binding pocket of NatC features a similar 
chemical environment to the one found in the NatA and NatE complexes, the location in 
the architecture of these NAT complexes differs. In NatC, IP6 is located close (~8 Å) to 
the peptide substrate entrance site, while the pocket found in NatA and NatE is close to 
the Ac-CoA entrance site (Figure 5.5). Therefore, the NatC-bound IP6 molecule could be 
in position to impact NatC activity. To evaluate this possibility, we assayed the effects of 
IP6 on NatC activity and found that IP6 had a relatively modest inhibitory effect on NatC 
activity, comparable to its similar modest inhibitory activity on SpNatA and hNatB 
(Figure 5.6).  While we cannot exclude the possibility that this modest inhibitor activity is 
an artifact of the effect of IP6 on the radioactive activity, it appears that IP6 plays a 








Figure 30.5 Comparison of NatC with Nat and NatB reveals divergent NatC 
architecture 
The auxiliary subunits are shown as transparent surface in grey or brown, while the 
catalytic subunits are shown as cartoon in light pink (catalytic subunits are aligned in the 
same orientation). The blue spheres, cyan spheres, and magenta sticks represent Ac-
CoA, peptide substrate, and IP6, respectively. The highlighted green loops shown are 
α1-α2 and β6-β7 substrate binding loops of the catalytic subunits. The PDB models for 
generating this figure: HsNatA with IP6, PDB: 6C9M (the bisubstrate shown is aligned 
from SpNatA, PDB:4KVM); HsNatB with the bisubstrate analogue, PDB: 6VP9; model of 
SpNatC with the bisubstrate analogue and IP6, PDB: 7L1K. As NatE is a complex with 
dual catalytic subunits and shares the same auxiliary subunit with NatA, for simplicity, it 










Figure 31.6 The activity impacts of IP6 on selective NATs  
50 nM of either SpNatC, SpNatA, and hNatB was mixed with 2 µM or no IP6 for 
measuring production formation. Data was normalized to NATs activity without IP6. Error 





5.2.7 NatC displays significant differences with NatA, NatE, and NatB 
Overall, there are three notable differences between NatC and the other multi-
subunit NATs – NatA, NatE and NatB. First, the auxiliary subunits of NatA, NatE and 
NatB contain only helical secondary structure, forming 10-13 conserved tetratricopeptide 
repeat (TPR) motifs (Gottlieb and Marmorstein 2018; Liszczak et al. 2013; Hong et al. 
2017; Deng, Pan, et al. 2020; Deng, McTiernan, et al. 2020; Deng et al. 2019). In 
contrast, the NatC auxiliary subunits (Naa35 and Naa38) do not contain TPR repeats 
and but do contain several beta strands that make key interactions in the complex 
(Figure 5.4b). Secondly, the auxiliary subunits of NatA, NatE, and NatB form a closed 
ring-like cradle to completely wrap around their corresponding catalytic subunit. In 
contrast, NatC auxiliary subunits arrange themselves into a clamp-like structure to only 
wrap roughly half-way around the Naa30 catalytic subunit (Figure 5.5). Thirdly, the 
Naa30 β6-β7 peptide substrate recognition loop is buried within the auxiliary subunit, 
while the corresponding loops in NatA, NatE, and NatB are largely exposed to solvent 
(Figure 5.5). Thus, the relative orientation of the catalytic subunit to the auxiliary subunit 
(s) is different in NatC relative to NatA and NatB. In turn, this has implications in altering 
the NatC substrate binding mode: the NatC substrate binding tunnel is roughly 
perpendicular to the Naa30-Naa35 interface, while the substrate binding tunnel of NatA, 
NatE, and NatB is parallel to the catalytic-auxiliary subunit-interface (Figure 5.5). Taken 






5.2.8 Substrate recognition by NAA30 shows similarity to NAA50 
Overall, Naa30 displays a typical NAT fold containing four α-helices and seven β-
strands with similar substrate binding modes: Ac-CoA enters the catalytic active site 
through a groove formed by α3 and α4 of the catalytic subunit, while the peptide 
substrate enters the active site on the opposite side of the catalytic subunit flanked by 
the α1–α2 and β6-β7 peptide substrate binding loops (Deng and Marmorstein 2021) 
(Figure 5.7a and 5.7b). In the Cryo-EM map, density for the CoA-Ac-MLGP conjugate 
bisubstrate is well-resolved, allowing us to confidently model both the CoA portion and 
all four residues of the peptide portion (Figure 5.7c). 
Naa30 harbors a conserved Ac-CoA binding motif R82XXG85XA87 where Ac-CoA 
binding is mediated by a series of hydrogen bonds, mainly to the pyrophosphate group. 
Specifically, the sidechains of Arg82, Ser119, Arg123 and backbone atoms from Ile77, 
Gly85, Ile86, and Ala87 contribute to Ac-CoA hydrogen bonding (Figure 5.7d). 
In our NatC model, Naa30 binds the peptide substrate mainly through peptide 
backbone hydrogen bonding and hydrophobic pockets for the sidechains of the first two 
peptide residues. Direct hydrogen bonds are formed between the backbone amide 
groups of the peptide residues 1 and 2 to Naa30 residues Tyr27, Glu109, Thr110, 
Tyr121, and Tyr136 (Figure 5.7d). The binding pocket for the peptide Met1 is 
surrounded by residues Leu23, Ser24, Glu25, Glu111, and Tyr136 (Figure 5.7e), while 
the binding pocket for peptide Leu2 is half-open and surrounded by Tyr27, Val31, Tyr34, 
Phe35, Lys59, Tyr71, and Met74 (Figure 5.7f). Beyond the first two residues, there are 
no direct contacts between the peptide substrate and Naa30, with the exception of 
distant contacts between the backbones of peptide Gly3 and peptide Pro4 with Naa30-
159 
 
Tyr135 (4-4.5 Å) and Naa30-Glu25 (~4 Å), respectively. These two Naa30 residues likely 
play a role in recognizing positions 3 and 4 of high-affinity NatC peptide substrates, as 
supported by the recent report by Grunwald et al. (Grunwald et al. 2020) 
Previous studies have described the overlapping substrate profile of NatC and 
NAA50. Since our NatC model contains the canonical NatE (NAA50)-type peptide 
substrate (Met2-Leu2-Gly3-Pro4) in the bisubstrate inhibitor, we were able to evaluate 
this relationship by visual inspection of the inhibitor-bound SpNaa30 subunit from the 
model. The SpNaa30 model aligns well with the HsNAA50 structure (PDB: 3TFY) bound 
to the same MLGP peptide fragment, with a root-mean-square deviation (RMSD) of 1.23 
Å (over 105 common Cα atoms) (Figure 5.7b). A more detailed view of the peptide 
substrate binding site reveals that Met1 sits in similar binding pockets in both structures 
(Figure 5.7e), consistent with their high specificity for Met1. Specificity for Leu at 
position 2 is also similar. Notably, residues NatC-Tyr27 and Tyr71, which are 
responsible for Leu2 backbone recognition align well with the corresponding residues in 
NAA50 (Figure 5.7f). For Leu2 sidechain recognition, the residues, Naa30-Val31 and 
Lys59 are replaced by bulkier residues, NAA50-Phe35 and Arg62 (Figure 5.7f), 
respectively. However, Naa30-Phe35, Ala73 and Met74 are replaced by NAA50-Phe35, 
Met75 and Thr76 (Figure 5.7f), perhaps explaining the greater tolerance of NAA50 for 
other residues at position 2. In both models, the peptide substrates begin to diverge from 
the architecture of their respective models at residue 3, where the Ca atoms of the 
corresponding peptide Gly3 residues of both models are ~3 Å apart. This also seems to 
be correlated with a shift in the p-hydroxyl group of a nearby conserved Tyr residue 
(Naa30-Tyr135 and NAA50-Tyr138) by about 2.5 Å (Figure 5.7g). The corresponding 
peptide Pro4 residues also point in different directions (Figure 5.7g). We propose that 
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these differences in peptide substrate positioning beyond residue 2 is mediated by the 
different active site environments of Naa30 and NAA50 in this region, thus allowing 
these two enzymes to harbor varying activities toward substrates with the same residues 
at positions 1 and 2 but differing residues at position 3 and beyond (See discussion). 
Taken together, this comparison explains the overlapping yet distinct substrate profiles 
of NatC and NatE. 






Figure 32.7 Substrate recognition by NAA30 is similar to NAA50 
(a) The sequence alignment of NAA30 orthologs from Schizosaccharomyces pombe 
(Sp), Saccharomyces cerevisiae (Sc), Arabidopsis thaliana (At), Drosophila 
melanogaster (Dm), and Homo sapiens (Hs). Numbering and secondary structure 
elements for NAA30 are indicated above the sequence alignment. Residues of NAA30 
that contact the peptide backbone (✵), CoA (❆), Met1 (✧), Leu2 (⦾), NAA38 (⦿), IP6 
(✽), and catalytic residues (✚) are indicated. (b) Structural alignment of SpNAA30 
(bright orange) with HsNAA50 (cyan), with secondary structure elements indicated. (c) 
The fit of the bi-substrate inhibitor in the EM density map. The contour level is 5.0 sigma. 
(d) Highlighted polar and hydrophobic interactions between CoA-Ac-MLGP and NAA30 
are depicted in the 3D view. (e) Residues forming a hydrophobic pocket surrounding the 
substrate peptide Met1 side chain are shown in sticks (Orange, SpNAA30; Cyan, 
HsNAA50). (f) Residues forming a hydrophobic pocket surrounding the substrate 
peptide Leu2 side chain are shown in sticks. (Orange, SpNAA30; Cyan, HsNAA50). (g) 
Residues proposed as catalytic residues are shown in sticks. (Orange, SpNAA30, E109 
and Y121; Cyan, HsNAA50, Y73 and H112). 
 
5.2.9 Mutational analysis reveals that NAA30 Tyr-121 and Glu-109 play key catalytic 
roles 
In order to evaluate key Naa30 residues identified in our model and their 
functional roles in substrate binding and catalysis, we used a radioactive in vitro 
acetyltransferase activity assay in conjunction with the MLRF peptide as the peptide 
substrate to kinetically characterize WT and mutant SpNatC proteins. Each mutant was 
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purified to homogeneity and displayed identical gel filtration chromatography elution 
profiles (data not shown), consistent with their native folding and complex formation. 
Consistent with our structural observations, mutation of a majority of residues involved in 
peptide substrate recognition resulted in an increase in Km (Table 5.2). As the “YY motif” 
is shown to be conserved in most NATs (Stove et al. 2016) (except NatD/NAA40), single 
mutation of either Naa30-Tyr135 or Tyr136 to an alanine resulted in a significant loss in 
activity, with the Y136A mutant displaying almost no detectable activity. In previous 
studies, NAA50 residues Tyr73 and His112 were proposed to contribute to catalysis 
(Liszczak, Arnesen, and Marmorstein 2011). The corresponding residues in Naa30, 
Tyr71 and Glu109, however, had an unexpected effect on catalysis. Instead, Naa30-
Y71A or Y71F primarily altered the Km, which ultimately resulted in a minor decrease 
(12-67%) in catalytic efficiency in comparison with WT. On the other hand, mutation of 
Naa30-Glu109 to either alanine or glutamine led to >90% loss of catalytic efficiency, 
impacting both Km and kcat. NAA50-Tyr124 and hNatB-Tyr123 were recently proposed to 
play analogous catalytic roles (Deng, Pan, et al. 2020), and the corresponding mutation 
of Naa30-Tyr121 to alanine demonstrated that NatC activity was almost completely 
abolished (Table 5.2). While Glu109 is positioned to function as a general base to 
deprotonate the a-amino group of the peptide substrate, Tyr121 is positioned to function 
as a general acid to re-protonate the CoA leaving group. This is consistent with the 
proposed roles of the analogous Glu118 and Tyr130 residues in ScNatC (Grunwald et 
al. 2020), as well as the conserved nature of these residues (Figure 5.7a). In addition, 
Naa30-Asn114 is highly conserved among all NATs (data not shown) and it was recently 
suggested to play a structural role in orienting the catalytic tyrosine residues (SpNaa30-
Tyr135 and Tyr136) by ensuring the proper position of the active site helix (a4) for 
interaction with Ac-CoA (Deng, Pan, et al. 2020). Consistent with the importance of 
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Asn114, we observed that Naa30-N114A exhibited an ~50% loss in activity. Taken 
together, the conserved Naa30-Glu109 and Tyr121 residues likely play key catalytic 
roles in NatC complex activity (Figure 5.7g). 
 





















WT 23.9 ± 1.4 1.0 7.6 ± 2.1 1.0 1.0 
S24A 22.7 ± 1.6 0.95 10.3 ± 3.2 1.4 0.70 
E25A 49.3 ± 2.3 2.1 19.7 ± 3.6 2.6 0.79 
Y27A 7.33 ± 0.5 0.31 3.0 ± 1.0 0.39 0.79 
Y71A 44.7 ± 2.8 1.9 16.1 ± 4.2 2.1 0.88 
Y71F 30.2 ± 2.3 1.3 29.6 ± 8.5 3.9 0.32 
M74A 13.7 ± 1.1 0.57 18.7 ± 6.1 2.5 0.23 
E109A 10.5 ± 1.6 0.44 28.7 ± 16 3.8 0.11 
E109Q 3.2 ± 0.9 0.13 201 ± 130 27 0.0050 
N114A 9.5 ± 0.6 0.40 5.6 ± 1.7 0.74 0.53 
Y121A 1.2 ± 0.1 0.050 16.0 ± 5.4 2.1 0.023 
Y121F 1.4 ± 0.2 0.060 7.9 ± 4.3 1.0 0.057 
Y135A 6.3 ± 0.8 0.26 9.5 ± 5.7 1.3 0.21 
Y136A N.A N.A N.A N.A N.A 












Here, were report that the notably small SpNaa38 auxiliary subunit cooperates 
with the large Naa35 auxiliary subunit to stabilize the active N-terminal acetyltransferase 
NatC complex for its robust N-terminal acetylation activity. Through structure/function 
studies, we observed that Naa38 interacts with Naa30-α2, a region that directly 
contributes to recognition of peptide substrate backbone and sidechain residues. Based 
on these observations and similar ScNatC complex biochemical and structural findings 
described by Grunwald et al. (Grunwald et al. 2020), it appears that Naa38 is essential 
for normal NatC acetylation activity. Therefore, we propose that Naa38 plays a 
conserved role in yeast. Future studies are needed to further interrogate this in the plant 
or human systems, as some reports suggest that Naa38 may not be as important in 
higher eukaryotes (Pesaresi et al. 2003; Starheim et al. 2009), but there has also been a 
report of a human developmental disorder linked to NAA38 deletion (Zhao et al. 2016). 
In S. pombe, we have found that the ternary SpNatC complex displays 
acetylation activity toward both canonical NatC and NatE-type peptide substates, but 
with a preference for NatC-type substrates. While recognition of residues 1 and 2 of the 
cognate substrate appears highly homologous between the Naa30 and NAA50 catalytic 
subunits of NatC and NatE, respectively, the substrate binding pockets responsible for 
recognizing substrate residues beyond the penultimate sidechain diverge significantly. 
This likely explains the divergence in substrate profiles observed between these two 
NATs. 
IP6 was previously found to play a stabilizing role at the interface between the 
NAA15 and NAA10 subunits of the NatA and NatE complexes (Deng, McTiernan, et al. 
2020; Deng et al. 2019; Gottlieb and Marmorstein 2018), (Cheng et al. 2019). Here, we 
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find that IP6 also appears to play a stabilizing role in both ScNatC and SpNatC, and that 
the SpNatC structure reveals that IP6 binds at the Naa35-Naa30 interface located near 
the peptide substrate entrance site, although it does not appear to play a major direct 
role in modulating NatC activity. 
Grunwald et al. recently reported X-ray crystal structures of ScNatC in several 
liganded states along with associated biochemical studies (Grunwald et al. 2020). 
Overall, their findings are in agreement with our findings on SpNatC reported here. 
There are, however, some notable differences when comparing NatC from S. pombe 
and S. cerevisiae, which have implications for the conserved and unique features of 
NatC. 
The ScNatC structures bound to cognate NatC-type peptide substrates shows 
specificity for the first four residues, which is consistent with their reported peptide 
substrate mutation and binding data. In contrast, our structure, featuring SpNatC bound 
to a peptide sequence that is optimal for NatE (NAA50) acetylation, shows SpNaa30’s 
specificity for only the first two residues. This mode of recognition is consistent with 
recognition for these same residues by NAA50, while there is significant divergence in 
the regions of the peptide binding grooves of Naa30 and NAA50 that are responsible for 
interaction with substrates residues beyond residue 2. This comparison suggests that 
discrimination between Naa30 and NAA50 substrates is largely dictated by the identities 
of the third and fourth residues in an N-terminal substrate. As NatC-type and NatE-type 
substrates can include many different hydrophobic/amphipathic N-termini (ML- MI-, MF, 
MW-, MV-, MM-, MH-, and MK-) (Ree, Varland, and Arnesen 2018), it may be difficult for 
a single enzyme to cover acetylation of such a broad repertoire of protein N-termini. 
Given that Naa50 is inactive in yeast (Deng et al. 2019), we propose that the overlapping 
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substrate profile for residues at positions 1 and 2 by NatC and NatE may have evolved 
in higher eukaryotic cells to fully cover the acetylation on these types of N-terminal 
substrates. 
Grunwald et al. identified several electropositive regions (EPR) on ScNatC that 
are implicated in ribosome association. Of these regions, labeled EPR1-EPR4 
(Grunwald et al. 2020) (Figure 5.8), mutation of only EPR2 was found to influence 
ribosome association. Comparison with the electrostatic surface potential of SpNatC 
shows notable differences with ScNatC (Figure 5.8). Specifically, EPR2 is not present in 
SpNatC, since the ScNatC “ScNaa35 tip” is missing in SpNatC. While EPR1 is 
conserved, this electropositive patch harbors the IP6-binding pocket in SpNatC and, 
therefore, is likely the IP6 binding site in ScNatC. In addition, the surface region of 
SpNatC corresponding to EPR3 is broader compared to the corresponding surface of 
ScNatC and is located close to where ScNatC-EPR2 would be. It is therefore possible 
that SpNatC utilizes EPR3 to compensate for the absence of EPR2. Taken together, this 
comparison suggests that the mode of ribosome association utilized by SpNatC and 
ScNatC and, by extension, NatC complexes from other species, may differ. Future 
studies would investigate the molecular details of these differing interactions. 
NatC has been shown to be important for proper chloroplast (Pesaresi et al. 
2003) and mitochondrial (Van Damme et al. 2016a) function, essential for embryonic 
development (Wenzlau et al. 2006), cell viability and p53-dependent apoptosis (Starheim 
et al. 2009), and as a potential therapeutic target in cancer (Mughal et al. 2015). In light 
of these important connections to NatC function, the studies reported here have 





Figure 33.8 Divergent structural features exist between NatC in S. pombe and S. 
cerevisiae 
(a) Electrostatic surface potential of the ScNatC structure (PDB:  6YGB) with previous 
EPRs indicated. (b) Electrostatic surface potential of SpNatC (PDB: 7L1K) aligned with 




5.4 Materials and Methods 
5.4.1 SpNatC expression and purification 
SpNaa3531-708 (with truncation of the N-terminal 30 residues) and full-length 
SpNaa30FL were cloned into a modified pET DUET vector containing an N-terminal His6-
SUMO tag. SpNaa3848-116 (with truncation of the N-terminal 47 residues) was cloned into 
a pCDF vector with an N-terminal His6 tag. To obtain the heterotrimeric NatC complex 
(WT ternary SpNatC), these two plasmids were used to co-transform Rosetta 
(DE3)pLysS competent E. coli cells, which was then cultured to grow at 37 °C in the 
presence of both ampicillin (100 µg/mL) and streptomycin (50 µg/mL). When the 
absorbance OD600 reached ~ 0.7, protein expression was induced at 16°C with 0.5 mM 
isopropyl 1-thio-β-galactopyranoside (IPTG) overnight. Cells were harvested by 
centrifugation, resuspended, and lysed by sonication in lysis buffer containing 25 mM 
Tris, pH 8.0, 300 mM NaCl, 10 mg/ml PMSF (phenylmethanesulfonylfluoride). The lysate 
was clarified by centrifugation and passed over Nickel-NTA resin (Thermo Scientific), 
which was subsequently washed with ~10 column volumes of wash buffer containing 25 
mM Tris, pH 8.0, 300 mM NaCl, 20 mM imidazole, 10 mM 2-mercaptoethanol (βME). 
The protein was eluted in batches with buffer containing 25 mM Tris, pH 8.0, 300 mM 
NaCl, 200 mM imidazole, 10 mM βME. After elution, His6-tagged Ulp1 protease was 
added to the eluate to cleave the His6-SUMO tag and dialyzed further into buffer 
containing 25 mM sodium citrate monobasic, pH 5.5, 10 mM NaCl and 10 mM βME. 
Protein was purified with a 5-mL HiTrap SP cation-exchange column (GE Healthcare) 
and eluted with a salt gradient (10–1000 mM NaCl). Peak fractions were concentrated to 
~0.5 mL with a 50 kDa concentrator (Amicon Ultra, Millipore), and loaded onto an S200 
gel-filtration column (GE Healthcare) in a buffer containing 25 mM HEPES, pH 7.0, 200 
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mM NaCl, 1 mM dithiothreitol (DTT). Peak fractions were pooled and concentrated to 
~15 mg/ml as measured by UV280 using a Nanodrop and flash-frozen for storage at −80 
°C until use. All protein mutants were generated using the QuikChange protocol from 
Stratagene and obtained following the expression and purification protocols described 
above. 
5.4.2 Binary and ternary ScNatC expression and purification 
ScNaa301-161 and ScNaa3519-733 were cloned into a pET DUET vector containing 
an TEV cleavable N-terminal His6-tag. Binary complex (ScNaa301-161/ScNaa3519-733) was 
obtained by transforming this plasmid in ScarabXpress T7lac (Scarab Genomics) 
competent E. coli cells, which were grown in terrific broth media (DOT Scientific) 
supplemented with ampicillin (100 µg mL-1) at 37°C to an OD600 of ~0.9 and induced by 
addition of 0.5 mM IPTG at 17°C for 16 hr. All subsequent purification steps were carried 
out at 4°C. Cells were isolated by centrifugation, lysed by sonication in lysis buffer 
containing 25 mM Tris, pH 8.0, 300 M NaCl, 10 mM β-ME and 10 mg/mL PMSF. The 
lysate was clarified by centrifugation and passed over nickel resin, which was 
subsequently washed with >20 CV of lysis buffer supplemented with 25 mM imidazole. 
The protein was eluted in lysis buffer supplemented with 200 mM imidazole by batch 
elution. TEV protease (~1 mg/ml) was added to the eluted protein and dialyzed into 
buffer containing 25 mM Tris, pH 8.0, 300 mM NaCl, 5 mM Imidazole, 10 mM β-ME. This 
solution was passed through an additional nickel column to remove TEV protease as 
well as any uncut binary ScNatC. The resin was then washed with approximately 3 CV 
of dialysis buffer supplemented with 25 mM imidazole, which was then pooled with the 
initial flowthrough. This solution was dialyzed into ion exchange buffer containing 25 mM 
HEPES, pH 7.5, 50 mM NaCl and 10 mM β-ME and loaded onto a 5 ml HiTrap SP anion 
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exchange column (GE HealthcarE). The binary complex ScNatC was then eluted using a 
salt gradient (50–750 mM NaCl). Peak fractions were concentrated using a 50-kDa 
MWCO concentrator (Amicon) and further purified Superdex 200 Increase 10/300 GL gel 
filtration column (GE Healthcare) in a buffer containing 25 mM HEPES, pH 7.0, 200 mM 
NaCl, 1 mM TCEP. Peak fractions were concentrated to a UV280 of ~4-5 mg mL-1 as 
measured by nanodrop. The protein was then flash-frozen and stored at -80°C until use. 
 
To obtain the ternary ScNatC complex, ScNaa381-70 was cloned into a pRSF 
vector with a TEV-cleavable N-terminal STREP-tag. This plasmid was co-transformed 
with the pET DUET plasmid containing ScNaa301-161 and ScNaa3519-733 and cultured as 
described above except with the addition of kanamycin (50 µg mL-1) to select for pRSF 
ScNaa381-70 plasmid. The purification of the ternary ScNatC complex was the same as 
described for the binary ScNatC complex. 
 
5.4.3 Acetyltransferase activity assays 
All acetyltransferase assays were carried out at room temperature in a reaction 
buffer containing 75 mM HEPES, pH 7.0, 120 mM NaCl, 1 mM DTT as described 
previously (Deng et al. 2019). The full sequence of peptide substrates are listed below: 
“SASE” peptide (NatA-type): NH2-SASEAGVRWGRPVGRRRRP-COOH; “MDVF” 
peptide (NatB-type): NH2-MDVFMKGRWGRPVGRRRRP-COOH; “MLRF” peptide 
(NatC-type): NH2-MLRFVTKRWGRPVGRRRRP-COOH; “MLGP” peptide (NatE-type): 
NH2-MLGPEGGRWGRPVGRRRRP-COOH; “SGRG”/H4 peptide (NatD-type): NH2-
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SGRGKGGKG LGKGGAKRHR-COOH). All peptides were purchased from GenScript. 
To evaluate SpNatC activity against these peptides, 50 nM SpNatC was mixed with 50 
μM Ac-CoA and 500 μM peptide, and allowed to react for 10 min. To determine steady-
state catalytic parameters of SpNatC (WT or mutants) with respect to the peptide 
substrate, 50 nM SpNatC (WT or mutants) was mixed with 50 μM Ac-CoA (14C-labeled, 
4 mCi mmol−1; PerkinElmer Life Sciences) and varying peptide concentrations (ranging 
from 1.95 μM to 500 μM, 9-data points) for 5-minute reactions. P81 paper was 
purchased from SVI (St. Vincent’s Institute Medical Research). All radioactive count 
values were converted to molar units with a standard curve created with known 
concentrations of radioactive Ac-CoA added to scintillation fluid. GraphPad Prism 
(version 5.01) was used for all data fitting to the Michaelis–Menten equation. The errors 
in Table 2 represent the standard deviation of the best fit values of the curves. 
For the comparison of ternary and binary ScNatC complex activity, 10 nM of 
either binary ScNatC or ternary ScNatC was mixed with 100 μM of 14C-labeled Ac-CoA 
and “MLRF” peptide, for a 12-minute reaction in buffer containing 50 mM HEPES, pH 
7.5, 150 mM NaCl and 1 mM DTT. 
For the activity comparison of ternary SpNatC and other NATs in the presence or 
absence of IP6, 50 nM of SpNatC, SpNatA or hNatB was mixed with 50 μM of 14C-
labeled Ac-CoA, 50 μM of their peptide substrate, in reaction buffer containing 75 mM 
HEPES, pH 7.0, 120 mM NaCl, 1 mM DTT, supplemented with either 0 or 2 μM IP6 
(Sigma-Aldrich), for a 5-minute reaction. The peptide substates for SpNatA and hNatB 
are SASE peptide and MDVF peptide, respectively. SpNatA (Liszczak et al. 2013) and 




5.4.4 ITC measurements 
ITC measurements were carried out using a MicroCal iTC200 at 20 °C. Samples 
were dialyzed into buffer containing 25 mM HEPES pH 7.0, 200 mM NaCl, and 1 mM 
DTT. 15 μM of SpNatC in the cell and 300 μM of IP6 in the syringe were used. The raw 
data were analyzed with the MicroCal ITC analysis software. 
 
5.4.5 Differential scanning fluorimetry assays 
Sypro Orange (50,000X stock, ThermoFisher Scientific) was diluted 1:200, and 4 
µL was mixed with 16 µL solution with 0.1 mg/ml of various NatC samples in pH 7.0, 200 
mM NaCl, and 1 mM DTT, with or without 10 µM IP6. Fluorescent readings were 
recorded using a qPCR (ABI 7900 RealTime PCR) with a 1% ramp rate, while heated 
from 20 °C to 95 °C. Melting curves were generated from these readings and melting 
temperatures were determined by taking the first derivative of the curves. DSF scans of 
all samples were performed in triplicate as technical replicates. Error bars in the figure 
indicates the Standard Deviation (SD) of each sample. 
 
5.4.6 Cryo-EM data collection 
For initial sample screening, 0.05 mg/ml fresh SpNatC sample was prepared with 
3-molar excess of both bisubstrate and IP6. SpNatC particles on cryo grids exhibited a 
severe preferred orientation, which generated an incorrect initial 3D model (data not 
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shown). Further screening by addition of detergent NP-40 in sample did not improve this 
situation. To solve this issue, 1 μL of 80 mM CHAPSO was mixed with 20 μL of 12 
mg/mL SpNatC. 3 μL of this mixed sample was applied to Quantifoil R1.2/1.3 holey 
carbon support grids, blotted and plunged into liquid ethane, using an FEI Vitrobot Mark 
IV. An FEI TF20 was used for screening the grids and data collection was performed 
with a Titan Krios equipped with a K3 Summit direct detector (Gatan), at a magnification 
of 105,000 ×, with defocus values from −0.1 to −3.0 µm. Each stack was exposed and 
counted in super-resolution mode with a total dose of 42 e-/Å2, resulting in 35 frames per 
stack. Image stacks were automatically collected with EPU. A full description of the 
Cryo-EM data collection parameters can be found in Table 5.1. 
 
5.4.7 Cryo-EM data processing 
Original image stacks were summed and corrected for drift and beam-induced 
motion at the micrograph level using MotionCor2 (Zheng et al. 2017), and binned 
twofold, resulting in a pixel size of 0.84 A˚ /pixel. After motion correction in Relion 3.0 
(Kimanius et al. 2016), corrected micrographs were imported into CryoSPARC (Punjani 
et al. 2017) to perform defocus estimation, the resolution range of each micrograph with 
Gctf (Zhang 2016) and all the subsequent data analysis. 2D classifications were 
performed on the particles auto-picked by “blob picker” with particle diameter of 100 - 
200 Å. The representative 2D classes were used as templates to further auto-pick 
1,860,276 particles from 5514 micrographs. After bad particles were removed by two 
runs of 2D classification, 849,844 particles were used to generate four Ab-Initio models 
and two rounds of heterogeneous refinement were performed using the four models. 
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508, 298 particles were used for auto refinement and per particle CTF refinement. The 
final map was refined to an overall resolution of 3.20 Å, with local resolution estimated in 
Cryo-SPARC (Punjani et al. 2017). 
5.4.8 Cryo-EM model building and refinement 
The SpNatC atomic model was manually built de novo using the program COOT 
(Emsley and Cowtan 2004) according to the Cryo-EM map, with the guidance of 
predicted secondary structure and bulky residues such as Phe, Tyr, Trp and Arg. The 
complete model was then refined by real-space refinement in PHENIX (Adams et al. 
2010).  All representations of Cryo-EM density and structural models were performed 
with Chimera (Pettersen et al. 2004) and PyMol (Schrodinger 2015) 
(https://pymol.org/2/). The sequence alignments with secondary structure display were 
created by ESPript 3.0 (Robert and Gouet 2014a). The surface area calculation was 
performed using PDBePISA (Krissinel and Henrick 2007) (Proteins, Interfaces, 


































While Nt-acetylation is a protein modification present in all kingdoms of life, it’s 
much more abundant and complicated in eukaryotes than in bacterial and archaea, in 
term of target substrate profile. Meanwhile, the biological relevance of Nt-acetylation is 
also comparably more significant in eukaryotes, impacting diverse cellular processes 
and diseases. In correspondence to these, eukaryotic NATs have evolved some distinct 
features. Among these features, the major one is that some eukaryotic NATs, like NatA, 
B, C, and E collaborate with at least one auxiliary subunit, a small molecule (IP6, for 
NatA, NatC, and NatE), and in the case of NatA and NatE, the HYPK regulatory protein 
to form multi-subunit enzyme complexes and perform the acetylation co-translationally in 
a controlled manner. Overall, these enzymes are collectively responsible for Nt-
acetylation of over 80% human proteins and abnormal activities of them have been 
reported to be corelated with developmental diseases such as Ogden syndrome, 
neurodegenerative diseases, and cancers (Dorfel and Lyon 2015; Myklebust, Stove, and 
Arnesen 2015; Kalvik and Arnesen 2013).  Motivated by the biological significance and 
disease connections of these protein complexes, this thesis set out to provide 
comprehensive studies towards understanding the molecular and regulatory mechanism 
of these multi-subunit NATs, as described in previous chapters. 
 While important insights are provided here, some questions remain unanswered. 
How do NatA and NatE toggle between co-translational activity and post-translational 
activities? NAA10 has been reported to act alone towards acidic substrates (distinct from 
NatA-type), while human NAA50 per se is also active towards NatE-type substrates. 
Moreover, controversial reports indicate that both NAA10 and NAA50 can perform lysine 
acetylation and auto-acetylation (Magin, March, and Marmorstein 2016; Seo et al. 2010; 
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Evjenth et al. 2009). Thus, the biological relevance of these potential versatile activities 
of NAA10 and NAA50 requires further investigation.  
 Can NATs carry out cross regulation amongst themselves? Nt-acetylation is 
known to be important for protein complex formation and protein function in some cases. 
NATs themselves are also subjected to Nt-acetylation depending on their N-terminal 
sequence identity. A recent report highlighted that NAA20 maturation mediated by NatA 
activity is essential for NatB complex formation (Lasa et al. 2020).   
What is the molecular mechanism of co-translational acetylation on the ribosome 
of NatA/E, and other NATs that function co-translationally such as NatC/B/D? How do 
NATs with co-translational activities navigate the same or different ribosomes? How do 
ribosomes distinguish and selects the correct NAT for co-translational nascent chain Nt-
acetylation? How do NATs cooperate or compete with other N-terminal modification 
enzymes like NME? These are challenging but important questions that remain to be 
answered. For the known yeast NatE-ribosome architecture, ScNAA50 is inactive and 
remote from the ribosome exit tunnel. However, in humans, hNAA50 is active, and how 
hNAA50 shifts its distance relative to the exit tunnel when the nascent chain contains a 
NatE-type substrate is also an interesting question that remains to be answered. 
Recently, Electropositive regions (EPRs) on the surface of NatB and NatC were 
proposed to participate in ribosome association (Magin et al. 2017; Grunwald et al. 
2020), structural studies are required to confirm these results 
As HYPK reduces ~ 90% of hNatA activity and influences NatE activity as well in 
vitro (Gottlieb and Marmorstein 2018; Deng, McTiernan, et al. 2020), why are such 
strong inhibition effects on hNatA not observed in vivo? What is the biological function of 
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the presence of HYPK in humans, as HYPK is absent in most yeast? Do other NATs 
agonists or antagonists exist? Learning from HYPK, can we develop novel and specific 
inhibitors for NATs? In humans, NATs are frequently correlated with disease and 
cancers, especially hNatA. The development of bi-substrate analogues has been 
important for understanding NAT catalytic mechanism but are unsuitable as drugs. It will 
be of great interest to develop drug-like NAT-specific inhibitors.     
Lastly, to date, the structure and mechanism of the chloroplast localized NATs 
are unknown. What are the unique features of these NATs? These, among many other 
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